Clinical and pathological characterization of a novel transgenic animal model of diabetes mellitus expressing a dominant negative glucose-dependent insulinotropic polypeptide receptor (GIPR dn) by Herbach, Nadja
 1
From the Institute of Veterinary Pathology 
Department of General Pathology and Pathological Anatomy 
Chair: Prof. Dr. W. Hermanns 
and the 
Institute of Molecular Animal Breeding and Biotechnology 
Head: Prof. Dr. E. Wolf 
Ludwig-Maximilian-University Munich 
 
Under the supervision of Prof. Dr. R. Wanke and Prof. Dr. E. Wolf 
 
&OLQLFDODQGSDWKRORJLFDOFKDUDFWHUL]DWLRQRIDQRYHOWUDQVJHQLF
DQLPDOPRGHORIGLDEHWHVPHOOLWXVH[SUHVVLQJDGRPLQDQWQHJDWLYH
JOXFRVHGHSHQGHQWLQVXOLQRWURSLFSRO\SHSWLGHUHFHSWRU*,35   
 
 
Inaugural – Dissertation 
to achieve the doctor title of veterinary medicine  
at the Faculty of Veterinary Medicine of the 
Ludwig-Maximilian-University, Munich 
 
by Nadja Herbach 
from Berlin 
 
Munich 2002 
 

 2
Gedruckt mit der Genehmigung der Tierärztlichen Fakultät der Ludwig-Maximilians-
Universität  
München 
 
 
Dekan: Univ.-Prof. Dr. R. Stolla 
1. Referent: Univ.-Prof. Dr. R. Wanke 
2. Referent: Univ.-Prof. Dr. E. Wolf 
1. Korreferent: Univ.-Prof. Dr. W. Kraft 
2. Korreferent: Univ.-Prof. Dr. J. Braun 
3. Korreferent: Priv.Doz. Dr. R. G. Erben 
 
Tag der Promotion: 19. Juli 2002 
 3
7DEOHRIFRQWHQW
     
,QWURGXFWLRQ 7  

/LWHUDWXUHUHYLHZ 8
 
'LDEHWHVPHOOLWXV 8
2.1.1 Definition and description of diabetes mellitus   8 
2.1.2 Diagnosis of diabetes mellitus   9 
2.1.3 Classification of diabetes mellitus  10 
2.1.4 Screening for diabetes mellitus       12 
2.1.5 Screening for diabetes-associated organ lesions   13 
2.1.6 Diabetic animal models  14 
2.1.6.1 Animal models of type 1 diabetes  14 
2.1.6.2 Animal models of type 2 diabetes  17 
 
'LDEHWLFQHSKURSDWK\ 19
2.2.1 Diabetic glomerulosclerosis  20 
2.2.2 Tubular changes  21 
2.2.3 Interstitial changes  21 
2.2.4 Pathophysiology of proteinuria  22 
2.2.5 Development of proteinuria  23 
2.2.6 Animal models of diabetic kidney disease  23 
 
3DQFUHDVGHYHORSPHQW
  24 
2.3.1 Patterning and early pancreas development  24 
2.3.2 Morphogenesis and differentiation  26 
2.3.3 Transcription factors linked to pancreas development   27 
2.3.4 Postnatal pancreatic B-cell growth  32 
2.3.5 Incretin hormones and pancreas development   38 
 
7KHHQWHURLQVXODUD[LV
 40 
2.4.1 Definition  40 
2.4.2 Components of the enteroinsular axis  41 
 4
2.4.2.1 Neural components   41   
2.4.2.2 Hormonal components (Incretin candidates)  41 
2.4.3 Glucagon-like peptide-1 (GLP-1)  41 
2.4.4 Glucose-dependent insulinotropic polypeptide (GIP)   43 
2.4.5 GIP receptor  43 
2.4.5.1 GIP receptor structure   43 
2.4.5.2 GIP receptor signal transduction  44 
2.4.5.3 GIP receptor mediated functions  46 
2.4.6 Neural mediation of the incretin effect  47 
2.4.7 Quantification of the incretin effect  47 
2.4.8 Pathophysiology of the enteroinsular axis in diabetes   48 
 
*HQHUDWLRQRI*,35  WUDQVJHQLFDQLPDOV
  49 
2.5.1 Targeted mutation of the human GIP receptor  49 
2.5.2 ,QYLWUR analysis of the mutated GIP receptor  50 
2.5.3 Generation of mutant mice  51 
 
5HVHDUFKGHVLJQDQGPHWKRGV  52 
3.1 Transgenic animals  52 
3.2 Urine glucose  56 
3.3 Blood/serum glucose and serum insulin values   57 
3.4 Glycated hemoglobin (HbA1c)  57 
3.5 Oral glucose tolerance test (OGTT)  58 
3.6 Subcutaneous glucose tolerance test (SCGTT)  58 
3.7 Daily food and water intake, urine volume  59 
3.8 Serum parameters  59 
3.9 Body and organ weights  59 
3.10 Pancreas preparation and morphometric analysis  60 
3.11 Immunohistochemistry of pancreatic tissue  61 
3.12 Urine protein analysis  62 
3.12.1 Sodium dodecyl sulfate (SDS) polyacrylamide   63 
            gel electrophoresis (PAGE) 
3.12.2 Western blot analysis        65 
3.13 Immunohistochemistry of the kidneys  66 
 5
3.14 Kidney preparation and morphometric analysis  67 
3.15 Histological techniques  69 
3.16 Twelve-month survival  70 
3.17 Data presentation and statistical analysis   70 
 
5HVXOWV
  71 
4.1 Urine glucose  71 
4.2 Blood/serum glucose and serum insulin levels  72 
4.3 Glycated hemoglobin (HbA1c) levels  78 
4.4 Oral glucose tolerance test (OGTT)  80 
4.5 Subcutaneous glucose tolerance test (SCGTT)  83 
4.6 Daily food and water intake, urine volume  85 
4.7 Serum parameters  90 
4.8 Body weight   91 
4.9 Organ weights  96 
4.10 Descriptive histological and immunohistochemical findings  
  of the pancreas  99 
4.11 Quantitative-stereological findings of the pancreas   101 
4.11.1 Total islet volume 101 
4.11.2 Volume density of islets in the pancreas 102 
4.11.3 Total B-cell volume 102 
4.11.4 Volume density of B-cells in the islets 103 
4.11.5 Total volume of endocrine non-B-cells 104 
4.11.6 Volume density of non-B-cells in islets 105 
4.11.7 Total volume of isolated B-cells 107 
4.11.8 Volume density of isolated B-cells in the pancreas 108 
4.12 Urine protein analysis 109 
4.13 Macroscopical, histological and immunohistochemical  
 findings of the kidneys 111 
4.14 Quantitative-stereological findings of the kidneys 116 
4.14.1 Kidney volume 116 
4.14.2 Mean glomerular volume 117 
4.15 Twelve-month survival  119 
 
 6
'LVFXVVLRQ 125 

3HUVSHFWLYH
 136 
 
6XPPDU\ 137

5HIHUHQFHV 140 

$WWDFKPHQW
 156 
9.1 Silver stain for SDS-PAGE gels  156 
9.2 Drying of SDS-PAGE gels 156  
9.3 Staining procedures for plastic embedded sections 157 
9.3.1 H&E  157 
9.3.2 Periodic acid-Schiff stain (PAS) 158 
9.3.3 Periodic acid silver methenamine PAS stain 158 
9.4 Staining procedures for paraffin embedded sections 159 
9.4.1 H&E  159 
9.4.2 PAS stain 159 
9.4.3 Gomori’s silver stain (modified) 160 
9.4.4 Best’s carmine 161 
9.5 Fat red stain 162 
 
$FNQRZOHGJHPHQW
 165 
 
&XUULFXOXPYLWDH
 167 
 7
1. Introduction 
 
The connection of the gastrointestinal tract and the endocrine pancreas was shown 
in the 1960s when insulin became measurable in plasma. Comparison of oral and 
intravenous glucose tolerance tests revealed a much higher insulin secretory re-
sponse of the endocrine pancreas after oral or intrajejunal glucose administration 
than after intravenous glucose injection (McIntyreHWDO 1964). The enteroinsular axis 
was found to be in charge of approximately 50% of the insulin release after oral glu-
cose (Unger & Eisentraut 1969). One of the major incretin hormones responsible for 
the greater insulin secretory response after oral vs. intravenous glucose administra-
tion is GIP (glucose-dependent insulinotropic polypeptide or gastric inhibitory poly-
peptide). Immunoneutralization of GIP reduced the insulin secretory response by up 
to 72% and was therefore thought to be of major importance in regulating postpran-
dial glycemia.  
Disturbances in the enteroinsular axis have been described in diabetic patients and 
animal models of diabetes. Especially the insulin response to GIP administration was 
regularly found to be diminished in diabetes mellitus.  
In the present study, transgenic mice expressing a dominant negative GIP receptor 
(GIPRdn) under the control of the rat insulin gene promoter were investigated; non-
transgenic littermates served as controls. Since the GIP-/GIPR-axis is regarded to be 
of importance in the pathogenesis of diabetes mellitus, a precise clinical survey was 
performed in GIPRdn transgenic mice, in order to characterize the metabolic state in 
comparison to their non-transgenic counterparts.  
GIP was recently found to be a mitogenic factor for B-cells via pleiotropic signaling 
pathways and could therefore be of importance for the development of the endocrine 
pancreas. In this study, the effects of transgene expression on postnatal pancreatic 
islet and B-cell development were determined, using quantitative stereological meth-
ods. In addition, functional and morphological renal changes resulting from chronic 
disturbance of the metabolic state were investigated. 
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2. Literature review 
 
2.1 Diabetes mellitus 
 
2.1.1 Definition and description of diabetes mellitus 
 
Diabetes mellitus comprises a heterogeneous group of metabolic diseases, which is 
characterized by hyperglycemia resulting from defects in insulin secretion, insulin 
action or both. Chronic hyperglycemia leads to long-term damage, dysfunction and 
failure of various organs, especially the eyes, kidneys, nerves and the cardiovascular 
system (The expert committee on the diagnosis and classification of diabetes mellitus 
1997) 
 
At least three different factors are involved into the SDWKRJHQHVLV of diabetes mellitus 
(Table 2.1).  
 
Table 2.1 Pathogenetic factors of diabetes mellitus (Lehmann & Spinas 2000) 
 
1. Genetic predisposition, e.g. mutation in the glucokinase gene, in different  
 transcription factors, mutations in the insulin receptor 
2. Insulin resistance (muscle, liver, adipose tissue) 
3. Defective insulin secretion of the pancreatic B-cell  
 
6LJQV of diabetes mellitus include hyperglycemia, polyuria, polydipsia, weight loss, 
hyperphagia and sometimes blurred vision. Impairment of growth and susceptibility to 
certain infections may also accompany chronic hyperglycemia. Acute and life-
threatening consequences of diabetes are hyperglycemia with ketoacidosis or the 
nonketotic hyperosmolar syndrome. 
 
/RQJWHUPFRPSOLFDWLRQV of diabetes include retinopathy with potential loss of vision, 
nephropathy leading to renal failure (see 2.2), peripheral neuropathy with risk of foot 
ulcers, amputation and Charcot joints, and autonomic neuropathy causing gastroin-
testinal, genitourinary, cardiovascular symptoms and sexual dysfunction. Glycation of 
tissue proteins and other macromolecules and excess production of polyol com-
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pounds from glucose are among the PHFKDQLVPVthought to produce tissue damage 
from chronic hyperglycemia. Patients with diabetes have an increased incidence of 
atherosclerotic cardiovascular, peripheral vascular and cerebrovascular disease. Hy-
pertension, abnormalities of lipoprotein metabolism, and periodontal disease are of-
ten found in diabetic patients (The expert committee on the diagnosis and classifica-
tion of diabetes mellitus 1997). 
 
2.1.2 Diagnosis of diabetes mellitus 
 
There are different methods for diagnosing diabetes mellitus in humans (Mayfield 
1998): 
 
1. Casual plasma glucose levels (at any time of the day) ≥ 200 mg/dl and clinical 
symptoms of diabetes mellitus 
2. Fasting plasma glucose (FPG) (no caloric intake for at least 8 h) ≥ 126 mg/dl 
3. Plasma glucose two hours after an oral glucose load (75 g anhydrous glucose  
dissolved in water) ≥ 200 mg/dl 
 
According to the American Diabetes Association (ADA), the measurement of fasting 
plasma glucose (FPG) levels is sufficient for the diagnosis of diabetes mellitus (The 
expert committee on the diagnosis and classification of diabetes mellitus 1997). The 
World Health Organization (WHO) rather suggests performing an oral glucose toler-
ance test (OGTT), using 75 g glucose per person. Only if an OGTT cannot be per-
formed, FPG levels should be used for diagnosis, according to the WHO (Alberti & 
Zimmet 1998). FPG and OGTT do not identify the same persons; especially patients 
with impaired fasting glucose (IFG) can be actually diagnosed as diabetics in an 
OGTT (MannucciHWDO 1999). Epidemiological studies have shown that unlike FPG, 
impaired glucose tolerance (IGT) is a predictor for the risk of developing cardiovascu-
lar disease (TominagaHWDO 1999).  
 
The expert committee on the diagnosis and classification of diabetes mellitus (1997) 
recognizes an intermediate group of subjects whose glucose levels, although not 
meeting criteria for diabetes, are nevertheless too high to be considered normal. Di-
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agnostic criteria for non-diabetic subjects, the intermediate group and criteria for di-
agnosing diabetes mellitus are listed in Table 2.2. 
 
Table 2.2 Diagnostic criteria for diagnosing diabetes mellitus: fasting plasma glucose 
values and two-hour post-load plasma glucose (PG) values after oral glucose chal-
lenge (The expert committee on the diagnosis and classification of diabetes mellitus 
1997) 
 
Diagnosis     Criteria 
Non-diabetic     FPG < 110 mg/dl  
      2-hour post-load PG values < 140 mg/dl 
Impaired fasting glucose (IFG)  FPG ≥ 110 and < 126 mg/dl  
Impaired glucose tolerance (IGT)  2-hour post-load PG values ≥ 140 mg/dl and  
             < 200 mg/dl  
Diabetes mellitus    FPG ≥ 126 mg/dl 
      2-hour post-load PG values ≥ 200 mg/dl 
 
Since hyperglycemia can be transitory e.g., due to infections, cardiovascular epi-
sodes, trauma and other stress factors, the diagnosis should be confirmed on a dif-
ferent day, by one of the three methods (see above). 
 
2.1.3 Classification of diabetes mellitus 
 
The etiology is the main criteria for the new classification of human diabetes mellitus, 
according to the ADA and WHO (Lehmann & Spinas 2000). Therefore, terms like in-
sulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes melli-
tus (NIDDM) are no longer used. The same is true for the terms juvenile and adult 
diabetes, because 50% of type 1 diabetic patients are diagnosed when they are over 
20 years of age and the incidence is equal for every decade after the 20th year of 
one’s life. According to the ADA and WHO, four main types of diabetes mellitus can 
be distinguished (Table 2.3) (Lehmann & Spinas 2000). 
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Table 2.3 Etiologic classification of diabetes mellitus according to the ADA and WHO 
1998 (Lehmann & Spinas 2000)                                
 
7\SH'LDEHWHVPHOOLWXV
B-cell destruction, usually leading to absolute insulin deficiency 
- Immune mediated  
- Idiopathic (rare, no indices for autoimmune disease) 
 
7\SHGLDEHWHVPHOOLWXV  
Ranges from predominantly insulin resistance with relative insulin deficiency to a 
predominantly insulin secretory defect with insulin resistance 
 
6SHFLILFW\SHVRIGLDEHWHV
-   Genetic defects of B-cell function, maturity onset diabetes of the young (MODY): 
 MODY 1: Defective HNF (hepatocyte nuclear factor) -4α, chromosome 20 
 MODY 2: defective glucokinase, chromosome 7 
 MODY 3: defective HNF-1α, chromosome 12 
 MODY 4: defect of the insulin promoter factor-1 (IPF-1) 
 MODY 5: defective HNF-1β, mitochondrial diabetes and others 
- Genetic defects in insulin action (type A insulin resistance, Leprechaunism, Rab-
son-Mendenhall-Syndrome: defective insulin receptor, lipoatrophic diabetes and 
others) 
- Diseases of the exocrine pancreas (pancreatitis, trauma/pancreatectomy, cystic 
fibrosis, neoplasia, hemochromatosis, fibrocalculous pancreatopathy and others) 
- Endocrine disorders (acromegaly, Cushing’s syndrome, Conn’s syndrome,  
pheochromocytoma, hyperthyroidism and others) 
- Chemically induced (steroids, pentamidine, diazoxide, thiazides, nicotinic acid and  
others) 
-  Infections (congenital rubella, measles, Coxsackie viruses, cytomegaly virus)  
- Rare forms of immunogenic diabetes (Stiff-Man Syndrome, anti-insulin receptor  
 antibodies and others) 
- Other genetic syndromes, associated with diabetes mellitus (Down syndrome,  
 Klinefelter's syndrome, Turner’s syndrome, myotonic dystrophy and others) 
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*HVWDWLRQDOGLDEHWHVPHOOLWXV
Women who develop type 1 diabetes mellitus during pregnancy and women with un-
diagnosed asymptomatic type 2 diabetes mellitus that is discovered during preg-
nancy are classified with gestational diabetes mellitus. Most women with gestational 
diabetes mellitus develop a relative insulin deficiency during the second half of the 
pregnancy, leading to hyperglycemia. After delivery, hyperglycemia resolves in most 
women but places them with increased risk of developing type 2 diabetes mellitus 
later in life (Mayfield 1998).  
 
2.1.4 Screening for diabetes mellitus 
 
For screening and diagnosis of diabetes mellitus, FPG and 2-hour post-load PG val-
ues after oral glucose challenge are most suitable (see chapter 2.1.2). Due to non-
reproducible values in healthy subjects and a high range of variation, despite identi-
cal blood glucose values, glycated hemoglobine (HbA1c) is unsuitable for the screen-
ing for diabetes mellitus (KilpatrickHWDO 1998; SimonHWDO 1999). However, HbA1c 
levels above 6.2% have shown to correlate with the likelihood of having or develop-
ing macro- or microvascular disease; measuring this parameter has therefore been 
recommended for monitoring the treatment of diabetes mellitus and glycemia (The 
expert committee on the diagnosis and classification of diabetes mellitus 1997).  
 
6FUHHQLQJIRUW\SHGLDEHWHVPHOOLWXV
According to the depth of the prevalence and incidence of type 1 diabetes, a general 
screening for type 1 diabetes seems to be unsuitable (prevalence of type 1 diabetes 
mellitus in the total German population 0.3%; incidence of type 1 diabetes in Ger-
many 12/100,000 (Ziegler & Scherbaum 1998)). The determination of auto-antibodies 
in healthy subjects, especially of relatives of type 1 diabetics, is not being advised in 
other than clinical surveys because to date, there are no effective intervention strate-
gies for the prevention of type 1 diabetes (Mayfield 1998). 
 
6FUHHQLQJIRUW\SHGLDEHWHVPHOOLWXV
Determination of FPG should be performed from 45 years of age onwards and is rec-
ommended to be repeated in three-year intervals if normal. Screening for diabetes in 
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younger subjects is advisable if one or more of the following criteria are true (Mayfield 
1998): 
 
- Obesity (body mass index = body weight (kg) / height (m)2  ≥ 27 kg/m2). 
- First-degree relative with diabetes mellitus 
- Member of high risk-ethnic group (black, Asians, Hispanic, Native American and  
others) 
- History of gestational diabetes mellitus or delivering a baby weighing more than 
4 kg 
- Hypertension (≥ 140/90 mm Hg) 
- HDL-cholesterol < 0.9 mmol/l and/or triglyceride level ≥ 2.8 mmol/l 
- History of IGT or IFG on prior testing (FPG ≥ 110 and < 200 mg/dl) 
 
2.1.5 Screening for diabetes-associated organ lesions 
 
Screening for diabetes-associated organ lesions in type 1 diabetic patients should be 
first carried out five years after diagnosis. In contrast to type 1 diabetes, onset of type 
2 diabetes is not acute and cannot be clearly defined. Since 30-50% of type 2 diabet-
ics, even in western countries are not diagnosed and taking into account that 50% of 
newly diagnosed diabetics already exhibit secondary organ lesions, a regular screen-
ing for type 2 diabetes is recommended. In case of diagnosis, cardiovascular risk fac-
tors and secondary organ lesions should be surveyed according to the criteria in Ta-
ble 2.4 (The Diabetes Control and Complications Trial Research Group 1993). 
 
Table 2.4 Screening for secondary organ lesions in type 1 and 2 diabetes mellitus 
(The Diabetes Control and Complications Trial Research Group 1993) 
 
Retinopathy    yearly ophthalmologic examination   
Nephropathy    determination of urinary albumin excretion  
(night urine < 20 µg/min, 24-hour urine < 30 
mg/24h, albumin : creatinine ratio < 2.5 (male) /  
< 3.5 (female)) 
Peripheral neuropathy  yearly examination for the presence of peripheral  
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sensorimotor neuropathy, testing of nerve conduc-
tion in at least two peripheral nerves and autonomic 
nerve testing      
Cardiovascular risk factors measurement of blood pressure and detection of 
plasma lipids (in contrast to type 2 diabetics, in type 
1 diabetic patients, disturbances in plasma lipid 
content and hypertension only occur in coincidence 
with bad diabetes control and overt diabetic neph-
ropathy, respectively) 
 
2.1.6 Diabetic animal models 
 
Animal models have been used intensively in order to clarify the etiology and patho-
genesis of diabetes mellitus, as well as to try to prevent its development and pro-
gression. Some of these animal models are presented below in order to give a brief 
overview of the most commonly used models.  
 
2.1.6.1 Animal models of type 1 diabetes 

7KH%LR%UHHGLQJ%%UDW
 
The spontaneously diabetic rat syndrome was recognized in 1974 at the Bio Breed-
ing Laboratories, Canada. The inheritance pattern of susceptibility is that of an auto-
somal recessive gene, however, only 50% of the susceptible animals develop diabe-
tes (Janle-Swain 1985). Diabetes onset is mainly between 60 and 120 days of age; 
an abrupt onset with glucosuria, hyperglycemia, ketonuria, hypoinsulinemia and 
death from ketoacidosis within one or two weeks is typically found in younger ani-
mals, whereas in older animals, diabetes development is slower and less dramatic. 
Besides classic diabetic symptoms, rapid weight loss is a good predictor of diabetes 
development (Buschard 1996). A variety of hormonal and metabolic abnormalities 
have also been found in this strain. Glucagon and somatostatin are elevated in dia-
betic animals; growth hormone secretion is initially normal but decreases with meta-
bolic decompensation. Elevation in free fatty acids and branched chain amino acid 
levels are proportional to the severity of diabetes. There is an increased hepatic glu-
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coneogenesis and decreased glucose utilization comparable to human type 1 diabe-
tes (Janle-Swain 1985). The disease mechanisms have been intensively investi-
gated. As in human type 1 diabetes, insulitis is seen prior to clinical diabetes and in 
some BB rats, which do not develop diabetes mellitus. The infiltrate consists of CD4- 
and CD8-positive lymphocytes and NK cells. Macrophages are believed to be the first 
cells invading the islets. The BB rat shows lymphocytopenia, which can be recog-
nized before clinical onset of diabetes. NK cells have been suggested to be respon-
sible for the destruction of B-cells, due to their capability of lysing islet cells LQYLWUR. 
However, it now seems proven that the small number of CD4 cells is ultimately re-
sponsible. The BB rat displays islet cell antibodies, which can be detected up to two 
weeks before onset of diabetes. Furthermore, antibodies against lymphocytes as well 
as against smooth muscles and gastric parietal cell antigens have been found 
(Buschard 1996). 
 
7KHQRQREHVHGLDEHWLFPRXVH12'PRXVH 
 
The NOD mouse strain was established in 1974 in Osaka, Japan. In this strain, up to 
80-90% of females develop diabetes between 80 and 200 days of age. The incidence 
in male mice is between 10-50%, but there is a substantial variation in different colo-
nies. Gonadal sex hormones are important modulators of diabetes development in 
NOD mice: castrated males show higher incidence and oophorectomized females a 
lower incidence of diabetes. The appearance of diabetes is followed by classic symp-
toms, such as hyperglycemia, hypoinsulinemia, glucosuria, ketonuria, polydipsia and 
polyuria. In contrast to BB rats, NOD mice can survive up to several months after on-
set of diabetes. NOD mice display islet cell and islet cell surface antibodies with a 
peak after the age of six months and an incidence of up to 80%. Insulin autoantibod-
ies are present in up to 80% of the mice after three months. Up to 95% of the mice 
show insulitis, which may already be seen at 5-6 weeks of age. The earliest changes 
are periinsulitis followed by invasion of the islet capsule. In its final form, insulitis in 
NOD mice is typically present in one part of the islet, which is heavily infiltrated, 
whereas the other part is completely normal. The mononuclear infiltrate looks more 
like a leukemia infiltrate than an inflammatory process; its shape can be crescent. B- 
and T-cells, as well as NK cells and activated lymphocytes are seen in insulitis, the 
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first infiltrating cells being monocytes. The odd looking insulitis could be a major dis-
advantage in this otherwise convenient model (Buschard 1996). 
 
9LUXVLQGXFHGGLDEHWHV
 
Environmental factors are thought to play a pathogenetic role in the development of 
diabetes mellitus and in this context, virus is a likely candidate. For experimental 
models, encephalomyocarditis (EMC virus) is the most widely used. The result of the 
virus infection is dependent on the virus strain (diabetogenic, non-diabetogenic) and 
is also highly dependent on the mouse strain used (Buschard 1996). Encephalomyo-
carditis virus is a picornavirus possessing many of the biologic and pathogenetic 
properties of the group B Coxsackie viruses. Infection of genetically susceptible 
strains of mice leads to the development of lesions of the islets of Langerhans, ac-
companied by diabetes mellitus. The occurrence of diabetes in this model is affected 
by complex interrelated genetic, immunologic and environmental influences. After 
subcutaneous inoculation, encephalomyocarditis virus multiplies in the islets of 
Langerhans and causes lesions of the B-cells. During early stages of infection, B-
cells degranulate and the insulin content of the pancreas decreases markedly with 
hyperglycemia appearing concomitantly. A mononuclear cell infiltrate appears tran-
siently (until the second week of infection) around the islet with the persistence of the 
infection. During convalescence (two to three weeks after inoculation), three patterns 
of metabolic disease can be observed. Some animals display profound hyperglyce-
mia and ketoacidosis. These mice lose weight and die several months after inocula-
tion. Histologically, islets are shrunken, distorted and lack detectable amounts of in-
sulin. In other animals, hyperglycemia is less marked for an extended period of time. 
After several months, animals can recover, apparently due to the regeneration of in-
sular tissue. Finally, a number of animals exhibit normal fasting blood glucose con-
centrations and disturbed oral glucose tolerance (Craighead 1981).  
Four other human viruses are known to cause lesions of pancreatic islets in experi-
mental animals. Venezuelan encephalitis virus damages islets of hamsters and non-
human primates, resulting in carbohydrate intolerance. Further, rubella virus infec-
tion, reovirus and cytomegalovirus cause damage of pancreatic islets and B-cells 
(Craighead 1981). 
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6WUHSWR]RWRFLQLQGXFHGGLDEHWHV
 
The streptozotocin diabetic rat is a well-described and widely used model for the 
study of type 1 diabetes. Streptozotocin is a by-product of the bacterium 6WUHSWRP\
FHVDFKURPRJHQHV with extensive antimitotic properties (WeilHWDO 1976). It causes 
necrosis of B-cells of the pancreas and diabetes in the mouse, rat, guinea pig, and 
dog. Streptozotocin is administered intravenously or intraperitoneally in single doses 
(Janle-Swain 1985). Rats develop hypoinsulinemia, hyperglycemia, and increased 
gluconeogenesis, lipo- and glycogenolysis. Drawbacks of this chemical include 
nephro- and hepatotoxicity. In rats treated with streptozotocin, cystic changes occur 
in both liver and kidney. Furthermore, up to 30% of the animals rendered diabetic 
using streptozotocin develop renal tumors within six or seven months (Steffes & 
Mauer 1984). 
 
The mentioned models of type 1 diabetes have all proven useful in diabetes re-
search, however, none of them is ideal. The BB rat develops lymphopenia and a low 
percentage of CD4 cells; the NOD mouse has odd insulitis and female dominance, 
the virus model is difficult to handle and it does not simulate fully the picture of type 1 
diabetes in man (Buschard 1996), and streptozotocin causes the development of re-
nal tumors (Steffes & Mauer 1984).  
 
2.1.6.2 Animal models of type 2 diabetes 
 
&RKHQGLDEHWLFUDW
 
The strain was developed by genetic selection of albino rats from the Hebrew Univer-
sity strain for their propensity to develop overt diabetes and diabetes-related compli-
cations when fed a diet rich in sucrose or other refined sugars and poor in copper 
content (Velasquez HW DO 1990). Hyperglycemia, glucosuria and hyperinsulinemia, 
insulin resistance, and a decrease in the number and sensitivity of insulin receptors 
are characteristic findings in diabetic Cohen rats. When Cohen rats are fed a starch 
or stock diet, no overt diabetes develops (VelasquezHWDO 1990). 
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2EHVHVSRQWDQHRXVO\K\SHUWHQVLYHUDW6+5
 
The obese spontaneously hypertensive rat (SHR) strain was developed by mating a 
female SHR of the Kyoto-Wistar strain with a normotensive Sprague-Dawley male. 
After several generations of selective inbreeding, the obese SHR exhibited obesity, 
hypertension, and hyperlipidemia. In addition, some animals develop hyperglycemia 
and glucosuria associated with giant hyperplasia of pancreatic islets. Hypertension 
occurs early and precedes the development of kidney disease (Velasquez HW DO 
1990). 
 
2EHVHPRXVHRERE 
 
The obese mouse was discovered as a spontaneous autosomal recessive mutation 
at the Jackson Laboratory, Bar Harbor, Maine, USA, where the mutant originally pre-
sented with massive obesity and marked hyperglycemia. The mutation in the ob gene 
leading to leptin deficiency was transferred later and maintained in different inbred 
strains. Depending on the inbred background, the ob/ob mouse may present with 
different obesity-diabetic syndromes. Thus, the ob mutant maintained on the 
C57BL/6J mouse strain (C57BL/6J ob/ob) develops massive obesity, mild glucose 
intolerance, transient hyperglycemia, and severe hyperinsulinemia associated with 
hyperplasia of pancreatic islets. In contrast, the C57BL/KsJ ob/ob mouse develops 
severe diabetes marked by initial transient hyperinsulinemia, followed by rapidly de-
veloping insulinopenia due to pancreatic B-cell atrophy, leading to the early death of 
the animal (JanssenHWDO 1999). 
 
'LDEHWHVPRXVHGEGE 
 
The diabetes mouse is another strain derived from the autosomal recessive mutation 
discovered at the Jackson Laboratory in Bar Harbor, Maine, USA. This mutation oc-
curred spontaneously in mice of the C57BL/KsJ strain. On this background, the dia-
betes mouse (C57BL/KsJ db/db) consistently develops a severe diabetic syndrome 
similar to that in C57BL/KsJ ob/ob mouse, characterized by early onset (4-6 weeks of 
age) of hyperphagia, obesity, hyperglycemia, hyperinsulinemia, weight loss, down-
regulation of insulin receptors and early death. Diabetes is more severe in this strain 
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compared to other obese mutants. The db gene has also been transferred to the 
C57BL/6J strain; the C57BL/6J db/db mouse develops obesity with mild hyperglyce-
mia, and hyperinsulinemia (VelasquezHWDO 1990). 
 
.XR.RQGR..PRXVH
 
The KK mouse is one of a series of genetically diabetic strains, established by Kondo 
and coworkers (KondoHWDO 1957; Nakamura & Yamada 1967). The mode of inheri-
tance is not fully understood but assumed to be polygenetic. This strain is character-
ized by slowly developing obesity, mild hyperglycemia with hyperinsulinemia, and an 
increase in size and number of pancreatic islets. Metabolic abnormalities are maxi-
mal at 4-9 months and normalize at one year. Because of polygenic inheritance, 
there is a lack of an appropriate control mouse with which to make comparisons 
(JanssenHWDO 1999). From mating of KK females and yellow KKAy males at the Ta-
keda Chemical Corporation, Osaka, Japan, the KKAy mouse was established. It dif-
fers from the KK mouse, because it carries yellow obese and diabetic genes, 
whereas the KK mouse carries only the diabetic gene. KKAy mice are obese and 
have early onset and prolonged hyperinsulinemia and hyperglycemia (Janle-Swain 
1985; VelasquezHWDO 1990). 
 
2.2 Diabetic nephropathy 

Diabetic kidney disease is known for a long time, but it was only after insulin therapy, 
that renal complications became an important problem in diabetic patients. Longer 
life expectancy is probably the reason since the increased life span would give a 
longer time for the various structural changes to develop (Heptinstall 1991). Kimmel-
stiel and Wilson first described glomerular lesions characteristic for diabetes 
(Kimmelstiel & Wilson 1936). The knowledge of the structure of kidney lesions has 
extended ever since. Today, diabetic kidney disease is the single commonest cause 
of end-stage renal failure worldwide (Thomas & Viberti 2000). 
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2.2.1 Diabetic glomerulosclerosis 

The first morphological change of the human diabetic kidney after onset of diabetes 
is an increase in glomerular size and therefore, a rise in filtration area, resulting in an 
increase in glomerular filtration rate (Romen 1980). Approximately two years after 
onset of diabetes, glomerular basement membranes begin to thicken and the expan-
sion of capillary walls and the mesangium leads to the development of the so-called 
diffuse form of glomerulosclerosis. Nodular glomerulosclerosis may develop in more 
advanced kidney damage. Another group of lesions that comprises diabetic glomeru-
losclerosis are the exudative lesions (Ritz & Usadel 1999).  
The QRGXODUOHVLRQis the type of change originally described by Kimmelstiel and Wil-
son in 1936. It typically consists of a rounded, homogeneous, eosinophilic, PAS posi-
tive area situated in the central part of a lobule, usually toward the periphery. Several 
lobules within a given glomerulus can be affected, and the nodules are usually of 
varying size. The nodules are often acellular, but elongated cells may appear con-
centrically arranged near the periphery. Around the periphery of the nodule, the capil-
laries are usually patent with the capillary walls appearing thickened. Glomerular cap-
illaries may be dilated as to be microaneurysmal, and lipophages are sometimes 
seen, apparently in capillary lumens. The glomerular tuft often retains size, which is 
in contrast to the shrinkage that accompanies the purely ischemic glomerulus. In late 
stages, exudative lesions (see below) appear more frequently and glomeruli are re-
duced in size (Heptinstall 1991). It has been postulated that nodules result from re-
pair processes of microaneurysmal glomerular capillaries, breakage and lysis of the 
mesangium, as well as organization of mesangial destruction (Ritz & Usadel 1999).  
TheGLIIXVHOHVLRQ consists of an increase in eosinophilic, PAS-positive material in the 
mesangium. The process also includes thickening of the capillary walls, which is of-
ten wide spread within a glomerulus and may affect all glomeruli. In later stages, as 
thickening progresses, capillary lumens become reduced. The capsule of Bowman 
becomes thickened in more advanced lesions and both afferent and efferent arteri-
oles are hyalinized. Unlike the nodular lesion, the diffuse lesion is not specific for dia-
betes and can occur in other conditions, such as glomerulonephritis (Heptinstall 
1991).  
Another type of lesion seen in diabetic patients is the H[XGDWLYH OHVLRQ, which in-
cludes fibrinoid caps and capsular drops, as well as arteriolar hyalin changes. The 
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ILEULQRLG FDS appears as an eosinophilic, smooth, homogenous crescentic structure 
lying in the concavity of a capillary, usually at the periphery of a lobule. It has general 
appearance of fibrin, is sometimes foamy, and contains lipid. The lesion is most 
commonly in diabetic kidneys with severe vascular disease but not specific for dia-
betic glomerulosclerosis. &DSVXODU GURSV appear as small, rounded, eosinophilic 
masses on the inside of Bowman’s capsule between the basement membrane and 
the parietal epithelial cells (Heptinstall 1991). This lesion was first described in 
Kimmelstiel and Wilson’s (1936) original paper, but only later it was regarded as di-
agnostic aid for diabetic glomerulosclerosis. The DUWHULRODUK\DOLQFKDQJH is a lesion 
of both afferent and efferent arterioles, the walls of which are thick, homogenous or 
slightly fibrillar and vacuolated, and strongly eosinophilic and PAS positive. The nor-
mally occurring structures disappear and no muscle coat can be seen in an arteriole 
with well-developed hyalin change. The PAS positive arteriolar lesion is continuous 
with the diffuse lesion in the lobules through a PAS positive thickening in the capillary 
stalk (Heptinstall 1991; Olsen 1969). Arteriolar hyaline change of the afferent arteri-
oles may also be seen in patients with essential hypertension, whereas the hyalin 
change of the efferent arterioles is considered diabetes specific (Ritz & Usadel 1999). 
 
2.2.2 Tubular changes 
 
The proximal convoluted segment of the tubules often appears finely vacuolated, with 
lipid being demonstrable in frozen sections. In more advanced lesions there is tubular 
loss, with atrophic tubules showing thickened basement membranes. Glycogen con-
taining tubular epithelia (Armanni-Ebstein change), once considered characteristic for 
diabetes, are seen only very occasional now, being sited in the pars recta of the 
proximal tubule (Heptinstall 1991).
 
2.2.3 Interstitial changes 

The interstitial tissue is frequently fibrotic and may contain inflammatory cells. Lym-
phocytes and plasma cells may be so plentiful that the reaction is indistinguishable 
from that seen in chronic infections. Interstitial infiltrates become more numerous with 
the increasing duration of diabetes and with the degree of arteriolosclerosis 
(Heptinstall 1991).  
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These morphological changes of the human diabetic kidney are the underlying cause 
of functional abnormalities, such as proteinuria, with urinary albumin excretion being 
the most powerful predictor of progression of renal injury (WangHWDO 2000). Protein-
uria is no longer simply considered a marker for renal dysfunction – protein is nephro-
toxic and a causative agent for renal damage (Marshall & Williams 1998). 
 
2.2.4 Pathophysiology of proteinuria 
 
Due to filtration and re-absorption mechanisms of the healthy kidney, only very small 
amounts of protein are found in urine (Marshall & Williams 1998). The glomerular 
filtration system stops albumin (67 kDa) and larger proteins from passing into primary 
urine. Smaller serum proteins are filtrated but reabsorbed by the tubular system. 
Therefore, the localization of kidney damage can be estimated from the type of pro-
tein(s) present in urine. Large proteins prove a glomerulopathy, if postrenal serum or 
blood contamination can be excluded. Podocyte damage causes a VHOHFWLYHJORPH
UXODU proteinuria (60-150 kDa: transferrin, albumin, dimeric albumin), damage of 
glomerular basement membranes and mesangium cause an XQVHOHFWLYHJORPHUXODU 
proteinuria (60-350 kDa, dimeric albumin) (Bergstein 1999; Oser & Boesken 1993; 
StierleHWDO 1990). Both types of proteinuria can be observed in diabetic kidney dis-
ease. Small proteins reflect tubular or interstitial injury resulting in insufficient re-
absorption of microproteins. Depending on the grade of alteration, an incomplete PL
FURSURWHLQXULD (40-70 kDa) or a complete microproteinuria (10-70 kDa) can occur 
(Marshall & Williams 1998). 7XEXODU SURWHLQXULD can be observed in patients with 
chronic interstitial nephritis, rejected kidney transplantate and others. Many neph-
ropathies damage both, glomeruli and tubules and therefore, mixed types of glomeru-
lar and tubular proteinuria can be found (Marshall & Williams 1998). Since urinary 
proteins can already be altered before proteinuria can be detected with routinely 
used diagnostic methods, the urine profile determined using the SDS-PAGE (sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis) is an excellent diagnostic aid for 
early detection of nephropathy. Especially in individuals with systemic diseases, such 
as diabetes mellitus, and in follow up studies (diagnosed acute kidney diseases, 
transplantation), this method is recommended for early diagnosis of secondary kid-
ney damage. An important advantage is that the SDS-PAGE makes it possible to 
distinguish between renal and postrenal cause of blood appearance in urine. 
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Postrenal blood contamination of urine shows a characteristic protein profile in a 
SDS-PAGE, containing a specific microprotein (~30 kDa) and hemoglobin but the 
urine usually does not consist of proteins larger than 400 kDa or microproteins as 
observed in tubular proteinuria (Oser & Boesken 1993). 
 
2.2.5 Development of proteinuria 
 
The onset of clinically overt diabetic kidney disease in humans is defined as persis-
tent proteinuria. Diabetic patients that develop proteinuria pass through the different 
stages in sequence, from normoalbuminuria to microalbuminuria and finally proteinu-
ria (Parving HWDO 1996). Very low rates of albumin excretion, i.e. microalbuminuria 
are potent predictors of renal and cardiovascular risk in diabetic patients. The degree 
of albuminuria has turned out to be the most powerful predictor of progression of re-
nal injury (Wang HWDO 2000). This finding is in coincidence with the current opinion 
that exposure of tubular epithelial cells to protein is a crucial step in perpetuating 
progression through activation of tubular epithelial cells and the start of interstitial 
fibrosis (Klahr 1999; Odoni & Ritz 1999; WangHWDO 2000). The overall prevalence of 
microalbuminuria and macroalbuminuria is about 30-35% in both types of diabetes 
mellitus. The annual rise in urinary albumin excretion is about 20% in both type 1 and 
2 diabetic patients (ParvingHWDO 1996).  
 
2.2.6 Animal models of diabetic kidney disease 
 
Since Kimmelstiel and Wilson (1936) described diabetic glomerulosclerosis, numer-
ous studies have been conducted to investigate the disease. The validity of the find-
ings in human diabetics is limited, since studies were always carried out after pro-
longed duration of the disease. Hence introduction of experimental models of diabe-
tes constituted great progress since very early stages of the disease could then be 
studied (Wehner & Petri 1983). Rodents, particularly rats and mice are used as 
experimental models of diabetic kidney disease. Major advantages of these rodent 
models are the low cost of acquiring and maintaining and the fact that large numbers 
can be studied in a reasonable amount of time. However, there are several disadvan-
tages of rodent models. The renal lesions do not completely parallel the renal lesions 
in human diabetes, which might be due to short life span and lack of adequate time 
for the complete syndrome to develop or due to a difference in the pathological proc-
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ess in the rodent kidney. The lesions in the diabetic rat kidney only resemble the le-
sions of early human diabetes to a certain extent and do not tend to progress. Fur-
ther, because of the small size of the animals, repeated sampling of renal tissue is 
not always possible on the same animal. In models where diabetes is induced, study-
ing of the consequences of the metabolic state is being carried out without confound-
ing hereditary factors, which could influence the development of diabetic nephropathy 
(Janle-Swain 1985). As mentioned above, streptozotocin given in sufficient amounts 
to induce diabetes mellitus causes renal tumor development within 6-7 months in up 
to 30% of the animals (Steffes & Mauer 1984). The dog is considered a useful model 
for the study of diabetic nephropathy. Due to its large size, long life span, tractable 
nature, and ease of blood sampling, long-term studies with repeated blood and bi-
opsy sampling is possible. The diabetic dog kidney more closely resembles the le-
sions in human diabetes. Similar lesions, reminiscent of the nodular form of human 
glomerulosclerosis and exudative lesions have been observed in spontaneously dia-
betic dogs (Bloodworth HW DO 1969; Janle-Swain 1985). In contrast, another work-
group did not observe lesions identical to human diabetic glomerulosclerosis in spon-
taneous diabetic dogs or cats (Gepts & Toussaint 1967). A disadvantage of canine 
models of diabetes is the high cost of acquiring and maintaining large animals. The 
same is true for nonhuman primate models of diabetes. Furthermore, specialized fa-
cilities are required for maintaining primates and a long period is necessary for the 
renal lesions to develop (Janle-Swain 1985). Despite a number of similarities be-
tween human diabetic kidney and lesions produced in experimental animals, there is 
profound difference to the morphology of characteristic human lesions (Olsen 1969). 
The above listed disadvantages of currently used animal models for studying diabetic 
kidney disease explain the need for an animal model that develops kidney lesions 
which closely match the changes in the human diabetic kidney. 
 
2.3 Development of the endocrine pancreas 
 
2.3.1 Patterning and early pancreas development 
 
In mammals, the pancreas develops as two outpocketings – the dorsal and the ven-
tral bud – from the primitive foregut (PictetHWDO 1972). The two buds consist of en-
dodermal cells surrounded by mesenchyme, giving rise to both the endocrine and 
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exocrine division of the pancreas. The dorsal pancreatic bud forms at about 9.5 days 
(20-25 somites) post conception in the mouse, the ventral bud appears at around day 
10 post conception (30 somites) (PictetHWDO 1972). As the buds grow, they rapidly 
form new protrusions leading to a highly branched structure. Acini and ducts become 
clearly visible by about E14.5 in the mouse. Various terminally differentiated products 
are found throughout the pancreatic development. Endocrine cells can be detected in 
the forming pancreas from the earliest stages, being largely individual and associated 
with ducts. Islet formation of endocrine cells is first observed by the end of gestation 
(E18.5d) in the mouse (HerreraHWDO 1991). Pancreas organogenesis involves a se-
quential cascade of inductive events in association with the activation of specific 
transcription factors (St-Onge HW DO 1999). Early events that define and pattern the 
region of the endoderm, which will give rise to the pancreas are still unknown. How-
ever, a pre-patterning of the endoderm seems to occur that will define and specify the 
area of the embryonic foregut from which the pancreatic buds will form (St-OngeHW
DO 1999). Spatial expression of members of the hedgehog family of signaling mole-
cules in the endoderm strongly suggests such a patterning of the foregut. Both Sonic 
hedgehog (Shh) and Indian hedgehog (Ihh) are expressed along the entire endoder-
mic gut, apart from the region that will give rise to the future pancreas. The region 
devoid of hedgehog expression also coincides to the region where homeodomain 
transcription factor PDX-1 (pancreatic and duodenal homeobox gene-1) will first be 
expressed (Ahlgren HW DO 1996; Offield HW DO 1996). This part of the gut becomes 
committed to a pancreatic fate at the ~10 somite stage (E8.5), a few somite before 
this PDX-1 expressing region of the duodenal epithelium will begin to evaginate, thus 
forming the dorsal and ventral pancreatic buds. Notochord derived factors, such as 
activin-ß and fibroblast growth factor (FGF) 2 have been implicated in the initial re-
pression of Shh and Ihh expression in the presumptive dorsal pancreatic endoderm 
(Edlund 1999). Since the ventral pancreatic bud is never in contact with the noto-
chord, the exclusion of Shh and Ihh gene expression must be achieved by a distinct, 
notochord-independent mechanism. Several transcription factors (TF), including ho-
meodomain and basic helix-loop-helix families of TFs, have recently been implicated 
in the development of neural structures, and have also been found to be important for 
islet cell development and function (AhlgrenHWDO 1997; NayaHWDO 1997; SanderHW
DO 1997; Sosa-Pineda HW DO 1997; St-Onge HW DO 1997). Hlxb9 (encoding the tran-
scription factor Hb) is transiently expressed in the region that gives rise to the dorsal 
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and ventral pancreatic anlage. Hb9 expression becomes restricted to the insulin pro-
ducing B-cells later in development. In the dorsal bud, Hb9 expression precedes the 
expression of PDX-1, whereas in the ventral anlagen, Hb9 and PDX-1 are expressed 
concurrently (Edlund 1999). In mice lacking Hlxb9 function, dorsal pancreatic devel-
opment is blocked, whereas the ventral pancreas develops and contains both endo-
crine and exocrine cells; however, the relative proportions and spatial organization of 
the various endocrine cells is perturbed (HarrisonHWDO 1999; LiHWDO 1999). Immu-
nohistochemistry has demonstrated expression of PDX-1 in most cells of the early 
ventral and dorsal pancreatic buds (GuzHWDO 1995). Later in the development, PDX-
1 expression becomes restricted to insulin producing B-cells. Endocrine cells can be 
found even in the earliest buds, which are characterized by immunoreactivity for glu-
cagon, peptide tyrosine tyrosine (PYY), and insulin (Larsson 1998). Since all early-
appearing endocrine cells of the mouse and rat pancreas express PYY, the peptide 
was thought to constitute a marker for early differentiating endocrine cells. PYY could 
be expected to exert some functional role during pancreatic development. Thus, the 
earliest endocrine cells (E9.5) to appear are multihormonal and express PYY and 
glucagon; some are even triple positive for PYY, glucagon and insulin. Cells express-
ing somatostatin and pancreatic polypeptide (PP) appear rather late in the develop-
ing mouse pancreas. Bud cells expressing hormonal markers are negative for PDX-1 
(Larsson 1998). This suggests that PDX-1 is not needed for early expression of pan-
creatic insulin, glucagon or PPY. In mice lacking the PDX-1 gene (Jonsson HW DO 
1994), which fail to grow and form a pancreas, multihormonal cells (insulin, glucagon) 
can be detected in the early pancreatic buds (AhlgrenHWDO 1996). In contrast, Offield 
HWDO(1996) did not observe insulin positive cells using immunohistochemical analy-
sis, which is in coincidence with the proposed role for PDX-1 in the derivation of ma-
ture B-cells (further details are presented below) (GuzHWDO 1995).  
 
2.3.2 Morphogenesis and differentiation 
 
From E10 onwards, the pancreatic epithelium proliferates and invades the surround-
ing mesenchyme. Epitheliomesenchymal interaction(s) then stimulate the prolifera-
tion, branching and differentiation of the epithelium into endocrine and exocrine cells. 
The importance of mesenchymal factors for pancreatic development was already 
demonstrated in 1962 (Edlund 1998), however, the nature of these factors is cur-
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rently largely unknown. The mesenchyme is critically required for exocrine differentia-
tion, but impairs endocrine development (MirallesHWDO 1998). The branching of the 
pancreatic epithelium is an important aspect of pancreas morphogenesis. The factors 
responsible are presently unknown, but there is evidence, that FGF signaling is criti-
cally involved in controlling branching morphogenesis in the mouse (Edlund 1999). 
Islet morphogenesis is a complex process that involves differentiation, proliferation, 
and migration of pancreatic endocrine cells, culminating in the formation of properly 
organized, three dimensional, sphere-like structures. At about E14.5, developing en-
docrine cells aggregate in interstitial clusters, adjacent to the ductal epithelia. At this 
time of organogenesis, endocrine cell clusters do not exhibit the typical architecture 
of mature islets and do not contain all four islet cell types. In the remaining four days 
of gestation, the endocrine cells detach from the exocrine matrix, increase in number, 
and reorganize to form mature islets. Morphologically distinct islets are first detected 
with the proper distribution of endocrine cell types at E17.5 (HerreraHWDO 1991; Pic-
tet HWDO 1972). Although the molecular mechanisms that control islet formation are 
unknown, it has been demonstrated recently that members of the cadherin family of 
cell adhesion molecules (CAMs) and neural CAM (N-CAM) are expressed in the pan-
creas and also appear to have functional roles in the aggregation and organization of 
the principal endocrine cell types (DahlHWDO 1996; Larsson 1998). Mature pancreatic 
islets constitute 1-2% of total mass of the adult pancreas and are composed of the 
principal endocrine cell types: B-cells (~80%), A-cells, D-cells and PP-cells. In murine 
islets, the B-cells are localized in the core of the islet, surrounded by a mantle of A-, 
D- and PP-cells. The integrity of islet structure has been suggested to be essential for 
normal islet function of regulating glucose homeostasis (PipeleersHWDO 1982). 
 
2.3.3 Transcription factors linked to pancreas development 
 
As mentioned above, several transcription factors are linked to pancreas develop-
ment. In the following chapter, some of the most important transcription factors are 
discussed. 
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3'; SDQFUHDWLFDQGGXRGHQDOKRPHRER[JHQH
PDX-1 expression is initiated before hormone expression at the 10-12 somite stage, 
and is restricted to the dorsal and ventral walls of the primitive gut endoderm. The 
pattern of PDX-1 expression and its ability to stimulate insulin gene transcription sug-
gests that PDX-1 functions both in regionalization of the primitive gut endoderm and 
the maturation of the pancreatic B-cells (Ahlgren HW DO 1996; Ohlsson HW DO 1993). 
Homozygosity for mutations in the PDX-1 gene in mice and humans results in com-
plete agenesis of the pancreas (JonssonHWDO 1994; OffieldHWDO 1996). PDX-1 does 
not seem to be required for the evagination and initial bud formation, but rather ap-
pears to specify the early pancreatic epithelium, permitting its proliferation, branching 
and subsequent differentiation (AhlgrenHWDO 1996; OffieldHWDO 1996). Since early 
hormone producing cells appear in PDX-1 deficient embryos, additional transcription 
factors must exist, acting upstream of PDX-1. However, the subsequent morpho-
genesis of the pancreatic epithelium and progression of differentiation of the endo-
crine cells are arrested in PDX-1 deficient embryos. Since the mesenchyme that 
normally promotes pancreatic morphogenesis develops normal in these knockout 
mice, PDX-1 might act cell-autonomously, and the lack of pancreas is due to a defect 
in pancreatic epithelium (Edlund 1998). 
Recent studies provide further insights into PDX-1 function in differentiated B-cells. 
Heterozygous mice, carrying a targeted mutation of the PDX-1 gene (knockout) de-
velop diabetes with aging (AhlgrenHWDO 1998; DuttaHWDO 1998). Analysis of these 
PDX-1 +/- mice revealed that PDX-1 is required for maintaining the hormone produc-
ing phenotype of the B-cell by positively regulating insulin and islet amyloid polypep-
tide expression and by repression of glucagon expression. This transcription factor is 
also essential for expression of glucose transporter type 2 (GLUT2) in B-cells. The 
GLUT2 expression seems to be regulated by PDX-1 in a dose dependent manner, 
suggesting that lowered PDX-1 activity may contribute to the development of type 2 
diabetes by causing impaired expression of both GLUT2 and insulin (Ahlgren HW DO 
1998). Interestingly, heterozygosity for mutations in the human PDX-1 gene causes 
MODY 4, a form of diabetes that results from defects in insulin secretion, suggesting 
the PDX-1 function being conserved from mice to humans (Edlund 1998). 
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,6/LVOHW
During ontogeny, the expression of the LIM homeodomain protein islet 1 (ISL1) is 
initiated soon after the islet cells leave the cell cycle, and in adult pancreas, ISL1 is 
expressed in all classes of islet cells. ISL1 is also expressed in mesenchymal cells 
surrounding the dorsal, but not the ventral, evagination of the gut endoderm. In mice 
lacking ISL1 function, the dorsal pancreatic mesenchyme does not form, and there is 
an associated failure of exocrine cell differentiation in the dorsal but not the ventral 
pancreas. In addition, there is a complete loss of differentiated islet cells. Thus, ISL1 
is necessary for the development of the dorsal exocrine pancreas and ISL1 function 
is required for the generation of all endocrine islet cells (AhlgrenHWDO 1997; Edlund 
1998). 
 
3$;SDLUHGER[IDFWRU
Paired box factor 6 (PAX6) is a member of the SD[ gene family and, along with ISL1, 
is expressed in all endocrine cells both during development and in the adult pan-
creas. In mice lacking the PAX6 gene, the numbers of differentiated endocrine cell 
types are markedly reduced and there is a significant reduction in hormone produc-
tion (SanderHWDO 1997; St-OngeHWDO 1997). PAX6 expression cannot be detected 
in E9.5 ISL1 deficient mice, indicating that ISL1 may act upstream of PAX6 during 
pancreatic endocrine differentiation (Edlund 1998).   
 
3$;SDLUHGER[IDFWRU
PAX4 expression is evident in both pancreatic buds as early as E9.5 and becomes 
restricted to the developing B-cells later in ontogeny (Sosa-PinedaHWDO 1997). Inac-
tivation of PAX4 by homologous recombination results in the absence of mature insu-
lin and somatostatin producing cells in the pancreas of homozygous mutant mice. 
Glucagon producing A-cells are present in considerably higher numbers (Sosa-
PinedaHWDO 1997). Thus, PAX4 is possibly responsible for the B-cell fate and, in the 
absence of PAX4, the default fate would be to become a glucagon positive A-cell. 
Therefore, PAX6 might directly or indirectly be involved in repressing glucagon ex-
pression (Edlund 1998). 
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1N[
Nkx2.2 belongs to the Nk2 homeobox family of transcription factors and is expressed 
from at least E8.75 in the dorsal and ventral pancreatic epithelium. Later in develop-
ment, Nkx2.2 is expressed in B-, A- and PP-cells, but not in somatostatin producing 
cells. Mice homozygous for a null mutation of the Nkx2.2gene lack insulin producing 
B-cells and have fewer A- and PP-cells. Further, a large population of islet cells does 
not produce any of the four hormones, but express some B-cell markers such as 
PDX-1 and IAPP, while lacking other definitive B-cell markers including Nkx6.1 and 
GLUT2. Therefore, Nkx2.2 seems to be required for the final differentiation of pan-
creatic B-cells, and in the absence of this member of the Nk2 homeobox family, B-
cells are trapped in an incompletely differentiated state (SusselHWDO 1998). 
 
1N[
Nkx6.1 is another member of the Nk2 homeobox family of transcription factors, which 
is initially (E9.0-9.5) expressed predominantly in the dorsal pancreatic epithelium in a 
subset of PDX-1 positive cells. Later in development, Nkx6.1 becomes restricted to 
differentiated B-cells (JensenHWDO 1996) and preliminary analysis of Nkx6.1 knock-
out mice showed that they have drastically reduced numbers of B-cells, while the 
number of other islet cells remained normal (Edlund 1998). 
 
1HXUR'%(7$ 
NeuroD/BETA2 is a cell-type restricted basic helix-loop-helix (bHLH) transcription 
factor that is expressed in all pancreatic endocrine cells (Edlund 1998; Naya HW DO 
1997). Together with its ubiquitous counterpart, the E2A gene product E12, Neu-
roD/BETA2 binds to the E-boxes of the insulin regulatory region. In NeuroD/BETA2-
deficient mice, endocrine cells still appear, but at markedly reduced numbers: B-cells 
are reduced by ~75%, A-cells by 40%, and D-cells by 20%, and the remaining endo-
crine cells fail to form mature islets (NayaHWDO 1997). Mice carrying the targeted dis-
ruption of the BETA2 gene develop severe early onset diabetes and die perinatally. 
BETA2 is present in the earliest islet precursors within or adjacent to ductal epithelia 
in both +/- and -/- mice. NeuroD is thought to be the earliest marker of differentiating 
endocrine cells and is co-expressed with PAX6, glucagon and insulin (JensenHWDO 
2000 a). Disruption in pancreatic islet morphogenesis occurs after E14.5 in BETA2 
deficient mice. From E17.5 onwards, BETA2 expressing cells are localized exclu-
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sively to islets in +/- mice. The observed increase in the number of apoptotic cells in  
-/- mouse pancreata suggests that BETA2 is required for endocrine islet cell survival 
(NayaHWDO 1997). 
 
1JQ1HXURJHQLQ
Neurogenin3 (Ngn3) is another member of the bHLH family of transcription factors, 
which is supposed to act upstream of NeuroD in a bHLH cascade. Neurogenin3 is 
expressed in a subset of the proto-differentiated PDX-1 positive epithelial cells. A few 
Ngn3 positive cells co-express early endocrine markers, such as ISL1 and PAX6, 
whereas no co-expression with glucagon or insulin could be observed. Ki-67, a prolif-
eration marker is readily detected in Ngn3 positive cells, but not in NeuroD/BETA2 
positive cells. A molecular pathway has been suggested, where Ngn3 positive pre-
cursor cells become committed to endocrine differentiation, marked by activation of 
NeuroD and subsequently ISL1, PAX6 and the hormones, whereas Ngn3 expression 
is extinguished (JensenHWDO 2000 a). Ngn3 expression increases between E9.5 and 
E15.5, but then decreases until day E17.5, such that very few Ngn3 positive cells are 
detectable in neonatal pancreas. In contrast to the findings of Jensen HWDO (2000), 
Apelqvist HW DO (1999) did not observe co-expression of Ngn3 and ISL1 or PDX-1, 
which led to the conclusion that Ngn3 positive cells and post-mitotic endocrine cells 
represent distinct populations. Therefore, Ngn3 positive cells were suggested to be 
endocrine precursor cells that may correspond to the primary (endocrine) fate in a 
lateral specification model (i.e. generation of scattered differentiated cells from an 
initial homogenous field of cells, as in neuronal differentiation) (ApelqvistHWDO 1999). 
Overexpression of Ngn3 in transgenic mice results in an accelerated differentiation of 
pancreatic endocrine cells, paralleled by a depletion of the pool of pancreatic precur-
sor cells, similar to mice genetically altered in different steps of the Notch signaling 
pathway (Apelqvist HW DO 1999; Edlund 1999). Collectively, these data suggest that 
Ngn3 acts as a pro-endocrine gene during pancreatic development, a function analo-
gous to that of Ngn genes in neurogenesis (ApelqvistHWDO 1999). 
 
1RWFKVLJQDOLQJ+(6
Mammalian homologues of the Drosophila hairy and enhancer-of-split factors (HES 
proteins) are negatively acting bHLH proteins that antagonize members of the Neu-
rogenin and NeuroD family (Edlund 1999; Jensen HWDO 2000 a). HES1 mutant ani-
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mals display pancreatic hypoplasia due to accelerated differentiation of endocrine 
cells that results in a depletion of epithelial precursors (JensenHWDO 2000 b). HES1 
is a known downstream component of the Notch-signaling system, which is thought 
to generate endocrine precursor cells by lateral specification. Notch-1, -2, and -3 are 
expressed during pancreas development. Notch-1 is expressed in epithelium at E12 
in the developing mouse pancreas. At E15.5, Notch-1 mRNA is located in the forming 
exocrine tissue, at E17.5, localization of both Notch-1 and -2 in exocrine tissue and 
absence from endocrine tissue is evident. Notch-1 is also absent from most endo-
crine cells at E13.5, although a few PAX6 positive cells are still located in the Notch-1 
positive domain. The decline in Notch expression is marked by increased expression 
of insulin and amylase. The presence of Notch-1 and -2 and their ligands Jagged1 
(also known as Serrate1) and Dll1 (Delta-like gene1) in the pancreatic epithelium 
suggested that the Notch pathway could provide an inhibitory signal and thereby pre-
vent premature differentiation of Ngn3 positive precursor cells (ApelqvistHWDO 1999; 
Jensen HW DO 2000 a). Notch signaling is thought to be critical for the decision be-
tween endocrine and progenitor/exocrine fates in the developing pancreas (Apelqvist
HW DO 1999). Notch signaling appears to control the choice between endocrine and 
exocrine fates, so that lack of Notch-pathway signaling, resulting in high Ngn3 levels 
for example in mice deficient for Dll1 or Notch-3, promotes the endocrine fate. In con-
trast, cells with active Notch-signaling adopt the exocrine fate and/or remain as undif-
ferentiated progenitor cells, allowing the subsequent proliferation, morphogenesis 
and differentiation of the pancreatic epithelial cells (Edlund 1999). 
 
2.3.4 Postnatal pancreatic B-cell growth 
 
Until 15 years ago, the concept was that one was born with all pancreatic B-cells one 
ever had and therefore, insulin resistance would lead to diabetes without change in 
B-cell mass (Bonner-Weir 2000 c). Now the concept that diabetes only results where 
there is inadequate functional mass of B-cells has gained general acceptance. B-
cells actually do compensate for increased demand, resulting from obesity, insulin 
resistance or pregnancy. The new concept is that the B-cell mass is dynamic and 
increases and decreases both in function and mass to maintain glycemic level within 
a very narrow physiological range. The changes in mass can be both in number (hy-
perplasia) and size (hypertrophy). When the B-cell mass cannot increase adequately, 
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diabetes ensues. The general acceptance of dynamic rather than static B-cell mass 
is based on clear evidence of changes in B-cell mass in both normal rodents and 
transgenic or knockout mice. Varying replication rates of B-cells have been observed 
LQYLYR and LQYLWUR, and the presence of neogenesis of islets postnatally and in adults, 
and physiological loss of B-cells indicating turnover of B-cells has led to the new con-
cept (Bonner-Weir 2000 c).  
 
&KDQJHVLQWKH%FHOOPDVVLQQRUPDOURGHQWV
Replication is the major mechanism for adding new B-cells to the pancreas from 
shortly after birth onwards. In rats, a linear increase in the B-cell mass from weaning 
until 3-4 months of age was observed (FinegoodHWDO 1995). Morphometric data ob-
tained from male C57/B6/129 mice ranging from four weeks to six months of age 
show that the B-cell mass expands at least 10-fold and is linearly correlated with 
body weight (Bonner-Weir 2000 a). In a longitudinal study, the addition of new cells 
slowly distended B-cell mass in the male Lewis rat, but from 15 months onwards, hy-
pertrophy of the B-cell was the main mechanism of B-cell mass growth. Besides this 
age-related expansion in B-cell mass, pregnancy induces a stimulation of B-cell pro-
liferation through placental lactogen and cell volumes distend as a functional adapta-
tion. Post partum, the B-cell mass involutes by reduction of the B-cell volume, reduc-
tion of cell proliferation and an increase in B-cell apoptosis (ScagliaHWDO 1995).  
 
%FHOOUHQHZDOE\UHSOLFDWLRQDQGQHRJHQHVLV
As in the embryo, two mechanisms contribute to B-cell renewal in the adult: QHR
JHQHVLV or differentiation from ductal precursor cells and SUROLIHUDWLRQ of differentiated 
B-cells. Islet neogenesis appears frequently in the first few days after birth, and a 
second wave of neogenesis occurs at about weaning (Bonner-Weir 2000 b; Scaglia
HW DO 1995). B-cell replication is significantly higher during late gestation and the 
neonatal period than following weaning. After weaning throughout adult life, both 
neogenesis and a low level of replication is maintained, which can be stimulated for 
example by chronic glucose infusion, treatment with exendin-4, a long lasting GLP-1 
(glucagon-like peptide-1) agonist, and by pancreatectomy (Bonner-WeirHWDO 1993; 
Bonner-WeirHWDO 1989; XuHWDO 1999). Chronic glucose infusion leads to both in-
creased replication and hypertrophy of B-cells, treatment with exendin-4 stimulates 
both replication and neogenesis, resulting in a 40% expansion of the B-cell mass in 
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rodents. After pancreatectomy, both proliferation and neoformation of islet and exo-
crine tissue is observed (Bonner-Weir 2000 c). Similarly, new lobes of pancreas con-
tinue to form in 6-month-old mice (retired breeders), as evidenced by high bromode-
oxyuridine (BrdU) incorporation in some pancreatic lobes (Bonner-Weir 2000 b). The 
signaling responsible for stimulating neogenesis is unknown. ,QYLYR as well as in the 
pancreatic cell line AR42J, GLP-1 and exendin-4 cause endocrine differentiation (Xu
HWDO 1999; ZhouHWDO 1999). There might be functional difference between B-cells 
that can replicate and those that cannot. Adult B-cells are functionally heterogene-
ous, but this heterogeneity has not been correlated to replicative ability or age. It has 
been suggested that those B-cells that replicate might dedifferentiate and transiently 
lose function as they replicate (Bonner-Weir 2000 b). 
 
7XUQRYHURI%FHOOV 
With mathematical modeling of the B-cell mass, normal turnover of B-cells became 
evident. The B-cell mass in adult rodent pancreas can double within about one 
month, due to a 2-3% / 24 hour replication of B-cells. Between 1-2 months and 2-3 
months of age, the B-cell mass does almost double, thereafter it remains rather sta-
ble due to increased apoptosis which approaches the replication rate. Therefore, 
complete replacement of the B-cell population could occur in about one month for a 
rat (FinegoodHWDO 1995). The frequency of apoptotic B-cells was found to be 0.5% 
in the adult rat. As the steady-state replication rate is just over 2% per day, the life-
span of a rat B-cell can be estimated as ~58 days (Bonner-Weir 2000 b; FinegoodHW
DO 1995). 
In the neonatal rat pancreas, the B-cell mass does not increase between 1-3 weeks 
of age, even tough the replication rate observed was higher than in the adult. The B-
cell replication rate was found to be decreased (Scaglia HW DO 1997) and the inci-
dence of apoptotic nuclei in that period was significantly increased as compared to 
slightly younger and older rats (ScagliaHWDO 1997; TrudeauHWDO 2000). The apop-
totic index peaks at 12-14 days of age in Sprague-Dawley and Wistar rats and at 
about 11-13 days of age in BALB/c and NOD mice (TrudeauHWDO 2000). These find-
ings suggest a neonatal wave of neogenesis of B-cells to maintain a constant B-cell 
mass (Scaglia HW DO 1997; Trudeau HW DO 2000). The simultaneous high levels of 
apoptosis and replication of B-cells coincided with a marked change in both insulin-
like growth factor I (IGF-I) and IGF-II as well as IGF-binding proteins (IGFBP) 1 and 
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2, suggesting that the remodeling resulted from an inadequacy of available survival 
factors (PetrikHWDO 1998; ScagliaHWDO 1997). This hypothesis was supported by the 
suppression of the normal neonatal apoptosis by increased persistent IGF-II in trans-
genic mice (HillHWDO 2000). A dysregulation of this process could be detrimental, as 
a fine balance between cell renewal and cell death determines the pancreatic B-cell 
mass. This concept has been supported by two studies, one of which showed a low 
protein diet during pregnancy to increase apoptosis, reduce replication of B-cells, 
reduce pancreatic IGF-II and B-cell mass (PetrikHWDO 1999 b). Furthermore, the ab-
lation of insulin receptor substrate-2 (IRS-2) resulted in reduced B-cell mass, owing 
to decreased survival of differentiating B-cells mediated by the IGF-I receptor 
(Bonner-WeirHWDO 1999; WithersHWDO 1999; WithersHWDO 1998). 
Loss of B-cell mass has been observed in the post partum pancreas, in a rat model 
of transplantable insulinomas, after cessation of glucose infusion in db/db mice and 
in clinical reports as atrophy of islet tissue in pancreas neighboring insulinomas. The 
mechanisms involved varied with the model used; when insulinomas were trans-
planted, the B-cell mass decreased due to increased apoptosis. After stopping glu-
cose infusion, the return from B-cell hypertrophy takes one week, whereas the cell 
function reverts within 24 hours. In the post partum rat pancreas, both increased 
apoptosis and decreased replication rate and a reduction in cell size contributes to 
involution (Bonner-Weir 2000 c; Bonner-WeirHWDO 1989; ScagliaHWDO 1995).  
 
,VOHWFHOOUHQHZDOSUHFXUVRUDQGVWHPFHOOV 
Different areas of the ducts and smaller ductular elements have been suggested to 
harbor VWHP FHOOV, since islet cell budding from ductal structures is present during 
embryogenesis and during postnatal growth or regeneration (Bouwens & Kloppel 
1996; Slack 1995). By definition, stem cells should resemble embryonic cells, the so-
called “proto-differentiated” pancreatic cells that have not yet differentiated into exo-
crine or endocrine tissue. In order to identify such cells, the characteristics of proto-
differentiated cells described in fetal pancreas have to be looked at. In case of the rat 
pancreas, GLUT2, PDX-1 and vimentin are markers that could allow discrimination 
between proto-differentiated and differentiated duct-lining cells (Bouwens 1998; 
MadsenHWDO 1997; PangHWDO 1994). However, a proto-differentiated cell population 
has not yet been found in the duct compartment of normal postnatal rat pancreas and 
therefore, there is no evidence that stem cells exist in the pancreas (Bouwens 1998). 
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Furthermore, it is doubtful that stem cells would be involved in normal pancreatic 
growth or regeneration after injury such as pancreatectomy (Bonner-Weir 2000 c). In 
this model, expansion and differentiation of the duct cells give rise to the substantial 
regeneration (further details are discussed below) (Bonner-Weir 2000 b). 
Another mechanism for tissue regeneration is WUDQVGLIIHUHQWLDWLRQ. Trans-
differentiation is different from stem cell neogenesis in that it involves differentiated 
cells instead of undifferentiated ones. This mechanism consists of re-programming of 
gene-expression, which generally occurs via an intermediate stage of “de-
differentiation”. Thus, certain terminally differentiated cells retain the capacity to 
switch off a number of genes and switch on others resulting in a phenotypic switch. 
Importantly, budding of new B-cells and other hormone positive islet cells has been 
observed in cells of the ductal complex. Transitional forms were noticed that co-
expressed cytokeratin 20 (a ductal characteristic) and insulin as also occurs in the 
fetal and neonatal pancreas (BouwensHWDO 1994). Others reported about “interme-
diate” or “transitional” cells that co-expressed insulin and amylase even within the 
same secretory granule. These observations support the hypothesis that trans-
differentiating acinar and ductal cells can generate new B-cells (Bouwens 1998). The 
most likely source of SUHFXUVRU FHOOV would be pancreatic ducts because the adult 
duct epithelium retains the ability to give rise to all differentiated cell types of the pan-
creas (Bonner-Weir 2000 c). From studies of pancreatic regeneration in rats, the im-
pressive capacity of pancreatic duct cells to expand and differentiate has been 
shown (Bonner-Weir HW DO 1993). PDX-1 expression has been observed after rapid 
replication of duct cells in pancreatectomized rats and therefore, it was hypothesized 
that adult duct cells have a potential to lose their phenotype with replication, reverting 
into pluripotent stem cells that can differentiate into islet cells with appropriate stimuli 
(SharmaHWDO 1999). In normal rodent and human pancreas, single B-cells or small 
extra-islet B-cell clusters (isolated B-cells) occur as a portion of the endocrine com-
ponent of the pancreas. These clusters differ from islets in not being associated with 
the islet sinusoidal vascular system, and by the lack of intercellular contacts with non-
B endocrine cells. In normal rat pancreas, single B-cells account for 0.9% of the total 
insulin-immunoreactive area. In normal human pancreas, these isolated B-cells occur 
much more frequently; they represent 9% of the total insulin-immunoreactive area 
(Bouwens & Pipeleers 1998). In the rat, the appearance of single B-cells can be acti-
vated under different experimental conditions. Since there is no other way of explain-
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ing the presence of single B-cells, those cells have been considered as indirect evi-
dence that B-cell neogenesis occurs normally in human and rodent pancreas 
(Bouwens 1998).  
 
%FHOOUHSOLFDWLRQDQGK\SHUJO\FHPLD 
Glucose is one of the best stimuli for B-cell replication LQYLWUR and LQYLYR (Bonner-
Weir HW DO 1989). It has been suggested that glucose is the driving force for B-cell 
compensation. Mild hyperglycemia, due to inadequate plasma insulin or insulin resis-
tance could signal the B-cell to compensate, including functional adaptation as well 
as enhanced B-cell replication and hypertrophy (Bonner-Weir 2000 c). In contrast to 
mild acute hyperglycemia, chronic or severe hyperglycemia is detrimental. The term 
“glucose toxicity” has been used to describe detrimental effects, such as B-cell death. 
In chronic hyperglycemia, oxidative stress is increased and can lead to apoptosis, 
which can be prevented by administration of an antioxidant (Bonner-Weir 2000 b). 
Additionally, B-cells exposed to high glucose accumulate intracellular proteins modi-
fied with O-linked monosaccharide N-acetylglucosamine (O-Glc-Nac). The accumula-
tion of such modified proteins has been suggested to cause hyperglycemia induced 
B-cell apoptosis (Bonner-Weir 2000 b). Further secondary effects of a hyperglycemic 
environment include loss of glucose-induced insulin secretion (LeahyHWDO 1992) and 
loss of specific B-cell differentiation (JonasHWDO 1999). The loss of glucose induced 
insulin secretion is a reversible process, involving a reduction of glucose transporter 
2 (GLUT2) protein in the B-cells due to reduced GLUT2 expression (Zangen HW DO 
1997). However, the role of the lowered transporter protein in loss of glucose-induced 
insulin secretion is unknown (LeahyHWDO 1992). In the pancreatectomized rat model, 
where animals developed a stable chronic hyperglycemia, a reduction of several islet 
transcription factors involved in B-cell development and differentiation has been ob-
served (JonasHWDO 1999). The changes in transcription factor mRNA levels included 
a decrease in PDX-1, Nkx6.1 and PAX6 mRNA. The examination of mRNA levels of 
genes involved in glucose metabolism showed a decrease of GLUT2, glycerol-
phosphate dehydrogenase, pyruvate carboxylase and glucokinase. These global al-
terations observed in pancreatectomized rat islets were proposed to alter the prefer-
ential stimulation of oxidative metabolism by glucose and thus adversely influence 
glucose stimulated insulin release. In addition, islets of partially pancreatectomized 
rats were markedly hyperplastic and individual B-cells were also hypertrophic, a 
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common feature of many rodent models of type 2 diabetes (JonasHWDO 1999). Pro-
tection from apoptosis in these animals might result from the induction of a variety of 
stress-survival genes, such as those encoding heme oxygenase, Mn-superoxide 
dismutase, glutathion peroxidase, and fatty acid synthetase (FAS) (Laybutt HW DO 
2000). 
 
2.3.5 Incretin hormones and pancreas development 
 
Several hormones have been implicated in pancreas growth and development, in-
cluding the insulinotropic hormones glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP). 
 
*OXFDJRQOLNH SHSWLGH (GLP-1) is a gut-derived hormone, which stimulates post-
prandial insulin secretion and insulin gene transcription (see chapter 2.4.). Due to its 
capability of stimulating the cAMP/protein kinase A transduction system (see chapter 
2.4.) and the induction of immediate early response genes (IEG), which are known to 
be implicated in B-cell growth and differentiation, B-cell growth promoting actions of 
GLP-1 are considerable (ButeauHWDO 1999). Buteau HWDO(1999) showed that both 
GLP-1 and glucose stimulate DNA synthesis in beta (INS-1) cells, as assessed by 
the measurement of tritiated thymidine incorporation. GLP-1 could promote maximum 
cell growth, even at low glucose levels. The fact that glucose and GLP-1 did not act 
additively led the authors to suggest that the two agents act through a common 
mechanism. ,QYLWUR studies using CHO (Chinese hamster ovary) cells, which stably 
expressed the rat GLP-1 receptor (CHO/GLPR), demonstrated that the activation of 
p38 MAP (mitogen activated protein) kinase was triggered by the GLP-1 receptor 
(Montrose-Rafizadeh HW DO 1999). MAP kinases are cytoplasmatic serine/threonine 
kinases that transmit extracellular signals to the nucleus via phosphorylation of tran-
scription factors and other signaling molecules (Cobb & Goldsmith 1995). MAP 
kinases are activated by a number of external stimuli, including growth factors that 
interact with cell surface receptor tyrosine kinases (Cobb & Goldsmith 1995). A num-
ber of receptors that couple to heterotrimeric G proteins have recently been shown to 
stimulate the activity of two members of the MAP kinase superfamily, which includes 
the extracellular signal-regulated kinase (ERK) and p38 MAP kinase (Faure HW DO 
1994; FrodinHWDO 1995; YamauchiHWDO 1997). The activation of MAP kinase path-
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ways best explains the growth-promoting actions of GLP-1 on pancreatic islets 
(Stoffers HW DO 2000), since p38 MAP kinase is known to play an important role in 
various cellular functions, such as phosphorylation of transcription factors, control of 
apoptosis and cell cycle-mediated events (Montrose-RafizadehHWDO 1999). In a re-
cent study by Trümper HWDO (2001 c), the GLP-1- and glucose-induced cell prolifera-
tion, prevention of apoptosis and stimulation of phosphatidylinositol 3-kinase (PI3K) 
associated with insulin receptor substrate (IRS) isoforms was shown. PI3K is an en-
zyme that has been implicated in cell growth and differentiation (Withers & White 
2000). Inhibition of the GLP-1 induced PI3K activation, using the PI3K inhibitors 
LY294003 and wortmannin, led to the conclusion that the growth promoting action of 
both glucose and GLP-1 on beta (INS-1) cells involves the PI3K signal transduction 
pathway (ButeauHWDO 1999). Further, activation of protein kinase (PK) B alpha and 
PKB beta isoforms and also of glycogen synthase kinase-3 and forkhead transcrip-
tion factor (FKHR) was demonstrated. Therefore, pleiotropic activation of PI3K/PKB 
at the level of IRS-molecules, PI3K and PKB isoforms was found to occur following 
GLP-1 stimulation in beta (INS-1) cells. Signaling pathways of glucose metabolites, 
MAP kinase and protein kinase A converge at PKB, which plays a central role in mi-
togenic and anti-apoptotic regulation of B-cells (TrümperHWDO 2000 a; TrümperHWDO 
2001 c). Wang HWDO (1999) examined the influence of GLP-1 on the B-cell specific 
transcription factor PDX-1. The authors could show that GLP-1 increases PDX-1 
DNA binding activity, an effect that could be inhibited by LY294002 (Buteau HW DO 
1999). The peptide was also found to increase PDX-1, GLUT2, glucokinase, and in-
sulin mRNA expression (ButeauHWDO 1999; WangHWDO 1999). These data suggest 
that GLP-1 acts as a growth factor in isolated rat islet tissue and therefore, the pep-
tide could be important for B-cell mass expansion under conditions of increased insu-
lin demand. Recent LQ YLYR studies further confirmed some of the results obtained 
from beta (INS-1) cells. Both GLP-1 and exendin-4 induced an increase in PDX-1 
protein levels in pancreata from healthy C57Bl/6 mice, an effect that was abolished 
by co-administration of the GLP-1 antagonist exendin 9-39. Administration of ex-
endin-4 to GLP-1 receptor knockout mice (ScrocchiHWDO 1996) did not increase the 
level of PDX-1 protein, which confirms that exendin-4 acts solely through the GLP-1 
receptor. Morphometric analysis of islets in exendin-4 treated animals showed an 
increase in islet size as compared to a saline treated control group (Stoffers HW DO 
2000). In exendin-4 treated rats, the B-cell mass expanded due to both increased 
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replication and neogenesis (XuHWDO 1999). Similarly, GLP-1 administration to young 
normoglycemic Umeå mice stimulated islet growth (Edvell & Lindstrom 1999). Recent 
morphometric studies concerning alterations of the endocrine pancreas of GLP-1R 
knockout mice showed a change of the topography of the islets cells, with A-cells 
being located more centrally in the islets. Furthermore, the absence of GLP-1R sig-
naling leads to a shift from large to small and medium-sized islets (LingHWDO 2001). 
Only very few data are available concerning the effect of JOXFRVHGHSHQGHQWLQVXOLQR
WURSLFSRO\SHSWLGH (GIP, see chapter 2.4.) on pancreatic B-cell proliferation and sur-
vival. It was shown that GIP induces cellular proliferation and inhibits glucose- and 
starvation-induced apoptosis in beta (INS-1) cells by activation of pleiotropic signaling 
pathways (Trümper HW DO 2001 b). GIP stimulates PKA/cAMP responsive element 
binder (CREB), MAP kinase and PI3K in a dose-dependent manner synergistically 
with glucose. Activation of PI3K was associated with IRS isoforms and PI3K iso-
forms. Downstream of PI3K, GIP stimulated PKB alpha and PKB beta isoforms, gly-
cogen synthase kinase, FKHR and p70S6K, a regulator of translation. The data indi-
cate that mitogenic effects of glucose and GIP in B-cells may not only be caused by 
activation of transcription but also by initiation of protein translation. Signaling mod-
ules activated by GIP were dependent on glucose metabolism and calcium influx and 
were tightly linked by multiple converging pathways (TrümperHWDO 2001 a; Trümper
HW DO 2001 b; Trümper HWDO 2000 b). Therefore, both currently known incretin hor-
mones influence growth and survival of the pancreatic B-cell mass. 
 
2.4 The enteroinsular axis 
 
2.4.1 Definition  
 
The term HQWHURLQVXODU D[LV has been introduced by Unger and Eisentraut and it 
comprises hormonal, neural and substrate stimulation, i.e., all signals originating from 
the gut that reach the endocrine pancreas to stimulate, reduce or modify the secre-
tion of insulin, glucagon, somatostatin and PP (Creutzfeldt 1997; Creutzfeldt & Nauck 
1992; Unger & Eisentraut 1969). 
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2.4.2 Components of the enteroinsular axis 
 
2.4.2.1 Neural components 
 
Activation of the vagus following ingestion of nutrients is thought to augment insulin 
output via cephalic, gastropancreatic and enteropancreatic vagovagal reflexes. Sev-
eral gastrointestinal neuropeptides with insulinotropic inhibitory or stimulating action 
have been demonstrated in pancreatic nerves, e.g. VIP (vasoactive intestinal poly-
peptide), GRP (gastrin releasing peptide), somatostatin and NPY (neuropeptide tyro-
sine) (Creutzfeldt 1997; Creutzfeldt & Nauck 1992).  
 
2.4.2.2 Hormonal components (incretin candidates) 
 
The term LQFUHWLQHIIHFW denotes the phenomenon that glucose elicits a higher B-cell 
secretory response when administered via the gut as compared to the intravenous 
route. In the 1930’s, the name incretin was introduced for an insulinotropic gut factor 
when insulin was the only known pancreatic hormone (LaBarre & Still 1930). ,QFUHWLQ
KRUPRQHV today are defined as endocrine insulinotropic factors released from the gut 
in response to nutrient or more strictly glucose ingestion (Creutzfeldt & Nauck 1992). 
Under experimental conditions, a large number of peptides have been found to mod-
ify (stimulate or inhibit) the function of the endocrine pancreas. Gut factors, such as 
cholecystokinin, gastrin and secretin have been shown to stimulate insulin secretion 
only in pharmacological doses and are therefore considered to be of no or only minor 
importance as incretin hormones. To qualify as incretin candidate, an insulinotropic 
gut hormone must release insulin glucose dependently at plasma concentrations 
achieved by glucose or nutrient ingestion. Currently, there are only two gut hormones 
that fulfill the required characteristics for incretin hormones: GIP (glucose-dependent 
insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) (Creutzfeldt & Nauck 
1992).
 
2.4.3 Glucagon-like peptide-1 
 
GLP-1 has first been described in the late 1980`s (Göke HW DO 1991; Göke HW DO 
1988) and was considered an incretin hormone with powerful insulinotropic effects 
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(FehmannHWDO 1995). GLP-1 (7-36 amide) is the predominant product of intestinal 
processing of proglucagon and is localized in enteroendocrine L-cells that are mainly 
found in the lower gut. Indirect stimulation by the cholinergic enteric nervous system 
and hormonal signals from the upper gut have been discussed to play a role in the 
secretion of this incretin hormone. ,Q YLWUR studies, using fetal rat intestinal mucosa 
cells as well as perfused rat intestine, demonstrated that GIP is a secretagogue for 
GLP-1. In contrast, exogenous GIP does not lead to an increment in plasma GLP-1 in 
humans. The exact mechanisms that control GLP-1 release still need to be evalu-
ated. This incretin hormone stimulates the insulin secretion of pancreatic B-cells in 
the presence of elevated glucose levels and enhances proinsulin gene expression 
(FehmannHWDO 1995; GefelHWDO 1997; Holst 1994; Thorens 1995). In low concen-
trations, GLP-1 releases somatostatin from pig and rat pancreata. At physiological 
glucose levels, GLP-1 inhibits glucagon secretion in various animal species; this ef-
fect is more pronounced at low than high glucose levels. It was suggested that the 
effect of GLP-1 on insulin and somatostatin release is direct, while the effect on glu-
cagon secretion is indirect, possibly mediated by a paracrine effect on the soma-
tostatin cells. This agrees with the concept of intraislet interactions in which both in-
sulin and somatostatin are known as inhibitors of glucagon secretion. GLP-1 has 
several extrapancreatic effects on different organs, which are discussed elsewhere in 
detail (Fehmann HWDO 1995). GLP-1 is degraded by dipeptidyl peptidase present in 
serum (Holst 1994). 
Specific receptors for GLP-1 were first detected on RINm5F cells and consecutively 
on several other insulinoma cell lines. Furthermore, the receptor was found on soma-
tostatin secreting cells. The GLP-1 receptor shares sequence homology with the re-
ceptors for VIP, secretin, GHRH (growth hormone releasing hormone), PTH (parat-
hormone), calcitonin, and glucagon. All of these receptors, including the GLP-1 re-
ceptor, are coupled to G proteins. There is evidence that the GLP-1 receptor is func-
tionally coupled to the adenylate cyclase system by a stimulatory G protein. GLP-1 
enhances intracellular cAMP in pancreatic islet cells and several insulinoma cell 
lines. It also depolarizes cells and induces a rise in free cytosolic Ca2+ concentration, 
followed by an increase of the glucose-induced insulin release in rat pancreatic B-
cells. After binding to its receptor, GLP-1 is internalized into B-cells; it is currently un-
known, whether the receptor protein itself is being internalized after ligand binding 
(FehmannHWDO 1995). 
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2.4.4 Glucose-dependent insulinotropic polypeptide 
 
GIP was first isolated and identified by Brown and co-workers (BrownHWDO 1969). In 
man, the peptide is solely expressed in endocrine K-cells of the upper small intestine 
and in rats, expression of the GIP mRNA is found both in K-cells of the small intestine 
and the submandibular gland (BuchanHWDO 1978; FehmannHWDO 1995; TsengHWDO 
1993). GIP (rat, human, porcine and bovine) is a 42 amino acid polypeptide (GIP(1-
42)), which is derived from proteolytic processing of its preprohormone precursor 
(Gallwitz HWDO 1996). GIP is released into the blood stream in response to nutrient 
absorption, or more strictly, mainly by carbohydrate and fat absorption. The degree to 
which fat or glucose stimulate GIP release is species dependent. In rodents and pigs, 
whose diets usually contain less than 10% energy as fat, carbohydrates are more 
potent than fat in stimulating GIP release. In contrast, in man, who normally con-
sumes a diet relatively high in lipid content, fat is the more potent stimulator of GIP 
release (Yip & Wolfe 2000). Moreover, the postprandial level of circulating GIP is de-
pendent on meal size, and the contribution of the enteroinsular axis (see chapter 2.5) 
is proportionately greater after a large meal. The half-life of human GIP has been es-
timated at roughly 20 minutes as measured by radioimmunoassay (Brown HW DO 
1975; ElahiHWDO 1979; NauckHWDO 1989; Yip & Wolfe 2000). GIP is degraded by 
dipeptidyl peptidase IV present in serum (Morgan 1996). 
 
2.4.5 GIP receptor 
 
After being released from enteroendocrine K-cells, GIP reaches the specific GIP re-
ceptor via the blood stream. The structure, signal transduction and receptor-mediated 
functions will be discussed in the following chapter. 
 
2.4.5.1 GIP receptor structure  
 
Usdin et al. first cloned the rat GIP receptor in 1993; subsequently, cloning of the 
hamster and human GIP receptor has been performed (GremlichHWDO 1995; Usdin
HWDO 1993; VolzHWDO 1995; YasudaHWDO 1994). GIP receptor mRNA is present in 
pancreas, stomach, intestine, adrenal cortex, heart, lung, brain, endothelium of major 
blood vessels and adipose tissue of the rat (UsdinHWDO 1993). The receptor is a gly-
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coprotein belonging to the secretin/VIP (vasoactive intestinal polypeptide) family of 
receptors, a seven transmembrane G protein-coupled receptor family that includes 
receptors for e.g. secretin, VIP, glucagon, GLP-1, GHRH (growth hormone releasing 
hormone) and PACAP (pituitary adenylyl cyclase-activating polypeptide). The ligands 
in this receptor family are bound by their large N-terminal domain, where the first 222 
amino acids are necessary for ligand binding and receptor coupling to cAMP produc-
tion (GellingHWDO 1997; WheelerHWDO 1995).  
 
2.4.5.2 GIP receptor signal transduction 
 
GIP binding to its receptor activates a heterotrimeric stimulatory G-protein, which in 
turn activates adenylate cyclase. The resulting cAMP and a subsequent increase in 
Ca2+ influx via voltage-gated calcium channels (Ca-VS) are thought to represent the 
major signaling pathways by which GIP exerts its insulinotropic effect on pancreatic 
B-cells (LuHWDO 1993 a; LuHWDO 1993 b; WheelerHWDO 1995). GIP presumably initi-
ates activation of protein kinase A, which in turn may modify the gating properties of 
the potassium channels, whereas glucose operates via glycolysis-generated adeno-
sine triphosphate, which is known to close the channels. The resulting depolarization 
causes an opening of voltage-gated calcium channels whereby the intracellular cal-
cium concentration increases. This in turn starts insulin exocytosis (Figure 2.1 A/B). 
Recently, an additional but distinct signal transduction pathway for GIP was de-
scribed via PI3K mechanism (Yip & Wolfe 2000). The receptor undergoes rapid and 
reversible homologous receptor desensitization, typical for G protein coupled recep-
tors (FehmannHWDO 1991; TsengHWDO 1996 a). 
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Figure 2.1 (A) Proposed interaction of GIP with isolated B-cells. After binding and activa-
tion of GIP to its receptor, elevated cyclic adenosine monophosphate levels activate protein kinase A, 
which in turn phosphorylates regulatory sites on the adenosine triphosphate-sensitive potassium 
channel. Concomitantly, glucose regulates the potassium channels via adenosine triphosphate gener-
ated in glycolysis (Holst 1994).  
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Figure 2.1 (B) Proposed mechanism of stimulation of insulin release by GIP. After clo-
sure of the adenosine triphosphate-sensitive potassium channels (K-ATP) by the joint action of glu-
cose and GIP, the B-cell depolarizes, which causes voltage-sensitive calcium channels (Ca-VS) to 
open. This leads to an increase in free intracellular calcium levels, which in turn induces exocytosis of 
insulin. Repolarization is achieved by opening of calcium-sensitive potassium channels (K-Ca) (Holst 
1994). 
 
2.4.5.3 GIP receptor mediated functions 
 
([WUDSDQFUHDWLFIXQFWLRQRI*,3
When GIP was first isolated, the peptide was named “gastric inhibitory polypeptide” 
according to its inhibiting effect on gastric acid secretion. Since this effect was not 
observed under physiological conditions, the peptide has been renamed “glucose-
dependent insulinotropic polypeptide”, due to its main physiologic property (Morgan 
1996; Yip & Wolfe 2000). Yip HWDO have first described functional GIP receptors pre-
sent on adipose tissue in 1998. GIP can increase fatty acid incorporation, glucose 
uptake and lipoprotein lipase synthesis and release in adipose tissue. It further inhib-
its glucagon-induced lipolysis and increases insulin-binding affinity in adipocytes (Yip
HWDO 1998).  
GIP reduces glucagon-stimulated hepatic glucose production, an effect, which is 
more pronounced in the presence of insulin (Fehmann HW DO 1995). GIP receptor 
mRNA could not be detected in the liver, using LQVLWX hybridization and therefore, the 
effect might be indirect. GIP receptor mRNA has been detected in the brain but a pu-
tative effect of GIP is yet unknown, although a possible transmitter role has been dis-
cussed (Morgan 1996). A role for GIP in regulation of adrenal steroid release has 
been suggested from finding GIP receptor mRNA in the inner layers of the rat adrenal 
cortex (Yip & Wolfe 2000).
 
3DQFUHDWLFIXQFWLRQRI*,3
GIP has insulinotropic function on pancreatic B-cells; the peptide stimulates insulin 
secretion in the presence of elevated glucose levels and enhances proinsulin gene 
transcription. Pre-exposure of B-cells to GIP enhances the insulin secretory response 
during a subsequent stimulation with glucose or other secretagogues (“priming ef-
fect”) (Fehmann HW DO 1995). Recent studies also revealed a mitogenic and anti-
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apoptotic effect of GIP on B-cells via pleiotropic signaling pathways (see 2.3.5) 
(TrümperHWDO 2001 a; TrümperHWDO 2001 b).  
GIP stimulates glucagon secretion but only in the presence of 5 mmol/l glucose or 
lower. Therefore, GIP does not influence A-cells under physiological conditions. 
GIP is a weak stimulator of somatostatin secretion in the perfused pancreas of the rat 
(FehmannHWDO 1995). 
 
2.4.6 Neural mediation of the incretin effect
 
In man, the nervous system does not contribute much to the incretin stimulation of 
insulin secretion after oral glucose. In some animal species (e.g. rat, mouse), sweet 
tasting nutrients or mixed meals provoke a rapid, pre-absorptive burst of insulin se-
cretion. Therefore, gastric instead of oral glucose administration reduces glucose tol-
erance for example in rats, which underlines the importance of the cephalic phase of 
insulin release in this species (Creutzfeldt 1997; Creutzfeldt & Nauck 1992). 
 
2.4.7 Quantification of the incretin effect 
 
McIntyre HWDO (1964) and Elrick and coworkers (ElrickHWDO 1964) first evidenced the 
difference in B-cell secretory response to oral and intravenous glucose. Three years 
later, another workgroup found the plasma insulin response to isoglycemic intrave-
nous glucose to be only 30-40% of that seen after oral glucose ingestion (Perley & 
Kipnis 1967). The incretin effect has been quantified in several investigations 
(Creutzfeldt & Nauck 1992; NauckHWDO 1986 b). Its contribution was 20-60% of the 
C-peptide response after glucose ingestion, depending on the size of the glucose 
load (NauckHWDO 1986 b). GIP has been considered to be the more potent incretin 
hormone than GLP-1 (Creutzfeldt & Nauck 1992; Nauck 1999; NauckHWDO 1993 a). 
Studies using a GIP-receptor antagonist revealed a 72% reduction of the postpran-
dial insulin response in rats (TsengHWDO 1996 b) and therefore, GIP seems to play a 
dominant role in mediating postprandial insulin release. 
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2.4.8 Pathophysiology of the enteroinsular axis in diabetes 
 
Besides insulin resistance, impaired insulin secretion is a characteristic of type 2 dia-
betes mellitus. The total volume of pancreatic islets can be reduced up to 60-70% in 
type 2 diabetics as compared to weight-matched normal subjects (Rahier HW DO 
1989). Taking into account that the islet reduction has to approach 90% before meta-
bolic consequences occur, functional defects may also play a role in type 2 diabetic 
subjects (Eisenbarth 1986). Comparison of the B-cell response to oral and isoglyce-
mic intravenous glucose revealed a clearly reduced incretin effect in type 1 and 2 
diabetic patients (Nauck HWDO 1986 a; SuzukiHWDO 1990; TronierHWDO 1985). The 
effects of the incretin hormones GIP and GLP-1 in diabetic patients and animal mod-
els of both type 1 and 2 diabetes have been studied separately and it was evidenced 
that the GLP-1 effect is preserved in diabetes whereas GIP administration had no 
effect on the insulin response (Creutzfeldt HWDO 1996; Elahi HW DO 1994; Linn HW DO 
1996; NauckHWDO 1993 c; NauckHWDO 1993 b; YoungHWDO 1999). Several mecha-
nisms contributing to the reduced insulinotropic action of GIP have been discussed. 
Firstly, the homologous desensitization of the GIP receptor has been proposed from 
findings in diabetic rats, which exhibited largely elevated GIP serum levels and sig-
nificantly higher duodenal GIP mRNA expression as compared to normal rats (Tseng
HWDO 1996 a). ,QYLWUR studies using LGIPR2 cells exposed to elevated GIP levels re-
vealed a reduction in GIP-stimulated cAMP formation and therefore, the chronic de-
sensitization of the GIP receptor by its ligand was proposed (Tseng HW DO 1996 a). 
Further, LQYLWUR studies revealed a higher expression of RGS2 (regulator of G protein 
signaling) after GIP stimulation and showed an interaction of RGS2 and the α subunit 
of the G protein complex (Tseng & Zhang 1998). Agonist induced stimulation of 
RGS2 expression is therefore thought to result in a feedback desensitization of the 
stimulated receptor. Secondly, Holst HW DO (1997) discussed the possibility of a re-
duced or defective expression of the GIP receptor in diabetics. Actually, a more re-
cent study revealed a decreased receptor expression in diabetic fatty Zucker rats, 
which was suggested to explain the decreased effectiveness of GIP administration on 
insulin release (LynnHWDO 2001). So far, no mutations of the GIP receptor gene have 
been found to correlate with the development of diabetes mellitus but geneticists 
were encouraged to look in the GIP receptor gene or gene regulation to investigate 
this possibility (HolstHWDO 1997). MiyawakiHWDO. (1999) generated GIP receptor defi-
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cient mice, which only exhibited mild glucose intolerance. Some investigators have 
assumed adaptive developmental mechanisms to compensate for the loss of one 
incretin hormone receptor early in development (Baggio HW DO 2000; Lewis HW DO 
2000). In mice, lacking GLP-1 receptor function (ScrocchiHWDO 1996), elevated GIP 
serum levels were observed and considered to play a role as such compensatory 
factor (PedersonHWDO 1998).   
 
2.5 Generation of GIPRdn transgenic animals 
 
The generation of transgenic mice, expressing a dominant negative GIP receptor has 
been described in detail by Volz (1997). The following shall only give a brief review of 
the methods and results presented by Volz(1997). 
 
2.5.1 Targeted mutation of the human GIP receptor 
 
The targeted mutation of the human GIP receptor was supposed to result in a sus-
tained GIP binding affinity but a loss in its ability to induce signal transduction (domi-
nant negative GIP receptor, GIPRdn). 
The third intracellular G-protein coupling loop of the GIP receptor is essential for sig-
nal transduction. Therefore, the cDNA of the human GIP receptor was mutated in the 
region, coding for the third intracellular loop by introducing a point mutation at nucleo-
tide position 1018-1020 (amino acid position 340) (Ala → Glu) and a deletion of 24 
base pairs/8 amino acids (nucleotide position 955-978/ amino acid position 319-326), 
using oligonucleotides containing the specific mutations.  
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Figure 2.2
 
Amino acid sequence of the human GIP receptor and areas where tar-
geted mutations have been performed. The cDNA of the human GIP receptor was mutated in 
the region coding for the third intracellular loop by introducing a point mutation at amino acid position 
340 (Ala → Glu, red) and a deletion of 8 amino acids at position 319-326 (green) (Volz 1997).  
 
2.5.2 ,QYLWUR analysis of the mutated GIP receptor 
 
Stably transfected CHL (Chinese hamster leucoblastom) cells were used for compar-
ing the affinity of GIP to the wildtype and the mutated GIP receptor. The binding affin-
ity of GIP has been shown to be nearly equal for both receptors (KD wildtype : KD 
GIPRdn = 0.22*19-9 M : 0.35*10-9 M). Furthermore, cAMP production following GIP 
stimulation has been compared in CHL-cells expressing the wildtype and the mutated 
GIP receptor. In CHL-cells expressing the wildtype GIP receptor, the cAMP concen-
tration rose with increasing GIP concentration (between 10-12 and 10-8 M hGIP(1-42)). 
In contrast, CHL-cells expressing the mutated GIP receptor do not exhibit an in-
crease in intracellular cAMP concentration following GIP stimulation. Therefore, the 
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mutated GIP receptor carries the desired properties of a dominant negative receptor: 
normal binding affinity to its ligand but loss of cAMP induced signal transduction.  
 
2.5.3 Generation of mutant mice 
 
The mutated cDNA of the human GIP receptor was cloned into the ;EDI+LQGIII site 
of the RIP1 vector (Hanahan 1985), which includes the rat proinsulin gene promoter 
II. This vector has been successfully used to achieve B-cell specific expression of 
cDNA constructs in transgenic mice (Hanahan 1985; KatoHWDO 1994). Parts of the 
vector were released by 6DOI/6VSI digestion and the resulting fragments were sepa-
rated using an ethidiumbromide-free gel. After further purification and dialysis, the 
RIP1-GIPRdn cDNA construct was injected into the male pronucleus of mouse zy-
gotes (CD-1 females) at a final concentration of 400 copies/pl. The zygotes were then 
transferred into cycle-synchronized females. Twelve out of 57 offspring were identi-
fied GIPRdn transgenic by PCR analysis (see 3.1).  
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3. Research Design and Methods 
 
3.1 Transgenic animals 
 
Transgenic animals were generated as previously described by Volz-Peters HW DO 
(2000) and Volz (1997) (Model patent number: DE/11.08.99/19836382). Transgenic 
males were bred onto a CD1 background (Charles River-Wiga, Germany). Animals 
investigated in the present study were hemizygous male and female transgenic mice 
and age- and sex-matched non-transgenic littermate controls. Mice were maintained 
on a 12-h light, 12-h dark cycle and fed standard rodent chow (Diet 1: Altromin 
C1324, Germany, Table 3.1) and tap water ad libitum. For determination of urine glu-
cose excretion, a total number of 112 animals were investigated. 24 animals were 
included in monthly blood glucose and body weight determination. At the age of ten, 
30 and 90 days, blood/serum glucose and serum insulin levels of 48 animals were 
measured. Serum glucose and insulin values were determined in 23 animals at eight 
months of age. HbA1c levels were measured in the same animals at four months of 
age. For OGTT, a total number of 20 animals were investigated. Food and water in-
take was determined in 25 animals. The total number of animals for morphometric 
analysis of the pancreas in each age group (10, 30 and 90 days) was 16 (four male 
and four female GIPRdn transgenic as well as four male and four female non-
transgenic mice). For morphometric analysis of the kidneys, 23 animals were studied 
altogether. 54 animals were included in the determination of the 12-month survival 
rate. In order to investigate the influence of carbohydrate intake on the metabolic 
state, a separate group of mice was fed a carbohydrate-restricted diet (Diet 2: Al-
tromin C1009, Germany, Table 3.1) from weaning until four months of age, after-
wards they were fed the standard rodent chow. 38 animals were included in monthly 
blood glucose and body weight determination. HbA1c levels were measured in 31 ani-
mals at four months of age. Food and water intake was determined in 26 animals. 43 
animals were included in the 12-month survival study.  
The numbers of animals studied in the different investigations are listed in Tables and 
Figures according to their age, sex and transgenity.  
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Table 3.1 Composition of the different diets 
 
 Diet 1: 
Altromin 
C1324 
Diet 2: 
Altromin 
C 1009 
Protein (%) 18.5 17.0 
Fat (%) 3.8 7.0 
Fiber (%) 6.0 34.0 
Ashes (%) 6.8 8.0 
Disaccharides (%) 5.3 1.3 
Energy (kcal/kg) 2,473.7 1,343.6 
 
3&5$QDO\VLV  
 
Transgenic mice were identified by polymerase chain reaction using 5’-ACA GNN 
TCT NAG GGG CAG ACG NCG GG-3’ sense (Tra1) and 5’-CCA GCA GNT NTA 
CAT ATC GAA GG-3’ antisense (Tra3) oligonucleotides. These primer sequences 
bind to both the human cDNA of the mutated GIP receptor and the endogenous mur-
ine GIP receptor (Figure 3.1). Since the sequence of the murine GIP receptor has not 
been evaluated yet, oligonucleotides were chosen in areas where the known se-
quences of the human, rat and hamster GIP receptor are highly conserved. In case of 
sequence variation within these animals, oligonucleotide synthesis was performed 
allowing all nucleotides (“N” in primer sequence) to integrate (Volz 1997). 
 
Figure 3.1 PCR result 
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Figure 3.1 shows a PCR result of GIPRdn transgenic and control mice. At the beginning 
of each row, the PUC Mix Marker #8 (M) is shown. Probes from control animals show a DNA fragment 
of 500 base pairs (endogenous GIP receptor). Transgenic animals exhibit a DNA-fragment of 140 
base pairs (mutated GIP receptor, GIPRdn). The number of the animals is shown underneath the PCR 
printout, transgenic animals are written in bold numbers. 
 
a) Method 
 
Materials used are listed under 3.1.b. 
Tail tip biopsies were taken at weaning and stored at –80°C until assayed. DNA was 
extracted from tail tips as previously described (Hoeflich HW DO 1999); the tail tip of 
approximately 0.4 cm length was digested over night in 200 µl Kawasaki buffer and 
12 µl proteinase K (20 mg/ml). Subsequently, proteinase K was inactivated by heat-
ing for 15 minutes at 95°C. Large components were separated by centrifugation (2 
min/10000xg) and the supernatant was diluted 1:5 in sterile redistilled water.  
19 µl of the Master Mix and 1 µl of the 1:5 diluted digest were mixed carefully in PCR-
analysis cups (Eppendorf, Germany), which were then placed in a Mastergradient 
thermocycler (Eppendorf, Germany) and the program was run. In the meantime, a 
2% agarose solution containing 2 µl ethidium bromide per 100 ml was casted in a 
gel-casting chamber (Easy Cast™, PeqLab, Germany). After the gel was polymer-
ized, the tray was put into the Easy Cast™ gel chamber (PeqLab, Germany) and the 
chamber was filled with 1*TAE buffer. 
After amplification, 4 µl loading dye (MBI Fermentas, Germany) was added to each 
sample and then transferred into the sample wells of the agarose gel. At the begin-
ning of each row, 12 µl PUC Mix Marker #8 (MBI Fermentas, Germany) was placed 
in a well in order to allow estimation of amplified fragment size. Electrophoresis was 
run for approximately 45 min at 90 volt. Subsequently, the gel was placed on an Ul-
traviolet Transilluminator and a Polaroid picture (AGS, Germany) was taken for result 
documentation. 
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b) Material 
 
Proteinase K (Roche, Germany): 20 mg/ml diluted in redistilled water 
 
Kawasaki buffer:  30 mg MgCl2 *6 H2O (Sigma, Germany) 
186 mg KCl (Sigma, Germany) 
500 µl Tween 20 (Sigma, Germany) 
diluted in 100 ml 20 mM Tris/HCl pH 8.3 (Roth, Germany) 
  
 Primer concentration (Tra1, Tra3) 10 pmol/µl each (Genzentrum/DNSynthese,  
  Germany) 
 
 dNTP (Eppendorf, Germany): dATP, dGTP, dTTP, dCTP, 100 mM each 
 
 Master Mix: PCR-KIT (Quiagen, Germany) 
  dNTP 1mM   4 µl 
  10*Buffer   2 µl  
  MgCl2   1.25 µl 
  Primer sense (Tra1) 1 µl 
  Primer antisense (Tra3) 1 µl 
  Redistilled water  5.7 µl 
  Q-solution   4 µl 
  Taq polymerase  0.125 µl 
 
EDTA 0.5 M pH 8.0 (stock solution) 
  186.1 g EDTA (Roth, Germany) 
  800 ml distilled water 
 add approximately 20 g sodium hydroxide pellets (Merck,  
 Germany) diluted in 50 ml distilled water until pH 8.0 is reached 
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50* TAE stock solution:  
  121 g Tris base (Roth, Germany) 
  28.55 ml glacial acetic acid (Sigma, Germany) 
  50 ml 0.5 M EDTA pH 8.0 (Roth, Germany) 
  ad 500 ml distilled water 
 
Agarose gel (GIBCO BRL, Germany):  
  2 g Agarose/100 ml 1*TAE buffer, add 2 µl  
  ethidium bromide (Merck, Germany) 
 
Program for DNA amplification  
a) 4 min 94°C 
  b) 1 min 94°C 
  c) 1 min 60°C 
  d) 2 min 72°C 
  e) 10 min 72°C 
  f) Hold on 4°C 
Steps b) - d): 35 cycles 
 
3.2 Urine glucose 
 
In order to determine the onset of diabetes, urine glucose was measured at 14, 21 
and 30 days of age in 86 mice (25 male and 16 female control mice, 18 male and 27 
female transgenic mice). In addition, a separate group of 10-day-old mice, including 
nine male and nine female transgenic and four male and four female control mice, 
was screened for urinary glucose excretion. Up to 21 days of age, urine was col-
lected onto the test stripe by gently rubbing the vulva/preputium. In older animals, 
spot urine samples were taken by carefully squeezing the bladder with two fingers if 
no spontaneous urine could be obtained. Urinary glucose excretion was measured 
semiquantitatively using the glucose-oxidase-peroxidase method (Combi-screen® 
Glucose, ANALYTICON, Germany). 
Furthermore, spot urine samples were taken from 110 and 140 days old animals of 
the different diet groups both after a twelve-hour fasting period and two hours after 
refeeding. 
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3.3 Blood/serum glucose and serum insulin values 
 
Blood was collected from the retroorbital plexus under ether anesthesia in fed 10- 
day-old mice and 1-, 3-, and 8-month-old mice. The number of animals included four 
male and four female controls and four male and four female transgenic mice each at 
ten days and one and three months of age. At eight months of age, eleven male con-
trols, six male transgenic mice and three female controls and three female transgenic 
animals were investigated. From the age of three months onwards, the animals were 
starved over night (twelve hours) and fed for two hours prior to sampling. Serum was 
separated by centrifugation (ten minutes, 10,000 x g) and stored at –80°C until as-
sayed. In 10-day-old animals, blood glucose was determined immediately using the 
Precision QID System (Medisense, Germany). Serum glucose of 1-, 3-, and 8-month-
old mice was measured using a Hitachi 717 autoanalyzer and adapted reagents from 
Roche (Germany). Serum insulin in mice from all age groups was quantified using 
the Ultrasensitive Mouse-Insulin ELISA kit (Mercodia, Sweden). 
Twelve-hour fasting blood glucose levels were determined from two groups of ani-
mals fed different diets (see 3.1) in monthly intervals between 80 and 230 days of 
age. The number of animals investigated is listed in Figures 4.1 and 4.2. Blood sam-
ples (4 µl) were directly placed onto a sensor electrode from a small incision of the 
tail tip. Blood glucose was determined using the Precision Q.I.D. system (Medisense, 
Germany). 
 
3.4 Glycated hemoglobin (HbA1c) 
 
Glycated hemoglobin (HbA1c) levels were measured in 4-month-old mice using 
freshly hemolyzed blood samples. Reagents were obtained from Recipe Chemicals 
and Instruments (Germany); measurements were performed on a modular automated 
analyzing system (Merck, Germany), which was kindly provided by Recipe Chemicals 
and Instruments. The numbers of animals investigated in both diet groups are shown 
in Figure 4.4 and 4.5. 
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3.5 Oral glucose tolerance test (OGTT) 

An oral glucose tolerance test (OGTT) was performed at four months of age in seven 
male controls and seven male transgenic mice as well as six female controls and four 
female transgenic mice constantly fed standard rodent chow. Animals were fasted 
twelve hours and a basal blood sample was collected from the nicked tail tip for de-
termination of serum insulin and blood glucose (t=0 minutes). Mice were then gently 
fixed and 1.5 mg glucose per gram body weight was administered orally. Further 
blood samples were collected at 10, 20, 30, 60, 90 and 120 minutes for determination 
of blood glucose, and at 45 and 120 minutes for determination of serum insulin lev-
els. During glucose challenge, blood glucose was determined in freshly hemolyzed 
samples (Kabe, Germany) by automated analyzer technique (Merck, Germany). 
For the determination of serum insulin, blood was collected from the nicked tail tip by 
gently stripping the tail and collecting the blood in heparinized capillary tubes. Serum 
was separated from cellular components by centrifugation (10 min, 10,000 x g), col-
lected and stored at –80°C until assayed. Serum insulin levels were determined us-
ing a RIA kit (Linco Research, USA).  
 
3.6 Subcutaneous glucose tolerance test (SCGTT) 
 
The subcutaneous glucose tolerance test (SCGTT) was performed at 4 months of 
age in 24 animals (six male and six female controls and six male and six female 
transgenic mice) constantly fed standard rodent chow. In the first experiment, 130 µl 
of a 2 M glucose solution in 0.9% NaCl was administered subcutaneously. After a 7-
day-recovery period, the same animals were used in a second experiment where 130 
µl of a 2 M glucose solution in 0.9% NaCl with 8% GIP (Bachem, Germany) was ad-
ministered. The third experiment followed another 7-day-recovery period using 8% 
GLP-1 (Bachem, Germany) in a 2 M glucose solution in 0.9% NaCl. The test proce-
dure was equal within experiments: After a 15-hour fasting period, a basal blood 
sample for the determination of fasted serum insulin levels and blood glucose was 
collected from the tail tip as described in 3.5. Further blood samples were collected at 
10, 20, 30, 60, 90 and 120 minutes after subcutaneous administration of the glucose 
solution for determination of blood glucose, using the Precision QID System 
(Medisense, Germany). At 10 minutes, a blood sample (100 µl) was collected for the 
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determination of serum insulin levels. The serum was separated and insulin meas-
ured as described in 3.5. The area under the glucose curve (AUC glucose) was cal-
culated using the basal blood glucose values as a baseline under the curve that re-
sulted from the different glucose values after administration of the glucose solutions. 
The program GraphPad Prism 3.0 (GraphPad Software, USA) was used for the cal-
culation of the AUC glucose.  
 
3.7 Daily food and water intake, urine volume  

Daily food and water intake was surveyed five times in a two-day interval, both at four 
and seven months of age in animals fed the different diets (see 3.1). In addition, the 
24-hour urine volume was determined using metabolic cages (Tecniplast, Germany) 
at the age of seven months. The numbers of animals investigated are shown in Table 
4.5 and 4.6. 
 
3.8 Serum parameters 
 
Blood was collected under ether anesthesia, by puncture of the retroorbital plexus. 
Serum was separated by centrifugation (10 min, 10,000 x g) and stored at –80°C un-
til assayed. Various serum parameters, including sodium, chloride, creatinine, urea, 
cholesterol, triglycerides, total protein and albumin were determined at three months 
of age in four male controls, four male transgenic mice, four female controls and four 
female transgenic mice, using a Hitachi 717 autoanalyzer (Boehringer, Germany) and 
adapted reagents from Roche (Germany). 
 
3.9 Body and organ weights  

The same animals that were used for determination of fasted blood glucose levels 
were weighed in monthly intervals between 80 and 230 days of age after the twelve-
hour fasting period. Organ weights were determined at 90 days of age as described 
elsewhere in detail (Hoeflich HW DO 1999); briefly, organs were removed, carefully 
separated from adjacent tissues and weighed to the nearest mg. For the calculation 
of gastric and intestinal content, the gastrointestinal tract was weighed before and 
after removal of the contents. At the age of 10, 30 and 90 days, body weight was de-
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termined in fed mice to the nearest 0.1 g. In 30- and 90-day-old animals, the body 
weight was corrected for gastric and intestinal content. The numbers of animals in-
vestigated are shown in Table 4.8. 
 
3.10 Pancreas preparation and morphometric analysis 
 
Morphometric analysis of the pancreas was performed at the age of 10, 30 and 90 
days. The number of animals investigated at each age group was four male controls, 
four male transgenic mice, four female controls and four female transgenic mice. 
Mice were killed by exsanguination under ether anesthesia and blood was collected 
for determination of glucose and insulin levels as described above. The pancreas 
was removed immediately, carefully separated from adjacent tissues, weighed to the 
nearest mg, placed in a tissue capsule on a piece of foam-rubber sponge to avoid 
distortion and fixed in 10% neutral buffered formalin. For the 10-day age group, an LQ
VLWX fixation was performed before removal of the pancreas to protect the organ from 
damage. After fixation at room temperature for 24 hours the pancreas was routinely 
processed and embedded in paraffin. The pancreas was sectioned perpendicular to 
its longitudinal axis into parallel slices of 1 mm thickness, with the first cut positioned 
randomly within an interval of 1 mm length at the splenic end of the pancreas. Slices 
were placed in tissue capsules with the right cut surface facing downward, and paraf-
fin embedding was finished. Approximately 5 µm thick serial sections for histology 
were cut with a HM 315 microtome (Microm GmbH, Germany) and mounted on 3-
aminopropyltriethoxy-silane-treated glass slides. Photographs of hematoxylin and 
eosin (H&E) stained sections, showing the complete cut surface of all pancreas 
slices, were taken at a final magnification of 11x using a Wild M 400 photomacro-
scope (Wild, Switzerland). At the beginning of each set, an object micrometer was 
photographed under the same conditions for calibration; prints of all negatives were 
made at a constant setting of the enlarger. Morphometric evaluation was carried out 
on a Videoplan® image analysis system (Zeiss-Kontron, Germany) attached to a mi-
croscope by a color video camera. The cross-sectional area of the pancreas was de-
termined planimetrically by circling the cut surface on the prints. Measurements of 
islet profiles and the various endocrine cell types were carried out on immunohisto-
chemically stained sections (see below). Images were displayed on a color monitor at 
an 850x final magnification, and the profiles of islets or endocrine cells were meas-
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ured planimetrically by circling their contours with a cursor on the digitizing tablet of 
the image analysis system. Cavalieri‘s principle was used to estimate the volume of 
the embedded, i.e. shrunken pancreas (V(Pan)s) as well as the volume of pancreatic 
islets (V(Islet,Pan)s) (Gundersen & Jensen 1987; Wanke HW DO 1994). The volume of 
pancreas (V(Pan)) before embedding was calculated from the pancreas weight divided 
by the specific weight of mouse pancreas (1,08 mg/mm3) (WankeHWDO 1994). A cor-
rection factor for tissue shrinkage due to histological processing was calculated for 
each organ by dividing the volume of the pancreas before embedding by the volume 
of the embedded pancreas. Assuming the same extent of shrinkage for islets and the 
whole organ, the total volume of pancreatic islets (V(Islet,Pan)) was calculated as the 
product of V(Islet,Pan)s and the individual correction factor. The volume density of the 
islets in the pancreas (Vv(Islet/Pan)) was calculated dividing the V(Islet,Pan) by the V(Pan). 
The volume density of the various endocrine cells in the islets (Vv(X-cell/Islet)) was cal-
culated by division of the sum of cross-sectional areas of A-, B-, D- and PP-cells, re-
spectively, by the sum of cross-sectional areas of all islet profiles (Weibel 1979). The 
total volume of the various endocrine cell types (V(X-cell,Islet)) was obtained from the 
product of the volume density of the endocrine cell-type in the islets and the total islet 
volume. 
Isolated B-cells (insulin positive single cells and small clusters of insulin positive cells 
that were not contained within established islets) were quantified separately as an 
index for islet neogenesis (PetrikHWDO 1999 a; XuHWDO 1999). The volume density of 
isolated B-cells in the pancreas was obtained by dividing the sum of cross-sectional 
areas of isolated B-cells by the sum of cross-sectional areas of whole pancreas. The 
total volume of isolated B-cells was obtained from the product of their volume density 
in the pancreas and the total volume of the pancreas. 
 
3.11 Immunohistochemistry of pancreatic tissue 
 
The indirect immunoperoxidase technique (Nakane & Pierce 1967) was applied to 
localize insulin, glucagon, somatostatin and pancreatic polypeptide (PP) containing 
cells. All required antisera were purchased from DAKO Diagnostika (Germany). Sec-
tions were deparaffinized in xylene, rehydrated in a descending ethanol series and 
washed in distilled water. Sections were then incubated in 1% hydrogen peroxide in 
phosphate-buffered saline (PBS) (pH 7.4) for 15 minutes to block endogenous per-
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oxidase activity, followed by a 10-minute washing in PBS (pH 7.4). Tissue sections 
were then pre-incubated with normal rabbit serum (detection of insulin) or normal 
swine serum (detection of glucagon, somatostatin and PP) for 30 minutes to reduce 
non-specific binding. Subsequently, slides were incubated for two hours with guinea 
pig anti-porcine insulin (dilution: 1:2,000), rabbit anti-human glucagon (dilution: 
1:500), rabbit anti-human somatostatin (dilution: 1:300) or rabbit anti-human pancre-
atic polypeptide (dilution: 1:700), respectively. All antisera were diluted in PBS (pH 
7.4) and incubations were performed at room temperature in a humidity chamber. 
After a 10-minute washing in PBS, horseradish peroxidase conjugated rabbit anti-
guinea pig IgG or porcine anti-rabbit IgG (diluted 1:50 in PBS containing 5% (vol/vol) 
mouse serum) was applied for one hour. The slides were washed in PBS for 10 min-
utes and immunoreactivity was visualized using 3,3’ diaminobenzidine tetrahydro-
chloride dihydrate (Fluka Chemie, Germany) as chromogen. Tissue sections were 
counterstained with Mayer s` hemalaun solution, dehydrated in an ascending series of 
alcohols, cleared in xylene and mounted under glass coverslips using Histofluid® 
(Superior, Germany). 
Specificity controls included substitution of primary antisera with nonimmune serum 
and omission of the secondary antiserum. 
 
3.12 Urine protein analysis 
 
In order to evaluate clinical features of kidney damage, urine protein analysis was 
performed. Urine samples of six male controls, six male transgenic mice and three 
female controls and three female transgenic mice were collected in monthly intervals 
between 56 and 240 days of age. Urine samples were always taken between two 
and three o’clock in the afternoon and immediately stored at -80 °C until assayed. 
The same animals were used for qualitative and quantitative morphologic analysis of 
the kidneys at the age of 240 days (see below). 
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3.12.1 Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) 
 
a) Methods 
 
Materials used are listed below. 
All urine samples were examined within one week. First, urine creatinine concentra-
tion was measured, using an automated analyzer technique (Hitachi, Merck, Ger-
many). Urine samples were then diluted to a creatinine content of 1.5 mg/dl, but at 
least 1:2 with sample buffer. Subsequently, the diluted samples were heated in a 
thermoblock TB1 (Biometra, Germany) for 10 minutes at 100°C for denaturation of 
the proteins. In the meantime, a SDS-12% polyacrylamide gel was casted in a gel-
casting chamber (Mini-Protean III, Biorad, Germany) and covered with isopropanol. 
After polymerization, the stacking gel was casted onto the SDS-12% gel; a comb for 
forming sample wells was immediately placed in the still fluid stacking gel. When the 
stacking gel was fully polymerized, the comb was removed and the gel was placed 
into an electrophoresis cell (Protean III, Biorad, Germany), which was then filled with 
running buffer to the top of the inside cell. The samples, a broad molecular weight 
standard (Biorad, Germany) and a mouse albumin standard (Biotrend, Germany) di-
luted 1:100 in sample buffer were then loaded onto the gel and electrophoresis was 
run for 60 minutes at 200 volt. The gel was removed from the glass frame and silver 
staining was performed due to a standard protocol (see 9.1). Clearly visible gel bands 
were registered and gels were photographed for documentation. Finally, gels were 
dried according to the manufacturers protocol (see 9.2), using the DryEase™Mini-Gel 
Drying System (Novex, Germany) for long-term storage. 
 
b) Materials  
 
Sample buffer 
 Distilled water  : 1 ml 
 Tris/HCl (Roth, Germany) 0.5 M pH 6.8 : 0.25 ml 
 Glycerol (Merck, Germany) : 0.2 ml 
SDS (Sigma, Germany) 10%  : 0.4 ml 
Bromphenol blue (Sigma, Germany) 0.05% : 0.125 ml 
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Tris/HCl 0.5 M pH 6.8 
 Tris base (Roth, Germany) : 6.075 g 
 ad 60 ml distilled water, adjust pH using 1N HCl (Merck, Germany) 
 
Running buffer (stock) 
 Tris base (Roth, Germany) : 30.3 g 
 Glycine (Merck, Germany) : 144 g 
 ad 1 l distilled water 
 
Running buffer (ready to use) 
 Stock solution : 40 ml 
 SDS (Sigma, Germany), 10%  : 4 ml 
 ad 400 ml distilled water 
 
SDS-12% polyacrylamide gel 
 Distilled water : 3.5 ml 
 Tris/HCl (Roth, Germany) 1.5 M, pH 8.8 : 2.5 ml 
 SDS (Sigma, Germany) 10% : 100 µl 
 Acrylamide (Roti Phenol, Germany) : 4.0 ml 
 Ammonium persulfate  
         (Biorad, Germany) 10% : 50 µl 
 Tetraethylethylenediamine  
                   TEMED (Sigma, Germany) : 5 µl 
 
Stacking gel 
 Distilled water : 6.1 ml 
 Tris/HCl (Roth, Germay) 0.5 M, pH 6.8 : 2.5 ml 
 SDS (Sigma, Germany) 10% : 100 µl 
 Acrylamide (Roti Phenol, Germany) : 1.3 ml 
 Ammonium persulfate  
         (Biorad, Germany) 10% : 50 µl 
 Tetraethylethylenediamine  
                   TEMED (Sigma, Germany) : 5 µl 
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3.12.2 Western blot analysis 
 
In order to clarify whether a lane of approximately 67 kDa in the SDS-PAGE reflects 
albumin, Western blot analysis was performed from the urine samples of 240-day-old 
animals.  
  
a) Methods 
 
Materials used are listed below. 
For Western blot analysis, a SDS-12% polyacrylamide gel was run as described 
above. After electrophoresis, gels were placed on a pre-wetted nitrocellulose mem-
brane (Schleicher & Schüll, Germany) between three layers of absorbent paper im-
bibed with buffer, and fiber pads each side, and the sandwich was set in the gel 
holder cassette. Two cassettes were placed into the electrode module, which was 
then inserted in the buffer tank along with a frozen cooling unit (Mini Trans-Blot Cell, 
Biorad, Germany). After filling the tank with Towbin buffer, the transfer was run over 
night at 30 volt. The next day, the membranes were dyed with ponceau S solution 
(Sigma, Germany) to confirm blotting was achieved. After washing in Tris buffered 
saline (TBS, pH 8.3), blocking was performed in 1% bovine serum albumin (BSA, 
Sigma, Germany) for one hour to avoid non-specific binding of the antibody probe to 
the membrane. Then incubation with rabbit anti-mouse albumin antibody probe (Biot-
rend, Germany; 1:300 in TBS-Tween and 1% BSA) was performed for three hours. 
The membrane was then incubated with horseradish peroxidase conjugated swine 
anti-rabbit antibody (DAKO Diagnostika, Germany; 1:1000 in TBS-Tween and 1% 
BSA) for one hour. After washing three times in TBS-Tween for ten minutes, immuno-
reactivity was visualized using 3,3’ diaminobenzidine tetrahydrochloride dihydrate 
(Fluka Chemie, Germany) as chromogen. Membranes were photographed and 
stored in a light protected cassette. 
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b) Materials 
 
Towbin buffer (stored at 4°C) 
 Tris base (Roth, Germany) : 3.03 g 
 Glycine (Merck, Germany) : 14.4 g  
 Distilled water : 800 ml 
 Methanol (Merck, Germany) : 200 ml 
 
Tris buffered saline (TBS) 10* stock solution (stored at 4°C)  
 Tris base (Roth, Germany) : 60.6 g 
 Sodium chloride (Merck, Germany) : 87.6 g 
 ad 1 l distilled water, adjust pH 7.5 using 1N HCl (Merck, Germany) 
  
TBS-Tween  
 1* TBS (10* TBS stock solution diluted 1:10) 
 0.05% Tween (Sigma, Germany) 
 
DAB (3,3’ diaminobenzidine tetrahydrochloride dihydrate)  
 DAB (Fluka Chemie, Germany) : 5 ml 
 Tris/HCl 50 mM pH 7.3 : 25 ml 
 Hydrogen peroxide (Merck, Germany), 30% : 10 µl 
 
3.13 Immunohistochemistry of the kidneys 
 
Kidneys used for immunohistochemistry were fixed by orthograde perfusion as de-
scribed under 3.14. Instead of glutaraldehyde, a 4% paraformaldehyde in PBS (pH 
7.4) was used for perfusion and kidneys were post-fixed LQVLWX by immersion in 4% 
paraformaldehyde for 24 hours. Both kidneys were cut into parallel transversal slices, 
half of which were embedded in paraffin for immunohistochemistry and the other half 
was embedded in plastic as described in 3.15. 
The indirect immunoperoxidase technique (Nakane & Pierce 1967) served to localize 
the extracellular matrix proteins collagen IV, laminin and fibronectin. Sections were 
deparaffinized, rehydrated, and endogenous peroxidase was blocked as described in 
3.11. The slides were then washed in tris-buffered saline (TBS) (pH 7.6) for 10 min-
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utes and proteinase K (Dako Diagnostika, Germany) was applied for 30 minutes at 
37°C to improve the accessibility of the antibodies to target sites within the tissue. 
After washing the slides in TBS for 10 minutes, tissue sections were pre-incubated 
with normal swine serum for 30 minutes at room temperature. Subsequently, slides 
were incubated with rabbit-anti human placental type IV collagen (Quartett, Ger-
many), dilution 1:40 in TBS, rabbit anti-mouse laminin (DCS, Germany), dilution 1:50 
in TBS, or rabbit-anti human placental fibronectin (Biocarta, Germany), dilution 1:100 
in TBS, in a humidity chamber for two hours at 37°C. After a 10-minute washing in 
TBS, porcine anti-rabbit IgG (diluted 1:100 in TBS containing 5% (vol/vol) mouse se-
rum) was applied for one hour; incubation took place at 37°C in a humidity chamber. 
Then slides were washed in TBS for 10 minutes and immunoreactivity was visualized 
using Sigma fast DAB (3,3’ diaminobenzidine; Sigma, Germany) tablets. The DAB 
tablet and the urea hydrogen peroxide tablet were dissolved in 5 ml of TBS and then 
the tissue sections were covered with the solution and incubated for 5 minutes. Tis-
sue sections were counterstained with Mayer s` hemalaun solution, dehydrated in an 
ascending series of alcohols, cleared in xylene and mounted under glass coverslips 
using Histofluid (Superior, Germany). 
Specificity controls included substitution of primary antisera with non-immune serum 
and omission of the secondary antiserum. 
 
3.14 Kidney preparation and morphometric analysis 
 
The numbers of animals investigated at four and eight months of age are listed in 
Tables 4.13 and 4.14.
For morphometric analysis, kidneys were fixed by orthograde perfusion at constant 
pressure of 100 mm Hg. The animals were killed by ether inhalation, the abdominal 
cavity and thorax were immediately opened and a needle to which the perfusion 
tubes were attached was inserted into the left ventricle of the heart. The vascular sys-
tem was pre-flushed with PBS (pH 7.4, 37 °C) for 20 seconds and then a 3% glu-
taraldehyde solution (37 °C) was perfused for five minutes; an incision of the inferior 
vena cava served as outlet for the perfusate. The kidneys were post-fixed LQVLWX by 
immersion in 3% glutaraldehyde for 2 days before further processing. Both kidneys 
were then carefully removed and trimmed free of attached tissue before weighing to 
the nearest mg on a precision balance (Mettler Instrument Corporation, Germany). 
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The length of each kidney was documented before it was cut into parallel transversal 
slices of approximately 2 mm thickness, with the first cut positioned randomly in a 1 
mm interval from one of the poles. The kidney slices were placed into tissue capsules 
onto a foam rubber sponge to avoid distortion and routinely processed for plastic em-
bedding in a Citadel 1000 (Shandon, Germany). Embedding in glycolmethacrylate 
and methylmethacrylate was performed as previously described (Hermanns HW DO 
1981). Approximately 1.5 µm thick sections for histology were cut using a Reichert-
Jung 2050 rotary microtome (Cambridge Instruments, Germany). Sections of each 
kidney slice were stained with H&E, PAS (Periodic Acid Schiff stain) and a modified 
protocol for a combined PASM-PAS (Periodic acid silver methenamine-PAS) dye, 
respectively (see attachment). Photographs of PAS stained sections, showing the 
complete cut surface of all kidney slices, were taken at a final magnification of 15x 
using a Wild M 400 photomacroscope (Wild, Switzerland). At the beginning of each 
set, an object micrometer was photographed under the same conditions for calibra-
tion; prints of all negatives were made at a constant setting of the enlarger. Mor-
phometric evaluation was carried out on a Videoplan® image analysis system (Zeiss-
Kontron, Germany) attached to a microscope by a color video camera. The cross-
sectional area of the kidney sections was determined planimetrically by circling the 
cut surface on the prints. Measurement of glomerular profiles was carried out on 
PASM-PAS stained sections. Images were displayed on a color monitor at an 850x 
final magnification (25x objective), and the profiles of glomeruli were measured 
planimetrically by circling their contours with a cursor on the digitizing tablet of the 
image analysis system. Cavalieri‘s principle was used to estimate the volume of the 
embedded, i.e. shrunken kidney (V(Kid)s) (Gundersen & Jensen 1987). The volume of 
the kidneys (V(Kid)) before embedding was calculated from the kidney weight divided 
by the specific weight of mouse kidney (1.05 mg/mm3). A correction factor for tissue 
shrinkage due to histological processing was calculated for each organ by dividing 
the volume of the kidneys before embedding by the volume of the embedded kid-
neys. Assuming the same extent of shrinkage for glomeruli and the whole organ, the 
mean glomerular volume (v(Glom)) was calculated as the product of mean glomerular 
area, shape coefficient (1.40) and the individual correction factor, divided by the size 
coefficient (1.04) as described elsewhere in detail (Wanke 1996; Weibel & Gomez 
1962). 
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3.15 Histological techniques 
 
a) Paraffin histology 
 
Organs were fixed by immersion in 10% neutral buffered formalin for 24 hours. After 
fixation, the organs were sliced and representative parts were placed in tissue cap-
sules. The tissues were routinely processed in a Histomaster 2050/DI (Bavimed, 
Germany) and embedded in paraffin. Approximately 5 µm thick sections for histology 
were cut using a HM 315 microtome (Microm GmbH, Germany); sections were trans-
ferred into a water bath and mounted on glass slides (Marienfeld, Germany). Rou-
tinely, sections were stained with H&E (for paraffin embedded tissue); additional 
staining was performed if necessary (PAS, Gomori’s silver stain).  
 
b) Frozen sections 
 
For determination of lipid, frozen sections were cut using a microtome (Leitz, Ger-
many) and stained with Fat red. Staining protocols are listed in the attachment. 
 
c) Plastic histology 
 
Organs were fixed by immersion in 10% neutral buffered formalin for 24 hours or by 
perfusion with 3% glutaraldehyde (details are given in chapter 3.14). After fixation, 
tissue samples were placed in tissue capsules and processed in a Citadel 1000 
(Shandon, Germany) for 18 hours. Subsequently, tissue capsules were transferred 
into a solution containing equal amounts of hydroxymethylmethacrylate (Fluka Che-
mie, Germany) and methylmethacrylate (Riedel de Haën, Germany); immersion of 
the tissue pieces in this solution took place at 4°C on a shaker for 18 hours. Tissue 
capsules were then brought into “solution A”, containing 338 mg of benzoylperoxide 
with 25% water (Merck, Germany), 20 ml methylmethacrylate, 60 ml hydroxymethyl-
methacrylate, 16 ml ethyleneglycol monobutylether (Merck, Germany) and polyethyl-
ene glycol 400 (Merck, Germany). After immersion for four hours at 4°C on a shaker, 
tissue pieces were placed in plastic cups and embedded, using 60 µl of dimethylani-
lin (Merck, Germany) in 40 ml of solution A as starter for polymerization. Cups were 
immediately placed into a water bath (4°C) making sure that the distance between 
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the cups was at least 3 cm. Polymerization took place at 4°C over night. On the next 
day, the casted blocks were removed from the cups and approximately 1.5 µm thick 
sections were cut on a Reichert-Jung 2050 rotary microtome (Cambridge Instru-
ments, Germany). Sections were transferred into a water bath (40-50°C) and 
mounted on glass slides. Tissue sections were left on a heating stage (60°C) for 30 
minutes before staining. Routinely performed staining procedure was H&E; additional 
staining was performed if necessary (PAS, PASM-PAS). Staining protocols are listed 
in the attachment. 
 
3.16 Twelve-month survival  
 
Two groups of GIPRdn transgenic and control mice were studied until the age of 
twelve months, one of them was constantly fed standard rodent chow (Diet 1) and the 
other was fed the carbohydrate-restricted diet from weaning until four months of age 
(Diet 2). The time of death was documented for each animal that died within the 12-
month period and the cause of death was examined by complete necropsy including 
paraffin or plastic histology if necessary. 
Number of animals studied per group: 
Diet 1: male control: 18, male transgenic: 9, female control: 7, female transgenic: 20 
Diet 2: male control: 11, male transgenic: 7, female control: 13, female transgenic: 12 
 
3.17 Data Presentation and Statistical Analysis  
 
Statistical significance of differences between two groups (quantitative-stereological 
kidney findings at four months of age) was calculated by non-parametric Mann-
Whitney U test using the SPSS 10.0 program for Windows (Leibniz Rechenzentrum, 
Germany). If more than two groups were tested, the general linear model procedure 
(GLM) was used in order to calculate the least squares means (LSM); comparison of 
the LSM of different groups was performed using the student’s t-test (SAS version 
6.4, SAS Institute, Germany). P values < 0.05 were considered significant. Mor-
phometric results (kidney, pancreas) were corrected for embedding shrinkage using 
the individual correction factor. Data are presented as means ± SEM, the SEM was 
calculated dividing the SD by the square root of the number of animals examined. 
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4. Results 
 
4.1 Urine glucose 
 
a) Animals receiving standard rodent chow 
 
To determine the onset of diabetes mellitus in GIPRdn transgenic mice, urinary glu-
cose excretion was measured at the age of 10, 14, 21 and 30 days. Animals were 
weaned at 28 days of age and had free access to standard rodent chow. Urinary glu-
cose excretion was not detectable in any transgenic or control animal at 10 days of 
age. At two weeks of age, glucose was present in urine samples of 1/18 male and 
1/27 female transgenic mice. All transgenic mice demonstrated severe glucosuria 
(>1,000 mg/dl) at three and four weeks of age. Glucosuria was not detected in con-
trols at any age studied (Table 4.1). 
Further, glucose excretion in urine was measured in a group of animals at 110 and 
140 of age, including seven male transgenic and three female transgenic animals. All 
transgenic animals from group Diet 1 showed fasting and postprandial glucosuria 
(>1,000 mg/dl). 
 
 
  
 
Age (days) 
 
Group (n) 10 14 21 30 
     
Co male 0/4 0/25 10/25 10/25 
Tg male 0/9 1/18 18/18 18/18 
Co female 0/4 0/16 10/16 10/16 
Tg female 0/9 1/27 27/27 27/27 
 
Table 4.1 Onset and incidence of diabetes mellitus in GIPRdn transgenic mice. Onset 
of diabetes in transgenic (tg) mice occurs between 14 and 21 days. Control (co) mice do not show 
glucosuria at any time point investigated. Data are presented as number of animals showing gluco-
suria / number of animals investigated in each group. 
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b) Animals receiving the carbohydrate restricted diet until four months 
 
Urine glucose was measured at 110 and 140 days of age. At 110 days of age, only 
one third of both male (2/7) and female (4/12) transgenic animals showed fasted glu-
cosuria. Postprandially, all transgenic males and 8/12 transgenic females examined 
showed glucosuria. After the diet was changed (at 120 days of age), all transgenic 
males showed fasted and postprandial glucosuria, whereas one third of fasted and all 
fed female transgenic animals exhibited severe glucosuria (>1,000 mg/dl). 
 
4.2. Blood/serum glucose and serum insulin levels  

a) Animals receiving standard rodent chow 
 
%ORRGDQGVHUXPJOXFRVHOHYHOV
From 80 days of age onwards, fasting blood glucose levels were determined in 
monthly intervals. Glucose values were significantly (> 4-fold) elevated in transgenic 
mice, as compared to age- and sex-matched littermate controls, irrespective of the 
age at sampling. From 80 to 230 days of age, blood glucose levels increased in 
transgenic males (p<0.05) and females (n.s.). Blood glucose levels of control mice 
remained stable over the period sampled (Fig. 4.1 A/B).  
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(B) Female animals 
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Figure 4.1 (A/B). Blood glucose values of animals receiving Diet 1 between 80 and 
230 days of age; (A) male animals, (B) female animals. Blood glucose values of both male 
(m) and female (f) transgenic (tg) mice are significantly higher than those of sex-matched controls (co). 
Data are means ± SEM; (n), number of animals investigated. * p<0.05 vs. control, † p<0.05 vs. previ-
ous time point. 
 
In addition, blood glucose levels were determined in fed animals prior to sacrifice. In 
10-day-old transgenic mice, blood glucose levels did not differ from those of control 
mice. Serum glucose concentration was elevated 3.9-fold (p<0.05) in one-month-old 
male transgenic mice, as compared to male littermate controls and 4.0-fold (p<0.05) 
in female transgenic mice vs. female littermate controls. At three months of age, 
postprandial serum glucose was 7.0-fold (p<0.05) elevated in male and 4.4-fold 
(p<0.05) elevated in female transgenic mice vs. sex-matched controls (Table 4.2).  
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   Age (days)   
Group (n) 10 30 90 
    
Co male (4) 110 ± 10 205   ± 14 152     ± 18 
Tg male (4) 111 ± 17 807* ± 22 1065* ± 39 
Co female (4) 114 ± 14 153  ±   9 197    ± 29 
Tg female (4) 106 ± 17 616* ± 51 865*   ± 33 
 
Table 4.2 Blood and serum glucose concentrations (mg/dl), Diet 1. Values at the age of 
10 days represent blood glucose, values at 30 and 90 days of age represent serum glucose levels. 
From 30 days of age onwards, transgenic (tg) mice exhibit severe hyperglycemia. Data are means ± 
SEM; (n), number of animals investigated. * p<0.05 vs. control (co). 
 
Two-hour postprandial serum glucose levels were largely elevated in 8-month-old 
transgenic males and females vs. controls (p<0.05) (Table 4.3). 
 
Group (n) Serum glucose Serum insulin 
 (mg/dl) (ng/ml) 
   
Co male (11)  193  ± 6 4.28*  ± 0.82 
Tg male (6) 1061*  ± 51 0.39*  ± 0.07 
Co female (3)  159  ± 2 4.52*  ± 0.44 
Tg female (3)  869*  ± 64 0.51*  ± 0.03 
 
Table 4.3 Postprandial serum glucose and insulin concentrations of 8-month-old 
mice, Diet 1. Transgenic mice (tg) exhibit severe hyperglycemia and hypoinsulinemia as compared 
to age- and sex-matched controls (co). Data are means ± SEM; (n), number of animals investigated; * 
p<0.05 vs. control. 
 
6HUXPLQVXOLQOHYHOV
At the age of 10 days, mean serum insulin levels were reduced 1.8-fold in male and 
2.2-fold in female transgenic animals as compared to sex-matched littermate controls 
(n.s.). Insulin values in one-month-old transgenic males were reduced 18.8-fold 
(p<0.05) and 6.1-fold (p<0.05) in female transgenic mice vs. sex-matched controls. 
Postprandial insulin levels were significantly reduced in 3-month-old male (6.9-fold) 
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and female transgenic mice (4.3-fold) vs. control mice (Table 4.4). Further, postpran-
dial serum insulin levels were determined at eight months of age and found to be 
significantly lower in GIPRdn transgenic males and females, as compared to age- and 
sex-matched littermate controls (Table 4.3). 
 
   Age (d)   
Group (n) 10 30 90 
    
Co male (4) 0.14 ± 0.03 5.63  ± 1.74 2.43  ± 1.59 
Tg male (4) 0.08 ± 0.01 0.30* ± 0.04 0.35* ± 0.12 
Co female (4) 0.60 ± 0.22 3.23  ± 0.39 0.81  ± 0.09 
Tg female (4) 0.27 ± 0.13 0.53* ± 0.15 0.19* ± 0.06 
 
Table 4.4 Serum insulin concentrations (ng/ml), Diet 1. Serum insulin levels are lower in 
transgenic (tg) animals at 10 days of age and are significantly lower in GIPRdn transgenic mice at 30 
and 90 days of age vs. age-matched control (co) mice. Data are means ± SEM; (n), number of animals 
investigated. * p<0.05 vs. control. 
 
b) Animals receiving the carbohydrate restricted diet until 4 months 
 
Fasting blood glucose levels were measured between 80 and 230 days of age in 
monthly intervals. All transgenic animals exhibited significantly higher blood glucose 
levels than sex- and diet-matched control mice, irrespective of the age at sampling. In 
all transgenic animals, blood glucose levels increased significantly between 110 and 
140 days of age, the interval when the diet was changed from carbohydrate-restricted 
to standard diet (Fig. 4.2 A/B). In male and female transgenic animals a 1.8- and 1.3-
fold increase was documented, in male and female control mice, the rise of blood 
glucose levels between 110 and 140 days was not significant (1.4- and 1.2-fold, re-
spectively).  
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Figure 4.2 (A/B) Blood glucose values between 80 and 230 days of age of animals 
receiving Diet 2; (A) male animals, (B) female animals. Blood glucose values of both male 
(m) and female (f) transgenic (tg) mice are significantly higher than those of sex-matched controls (co). 
Blood glucose values of all transgenic animals increase significantly between 110 and 140 days of 
age. The time point of diet change is indicated with an arrow. Data are means ± SEM; (n), number of 
animals investigated. * p<0.05 vs. control, † p<0.05 vs. previous time point. 
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c) Comparison of both diet groups 
 
Until 110 days of age, transgenic animals fed standard rodent chow showed signifi-
cantly higher fasted blood glucose levels than transgenic animals fed the carbohy-
drate-restricted diet. After the diet was changed, transgenic animals of the group 
Diet 2 still showed lower fasted blood glucose levels than transgenic animals perma-
nently fed standard rodent chow, however, this difference was not statistically signifi-
cant (Fig. 4.3 A/B).  
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Figure 4.3 (A/B) Comparison of blood glucose values of animals receiving Diet 1 and 
Diet 2 between 80 and 230 days of age; (A) male animals, (B) female animals. Blood 
glucose values of both male (m) and female (f) transgenic (tg) mice receiving Diet 1 are higher than 
those of transgenic animals receiving Diet 2. The time point of diet change is indicated with an arrow. 
Data are means ± SEM; (n), number of animals investigated; a-c: p<0.05, a: Diet 1 transgenic vs. con-
trol (co), b: Diet 2 transgenic vs. control, c: Diet 1 transgenic vs. Diet 2 transgenic.  
 
4.3 Glycated hemoglobin (HbA1c) levels 

In order to evaluate whether high blood glucose levels in transgenic mice are associ-
ated with high levels of glycated hemoglobin (HbA1c), HbA1c levels were determined 
at four months of age.  
 
a) Animals receiving standard rodent chow 
 
HbA1c levels were significantly higher in transgenic males and females as compared 
to age- and sex-matched control mice (Fig. 4.4). 
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Figure 4.4 Glycated hemoglobin of animals receiving Diet 1. HbA1c levels are significantly 
higher in transgenic (tg) males (m) and females (f) as compared to age- and sex-matched control (co) 
mice. Data are means ± SEM; (n), number of animals investigated. * p<0.05 vs. control. 
 
b) Animals receiving the carbohydrate restricted diet  
 
HbA1c levels were significantly higher in transgenic males and females as compared 
to age- and sex-matched control mice (Fig. 4.5). 
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Figure 4.5 Glycated hemoglobin of animals receiving Diet 2. In all transgenic (tg) animals 
studied, HbA1c levels are significantly higher than those of age- and sex-matched control (co) mice. 
Data are means ± SEM; (n), number of animals investigated; m, male; f, female. * p<0.05 vs. control. 
 
c) Comparison of both diet groups 
 
HbA1c levels were significantly higher in transgenic animals permanently fed the 
standard rodent chow as compared to transgenic animals fed the carbohydrate-
restricted diet (Fig. 4.6).  
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Figure 4.6 Comparison of glycated hemoglobin levels of animals receiving Diet 1 and 
Diet 2. Both male (m) and female (f) transgenic (tg) animals receiving Diet 1 exhibit significantly 
higher HbA1c levels than transgenic animals fed Diet 2. Data are means ± SEM; n, number of animals 
investigated. * p<0.05. 
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4.4 Oral glucose tolerance test (OGTT)  

In order to clarify whether the diabetic state is due to low insulin secretion or dis-
turbed insulin sensitivity, OGTT was performed in 4-month-old mice receiving Diet 1. 
Basal blood glucose levels were 459.9 ± 32.8 mg/dl for male and 450.7 ± 74.6 mg/dl 
for female transgenic mice. In control males, basal blood glucose levels were 80.3 ± 
5.9 mg/dl and 76.0 ± 8.3 mg/dl in females, respectively. Blood glucose levels of trans-
genic mice were significantly elevated at all time points examined and showed only a 
slight decrease 120 min after oral glucose challenge, whereas control mice reached 
near basal levels after 120 min (Fig. 4.7 A/B). These findings clearly show that 
GIPRdn transgenic mice are glucose intolerant.  
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(B) Female animals 
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Figure 4.7 (A/B) Oral glucose tolerance test of animals receiving Diet 1, (A) male 
animals; (B) female animals. Transgenic (tg) male (m) and female (f) animals exhibit significantly 
higher glucose values after oral glucose challenge than sex-matched controls (co). Data are means ± 
SEM; (n), number of animals investigated. * p<0.05 vs. control. 
 
Serum insulin levels were determined during the oral glucose tolerance test at 0, 45 
and 120 minutes. In male GIPRdn transgenic mice, serum insulin values were signifi-
cantly lower than those of control mice at the basal state (3.7-fold), at 45 min (10.3-
fold) and at 120 minutes (11.4-fold). Whereas insulin levels of control males showed 
a slight increase from basal levels at 45 minutes, serum insulin values of GIPRdn 
transgenic males were 2.6-fold decreased. At 120 minutes, serum insulin concentra-
tions had returned to basal levels in control males and were 3.6-fold lower than 
fasted levels in transgenic males, respectively. In female transgenic mice, basal insu-
lin levels were 4.7-fold lower than those of control mice. Values at 45 minutes were 
14.6-fold lower (p<0.05), and at 120 min after oral glucose load serum insulin con-
centrations were 5-fold lower than those observed in female controls. Insulin levels 
rose markedly from 0 to 45 min and decreased to near basal levels between 45 and 
120 min in female control mice, whereas in female transgenic mice insulin levels re-
mained at basal levels over the period sampled (Fig. 4.8 A/B).  
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(B) Female animals 
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Figure 4.8 (A/B) Serum insulin levels during an oral glucose tolerance test of animals 
receiving Diet 1; (A) male animals, (B) female animals. Serum insulin levels of transgenic 
(tg) male (m) and female (f) animals are lower than those of sex-matched controls (co). Data are 
means ± SEM; (n), number of animals investigated. * p<0.05 vs. control. 
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4.5 Subcutaneous glucose tolerance test (SCGTT)  
 
The SCGTT was performed in order to clarify whether the diabetic phenotype results 
from the disruption of GIP receptor signaling by the mutated receptor or a non-
specific affection of further B-cell associated G protein-coupled receptors. Since the 
GLP-1 receptor is also G protein-coupled, GLP-1 was used as an example to show 
the specificity of the alterations to the mutated receptor. The area under glucose 
curve (AUC glucose) was significantly elevated in transgenic animals receiving the 2 
M glucose solution in 0.9% NaCl as compared to sex-matched controls. The con-
comitant administration of 8% GIP had no effect on the AUC glucose in transgenic 
animals, whereas in controls, an at least 42% reduction of the AUC glucose was ob-
served as compared to animals receiving glucose without GIP (Fig. 4.9). The applica-
tion of GLP-1 during SCGTT had the same effects on the AUC glucose of transgenic 
and control animals: The GLP-1-induced reduction of the AUC glucose was between 
48-56% as compared to SCGTT without GLP-1 (Fig. 4.10). 
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Figure 4.9 AUC glucose during SCGTT with and without application of 8% GIP. During 
SCGTT, the AUC glucose of transgenic (tg) male (m) and female (f) animals is significantly higher 
than that of sex-matched controls (co). The application of GIP has no effect on the AUC glucose in 
transgenic animals. In controls, an at least 42% GIP-induced reduction of the AUC glucose can be 
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observed as compared to SCGTT without GIP. Data are means ± SEM; (n), number of animals inves-
tigated. * p<0.05 vs. control. 
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Figure 4.10 AUC glucose during SCGTT with and without application of 8% GLP-1. 
The application of GLP-1 has the same effect on the AUC glucose in transgenic and control animals. 
An at least 48% reduction of the AUC glucose can be observed in all animals receiving GLP-1 as 
compared to SCGTT without GLP-1. Data are means ± SEM; (n), number of animals investigated. * 
p<0.05 vs. control. 
 
The increase of insulin secretion was calculated from the basal and 10-minute insulin 
values during SCGTT. Glucose alone induced an at least 2.1-fold increase of serum 
insulin levels in controls, whereas in transgenic mice, no glucose-induced increase of 
insulin levels was observed. The concomitant application of GIP during SCGTT in-
duced a 6.3-fold increase of insulin levels in male controls and a 2.6-fold increase in 
female controls, respectively. In transgenic animals, GIP was not capable to augment 
the glucose-induced insulin secretion. GLP-1 induced a 4.9-fold increase of insulin 
levels in male and a 3.9-fold increase in female controls, respectively. GLP-1 did not 
augment the 10-minute insulin levels in transgenic mice (Fig. 4.11). 
 
 85 
0
2 5 0
5 0 0
7 5 0
1 0 0 0
-1 0 0
 c o  (6 )
 c o  GIP  (6)
 c o GLP -1  (6 )
 tg  (6 )
 tg  GIP  (6)
 tg  GLP -1  (6)
*
*
' ,
QV
XOL
Q
QJ
P
O
    Ma le  an im als         Female  an imals
 
Figure 4.11 Increase of serum insulin levels during SCGTT without and with GIP and 
GLP-1. Glucose alone induced an increase of the insulin levels in controls (co) but not in transgenic 
(tg) animals. GIP and GLP-1 further augmented the glucose induced insulin secretion in male (m) 
controls. In female (f) controls and transgenic animals, the peptides did not significantly increase the 
glucose-induced insulin secretion. Data are means ± SEM; (n), number of animals investigated. * 
p<0.05 vs. control. 
 
4.6 Daily food and water intake, urine volume  

To investigate the effect of the metabolic state on feeding behavior, food and water 
intake was measured in two groups of mice fed different diets at four and seven 
months of age. To evaluate whether polydipsia correlates with polyuria, the 24-hour 
urine volume was measured from the same group of mice at seven months of age.  
 
a) Animals receiving standard rodent chow 
 
Irrespective of the age at sampling, food intake was over 2.3-fold elevated in male 
transgenic mice vs. control males and more than 2.1-fold in transgenic females vs. 
control females, respectively (p<0.05) (Table 4.5). These findings indicate severe 
hyperphagia in GIPRdn transgenic mice. 
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Water intake of male and female transgenic mice was more than 8.4-fold higher vs. 
control mice, at both four and seven months of age (p<0.05) (Table 4.5). These re-
sults show that the metabolic state in GIPRdn transgenic animals is accompanied by 
severe polydipsia. 
The urine volume was more than 18-fold elevated in male and female GIPRdn trans-
genic mice vs. sex-matched littermate controls (Table 4.5). This finding demonstrates 
severe polyuria in GIPRdn transgenic mice. 
 
 Food intake Water intake  Urine volume 
 (g/g body weight/day) (g/g body weight/day) (ml/day) 
Group (n,n) 4 months 7 months 4 months 7 months 7 months 
      
Co male (8,8) 0.13  ± 0.01 0.10  ± 0.01 0.19  ± 0.02 0.17 ± 0.01 1.69    ± 0.28 
Tg male (7,7) 0.30* ± 0.02 0.27* ± 0.01 1.61* ± 0.08 1.43* ± 0.14 44.86*  ± 2.49 
Co female (6,3) 0.13  ± 0.01 0.15   ± 0.02 0.20  ± 0.01 0.21 ± 0.05 2.97    ± 0.55 
Tg female (5,3) 0.32* ± 0.04 0.32* ± 0.02 1.67* ± 0.36 1.88* ± 0.13 52.67*  ± 7.22 
 
Table 4.5 Daily food and water intake and daily urine volume of animals receiving 
Diet 1. All transgenic animals show polydipsia, polyuria and hyperphagia. Data are means ± SEM; 
(n,n), number of animals investigated at four and seven months of age; (co), control; (tg), transgenic. 
* p<0.05 vs. control. 
 
b) Animals receiving the carbohydrate-restricted diet  
 
Data are presented in Table 4.6. Transgenic animals receiving the carbohydrate re-
stricted diet showed significantly higher food and water intake as compared to age-, 
sex-, and diet-matched control mice, irrespective of the age at sampling. At 4 months 
of age, food intake was 1.2-fold higher in both male and female transgenic mice as 
compared to sex-matched controls. Water intake was 1.4-fold higher in male and 1.5-
fold elevated in female transgenic mice, respectively (p<0.05). When fed standard 
rodent chow for three months (at seven months of age), food intake was 1.4-fold 
higher in male (p<0.05) and 1.5-fold higher in female transgenic mice (p<0.05) as 
compared to sex-matched controls. Water intake was 9.2-fold elevated in male 
(p<0.05) and 6.1-fold elevated in female transgenic mice (p<0.05) as compared to 
controls. Water intake increased significantly between four and seven months of age 
in both male and female transgenic animals. At seven months of age, the 24-hour 
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urine volume was significantly higher in both male and female transgenic animals as 
compared to controls. 
 
 Food intake Water intake  Urine volume 
 (g/g body weight/day) (g/g body weight/day) (ml/day) 
Group (n,n) 4 months 7 months 4 months 7 months 7 months 
      
Co male (4,4) 0.33  ± 0.01 0.25†  ± 0.02 0.49  ± 0.04 0.19     ± 0.03 1.69    ± 0.11 
Tg male (6,6) 0.40* ± 0.02 0.36*   ± 0.01 0.71* ±  0.07 1.75*† ± 0.10 44.86* ± 1.78 
Co female (4,4) 0.36  ± 0.01 0.28    ± 0.02 0.50  ± 0.03 0.23    ± 0.02 2.97    ± 0.24 
Tg female (13,11) 0.42* ± 0.01 0.38*  ± 0.02 0.76* ± 0.05 1.40*† ± 0.25 52.67 *± 6.21 
 
Table 4.6 Daily food/water intake and urine volume of animals receiving Diet 2. Trans-
genic animals investigated show significantly higher food and water intake as well as 24-hour urine 
volume. Data are means ± SEM; (n,n), number of animals investigated at four and seven months of 
age; (co), control; (tg), transgenic. * p<0.05 vs. control; † p<0.05 vs. previous time point. 
 
c) Comparison of both diet groups 
 
At four months of age, both control and transgenic mice receiving the carbohydrate-
restricted diet (Diet 2) showed a significantly higher food intake than control and 
transgenic mice receiving standard rodent chow. At the same age, controls fed Diet 2 
showed a higher water intake than controls fed Diet 1 (n.s.). Transgenic animals fed 
Diet 2 exhibited a significantly lower water intake than transgenic animals fed Diet 1 
(Fig. 4.12 A/B). 
At seven months of age, food intake of all animals previously fed the carbohydrate-
restricted diet was significantly higher than that of animals constantly fed standard 
rodent chow (Fig. 4.13 A/B). Water intake and the 24-hour urine volume were nearly 
identical comparing the two diet groups (Fig. 4.13 C).  
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(A) Food intake, four months of age 
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 (B) Water intake, four months of age 
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Figure 4.12 (A/B) Comparison of the daily food and water intake of animals receiving 
Diet 1 and Diet 2 at four months of age; (A) food intake, (B) water intake. (A) The food 
intake of animals receiving Diet 2 is significantly higher than that of animals receiving Diet 1. (B) Water 
intake of transgenic (tg) animals receiving Diet 1 is significantly higher than that of transgenic animals 
receiving Diet 2. Water intake of control (co) animals fed Diet 1 is lower than that of animals receiving 
Diet 2. Data are expressed as gram (g) per gram body weight (g BW) per day (d). Data are means ± 
SEM; (n), number of animals investigated. * p<0.05 
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(A) Food intake, seven months of age 
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(B) Water intake, seven months of age 
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(C) Urine volume, seven months of age 
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Figure 4.13 (A/B/C) Comparison of the daily food and water intake and urine volume 
of animals receiving Diet 1 and Diet 2 at seven months of age; (A) food intake, (B) 
water intake, (C) urine volume. (A) The food intake of animals receiving Diet 2 is higher than 
that of animals receiving Diet 1. Data are expressed as gram (g) per gram body weight (g BW) per day 
(d). (B) Water intake of both diet groups is not significantly different. Data are expressed as gram (g) 
per gram body weight (g BW) per day (d). (C) The 24-hour urine volume of both diet groups is nearly 
equal. Data are expressed as volume (ml) per day (d).  
Data are expressed as means ± SEM; (co), control; (tg), transgenic; (n), number of animals investi-
gated. * p<0.05. 
 
4.7 Serum parameters 
 
Serum parameters were evaluated in 3-month-old animals receiving standard rodent 
chow. Sodium and chloride levels were significantly lower in male GIPRdn, as com-
pared to control males; in female transgenic mice only chloride levels were signifi-
cantly reduced as compared to sex-matched wildtype mice. Serum urea and 
creatinine were both significantly elevated in GIPRdn males and females. Serum 
triglyceride levels were higher in all transgenic animals than those observed in non-
transgenic mice. Values for total protein and albumin were both significantly lower in 
GIPRdn females vs. wildtype females (Table 4.7).   
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Group (n) Sodium Chloride Crea-
tinine 
Urea Choles-
terol 
Triglyc-
eride 
Total 
protein 
Albumin 
 (mmol/l) (mmol/l) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (g/dl) (g/dl) 
         
Co male (4)       162.5 112.0 0.30 63.5 102.0 188.5 5.0 2.4 
 ± 1.0 ± 0.1 ± 0.01 ± 5.4 ± 8.6 ± 43.0 ± 0.1 ± 0.2 
Tg male (4)       146.5* 94.5* 0.55* 113.0* 126.0* 877.5* 4.7 2.3 
 ± 2.1 ± 2.2 ± 0.07 ± 7.6 ± 4.9 ± 66.2 ± 0.3 ± 0.2 
Co female (4)    159.0 111.5 0.33 51.0 98.5 126.0 5.4 3.0 
 ± 1.8 ± 1.0 ± 0.03 ± 6.5 ± 5.6 ± 11.5 ± 0.2 ± 0.2 
Tg female (4)    152.5 104.0* 0.40* 96.8* 104.5 519.0* 4.5* 2.3* 
 ± 3.3 ± 2.2 ± 0.01 ± 1.4 ± 9.4 ± 87.4 ± 0.1 ± 0.1 
 
Table 4.7 Serum parameters. (co), control; (tg), transgenic. Data are presented as means ± 
SEM; (n), number of animals investigated. * p<0.05 vs. control. 
 
4.8 Body weight  
 
The fasted body weight was determined in monthly intervals between 80 and 230 
days of age in the two diet groups.  
 
a) Animals receiving standard rodent chow 
 
After a 12-hour fasting period, body weight of transgenic males receiving standard 
rodent chow was significantly lower than that of control mice, irrespective of the age 
at sampling. There was no difference in body weight of female transgenic and control 
mice (Fig. 4.14 A/B). The body weight increased significantly between 80 and 230 
days in male control animals, the body weight of female animals and male transgenic 
mice remained stable over the period sampled. 
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(A) Male animals 
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(B) Female animals 
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Figure 4.14 (A/B) Body weight between 80 and 230 days of age, animals receiving 
Diet 1; (A) male animals, (B) female animals. The body weight of transgenic males is signifi-
cantly higher than that of sex-matched controls. Data are means ± SEM; (n), number of animals inves-
tigated; (co), control; (tg), transgenic; (m), male; (f), female. * p<0.05 vs. control, † p<0.05 vs. previous 
time point. 
 
In addition, body weight of animals fed ad libitum was determined prior to sacrifice. At 
10 days of age, the mean body weight of transgenic animals did not differ from that of 
control animals. At one and three months of age, animals were weighed before ex-
sanguination and the net body weight was calculated by subtraction of gastric and 
 93 
intestinal contents. The body weight of transgenic animals was lower than that of 
control mice; only in three-month-old transgenic females this difference did not reach 
statistical significance (Table 4.8).  
 
   Age (d)   
Group (n) 10 30 90 
    
Co male (4) 6.0 ± 0.3 28.2†  ± 0.3 35.8†  ± 0.7 
Tg male (4) 5.5 ± 0.2 21.5*† ± 0.9 28.0*† ± 1.2 
Co female (4) 5.7 ± 0.3 21.1†  ± 0.1 30.1†  ± 1.4 
Tg female (4) 5.0 ± 0.5 19.2*† ± 0.4 26.9*† ± 1.2 
 
Table 4.8 Body weight (g). Body weight increases significantly with age in all groups investigated 
and is lower in transgenic (tg) animals at 30 and 90 days of age vs. age-matched control (co) mice. 
Data are means ± SEM; (n), number of animals investigated. * p<0.05 vs. control; † p<0.05 vs. previ-
ous time point.  
 
b) Animals receiving the carbohydrate restricted diet  
 
Male and female control mice showed a higher fasted body weight than sex-matched 
transgenic animals. Statistical significance was reached at 80, 140, 170 and 230 
days for male animals and at 80, 110, 140, 170 and 230 days for female animals, 
respectively. The body weight increased significantly in all animals between 110 and 
140 days of age, the time point when the diet was changed from carbohydrate-
restricted to standard diet (Fig. 4.15 A/B).  
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(B) Female animals 
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Figure 4.15 (A/B) Body weight between 80 and 230 days of age, animals receiving 
Diet 2; (A) male animals, (B) female animals. All animals exhibit significant weight gain be-
tween 110 and 140 days of age. The time point of diet change is indicated with an arrow. Data are 
means ± SEM; (co), control; (tg), transgenic; (m), male; (f), female. * p<0.05 vs. control, †  p<0.05 vs. 
previous time point. 
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c) Comparison of both diet groups 
 
Data are presented in Figure 4.16 A/B. Transgenic males permanently receiving 
standard rodent chow showed a significantly higher body weight than transgenic 
males while they were fed the carbohydrate-restricted diet at 80 and 110 days of age. 
Control males from group Diet 2 weighed significantly less than control males from 
group Diet 1, irrespective of the age at weight determination. Transgenic females 
permanently receiving standard rodent chow weighed significantly more than trans-
genic females from group Diet 2. The same is true for control females until 140 days 
of age. 
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(B) Female animals  
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Figure 4.16 (A/B) Body weight between 80 and 230 days of age, comparison of both 
diet groups; (A) male animals, (B) female animals. At 80 and 110 days of age, transgenic 
males receiving the carbohydrate-restricted diet (Diet 2) weigh significantly less than transgenic ani-
mals receiving the standard diet (Diet 1). After the change of diet (arrow) there is no difference in body 
weight. Transgenic females receiving Diet 1 weigh significantly more than transgenic females receiv-
ing Diet 2. Data are means ± SEM; (n), number of animals investigated; (co), control; (tg), transgenic; 
(m), male; (f), female; a-d p<0.05. a: Diet 1 transgenic vs. control, b: Diet 2 transgenic vs. control, c: 
Diet 1 transgenic vs. Diet 2 transgenic, d: Diet 1 control vs. Diet 2 control. 
 
4.9 Organ weights 

Organ weights were determined at 90 days of age (Tables 4.9 and 4.10). The signifi-
cant reduction of absolute and relative weights of skin, carcass and abdominal fat 
tissue contributed to the lower body weight of transgenic animals vs. controls. The 
absolute weight of the heart was significantly lower in male transgenic animals vs. 
male controls (Table 4.9). Both absolute and relative values for the weights of intes-
tine weight, gastric- and intestinal content, liver and kidney were significantly in-
creased in GIPRdn transgenic vs. control mice (Tables 4.9 and 4.10, Fig. 4.17 A/B). 
Pancreas weight was determined at 10, 30 and 90 days of age and found to be equal 
when comparing transgenic and sex-matched control animals (Table 4.11). 
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Group (n) Carcass Skin Intestine GIT 
content 
Liver Kidneys†  Abdomi-
nal fat 
Heart 
 (g) (g) (g) (g) (g) (mg) (g) (mg) 
         
Co male (4)     15.0 7.0 1.7 2.9 1.8 583 1.85 174 
 ± 0.8 ± 0.2 ± 0.1 ± 0.2 ± 0.6 ± 8 ± 0.33 ± 13 
Tg male (4)       10.0* 3.7* 3.3* 5.3* 2.1* 767* 0.24* 131* 
 
 
± 0.5 ± 0.3 ± 0.2 ± 0.5 ± 0.8 ± 20 ± 0.04 ± 6 
Co female (4)    12.5 5.2 1.5 2.3 1.4 382 2.22 144 
 ± 0.6 ± 0.4 ± 0.1 ± 0.5 ± 0.8 ± 29 ± 1.01 ± 7 
Tg female (4)    9.8* 3.4* 2.8* 6.7* 1.9* 619* 0.19* 151 
 ± 0.6 ± 0.1 ± 0.3 ± 0.7 ± 0.1 ± 62 ± 0.01 ± 20 
 
Table 4.9 Organ weights. Data are presented as means ± SEM; (n), number of animals investi-
gated; co, control; tg, transgenic; GIT content: gastric and intestinal content; †  cumulative weight of 
both kidneys per animal; * p<0.05 vs. control. 
 
Group (n) Body Carcass Skin Intestine GIT 
content 
Liver Kidneys Abdomi-
nal fat 
Heart 
 (g) (%) (%) (%) (%) (%) (%) (%) (%) 
          
Co male (4)     35.8 41.8 19.7 4.8 8.2 5.1 1.6 5.1 0.48 
 ± 0.7 ± 0.8 ± 0.5 ± 0.1 ± 0.7 ± 0.6 ± 0.4 ± 0.8 ± 0.03 
Tg male (4)       28.0* 35.5* 13.2* 11.9* 18.7* 7.6* 2.8* 0.8* 0.47 
 ± 1.2 ± 0.3 ± 0.7 ± 0.5 ± 1.3 ± 0.9 ± 0.1 ± 0.1 ± 0.02 
Co female (4)    30.1 41.7 17.2 5.1 7.8 4.8 1.3 7.1 0.48 
 
 
± 1.4 ± 1.7 ± 0.7 ± 0.3 ± 2.1 ± 0.3 ± 0.9 ± 1.5 ± 0.04 
Tg female (4)    26.9 36.2* 12.8* 10.2* 25.2* 7.1* 2.3* 0.7* 0.56 
 ± 1.2 ± 1.2 ± 0.5 ± 0.7 ± 3.1 ± 0.2 ± 0.1 ± 0.1 ± 0.05 
 
Table 4.10 Organ-to-body weight ratios. Data are presented as means ± SEM; (n), number of 
animals investigated; (co), control; (tg), transgenic; GIT content: gastric and intestinal content; * 
p<0.05 vs. control. 
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   Age (d)   
Group (n) 10 30 90 
    
Co male (4) 28 ± 1 241* ±   8 401* ± 18 
Tg male (4) 25 ± 4 232* ± 11 412* ± 50 
Co female (4) 27 ± 1 228* ±   7 342* ± 35 
Tg female (4) 19 ± 3 214* ±   4 437* ± 29 
 
Table 4.11 Pancreas weight (mg). Pancreas weight increases significantly with age but is not 
different comparing transgenic (tg) and age-matched control (co) animals. Data are means ± SEM; (n), 
number of animals investigated. * p<0.05 vs. previous time point. 
 
 
Fig. 4.17 (A) Intestinal tract of an 8-month-old male control (top) and an age-matched 
male GIPRdn transgenic animal (bottom). The length and the diameter of the stomach and 
small and large bowel of the transgenic animal are increased as compared to a weight-matched con-
trol. 
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Fig. 4.17 (B) Mesentery of a GIPRdn transgenic (left) and a control male (right) at 
eight months of age. The mesentery of the transgenic animal contains virtually no fatty tissue. 
 
4.10 Descriptive histologic and immunohistochemical findings of the pancreas 
 
Gross morphology and histologic appearance of the exocrine pancreas was incon-
spicuous in transgenic mice irrespective of the age investigated. In H&E-stained sec-
tions, pancreatic islet profiles of transgenic animals appeared to be much smaller 
both in size and number as compared to controls. Furthermore, immunohistochemis-
try for the four principal islet cell hormones revealed an atypical composition and or-
ganization of islets in transgenic mice. Very few islet cells stained insulin positive, 
whereas the proportion of cells expressing glucagon and somatostatin was in-
creased. All cell types were dispersed over the islet profile in GIPRdn transgenic mice, 
which was markedly different from the typical distribution of endocrine cells in murine 
pancreatic islets, being characterized by a ring of non-B-cells surrounding a core of 
B-cells (Fig. 4.18 A-H).  
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Figure 4.18 (A-H): Distribution of endocrine cells in islets in control (A, C, E, G) and 
GIPRdn transgenic (B, D, F, H) mice at 10 days of age. Immunohistochemistry of serial 
pancreas sections for the four principle islet cell hormones, insulin (A,B), glucagon (C,D), somatostatin 
(E,F) and pancreatic polypeptide (PP) (G,H). The distribution of endocrine cells in pancreatic islets 
from GIPRdn transgenic (tg) mice is severely altered as compared to control (co) mice. The amount of 
insulin positive cells is clearly reduced, whereas the proportion of islet cells expressing glucagon and 
somatostatin is increased. Magnification 40x12.5. 
 
4.11 Quantitative-stereological findings of the pancreas 
 
4.11.1 Total islet volume 
 
The total volume of the islets in the pancreas (V(Islet,Pan)) was significantly lower 
(range 54-69%) in transgenic vs. control mice at all time points examined. The 
V(Islet,Pan) remained stable comparing 10 and 30 day old animals. In all animals at 90 
days of age, the V(Islet,Pan) was higher than that of 30-day-old counterparts (Fig. 
4.19 A/B).  
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Figure 4.19 Total islet volume (V(Islet, Pan)) of GIPRdn transgenic and control mice; (A) 
male, (B) female animals. The V(Islet, Pan) in transgenic (tg) male and female animals is more than 
54% lower as compared to age- and sex-matched littermate controls (co). The V(Islet, Pan) remains sta-
ble between 10 and 30 days and increases between 30 and 90 days of age in all animals examined. 
Data are presented as means ± SEM; * p<0.05 vs. control; † p<0.05 vs. previous time point.  
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4.11.2 Volume density of islets in the pancreas 

The volume density of islets in the pancreas (Vv(Islet/Pan)) was reduced by over 52% 
(range 52-67%) in transgenic mice as compared to sex-matched littermate controls, 
irrespective of the age at sampling (p<0.05). The Vv(Islet/Pan) was significantly de-
creased in both transgenic and control mice at 30 days of age vs. 10-day-old mice 
(over 84%). Between 30 and 90 days of age, the Vv(Islet/Pan) remained stable in trans-
genic and control mice (Fig. 4.20 A/B). 
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Figure 4.20 Volume density of islets in the pancreas (Vv(Islet/Pan)) of GIPRdn transgenic  
and control  mice; (A) male, (B) female animals. The Vv(Islet/Pan) in transgenic (tg) male and 
female animals is at least 52% lower compared to age- and sex-matched littermate controls (co). The 
Vv(Islet/Pan) decreases between 10 and 30 days and remains stable between 30 and 90 days of age in 
all animals examined. Data are presented as means ± SEM; * p<0.05 vs. control; † p<0.05 vs. previ-
ous time point. 
 
4.11.3 Total B-cell volume 
 
In all transgenic animals, the total volume of B-cells in pancreatic islets (V(B-cells,Islet)) 
was severely (by 68-88%; p<0.05) reduced as compared to control mice at all time 
points investigated. At 90 days of age V(B-cells,Islet) exhibited the most marked reduc-
tion of 88% in male and 86% in female transgenic mice, respectively. The V(B-cells,Islet) 
was not significantly different comparing 10- and 30-day-old mice. In 90-day-old con-
trol mice, the V(B-cells,Islet) was almost twice that of 30-day-old control mice. In trans-
genic animals, the total B-cell volume remained stable over the period sampled (Fig. 
4.21 A/B). 
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Figure 4.21 Total B-cell volume (V(B-cells,Islet)) of GIPRdn transgenic and control mice; 
(A) male, (B) female animals. The V(B-cells,Islet) in transgenic (tg) male and female animals is more 
than 68% lower than that of age- and sex-matched littermate controls (co). The V(B-cells,Islet) remains 
stable between 10 and 30 days in all animals and nearly doubles between 30 and 90 days of age in 
control mice, whereas the V(B-cells,Islet) remains stable in transgenic animals until 90 days of age. Data 
are presented as means ± SEM; * p<0.05 vs. control; † p<0.05 vs. previous time point. 
 
4.11.4 Volume density of B-cells in the islets 
 
The volume density of B-cells in the islets (Vv(B-cells/Islet)) was severely reduced in all 
transgenic animals as compared to age- and sex-matched littermate controls 
(p<0.05). At 90 days of age, this difference was most distinct and corresponded to a 
63% reduction in male and a 71% reduction in female GIPRdn transgenic mice, re-
spectively. The volume density of B-cells in the islet (Vv(B-cells/Islet)) was significantly 
increased in transgenic animals at 30 days of age as compared to 10-day-old trans-
genic mice. Between 30 and 90 days of age, the Vv(B-cells/Islet) remained stable in con-
trol mice, whereas the volume density of B-cells in the islets in GIPRdn transgenic 
mice was significantly lower at 90 days of age (Fig. 4.22 A/B).  
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Figure 4.22 Volume density of B-cells in the islets (Vv(B-cells/Islet)) of GIPRdn transgenic 
and control mice; (A) male, (B) female animals. The Vv(B-cells/Islet) in transgenic (tg) male and 
female animals is largely reduced vs. age- and sex-matched control (co) mice at all time points inves-
tigated. The Vv(B-cells/Islet) increases significantly between 10 and 30 days in transgenic animals and 
remains stable between 30 and 90 days of age in control mice. In transgenic mice, Vv(B-cells/Islet) is sig-
nificantly decreased at 90 days of age as compared to the previous time point. Data are presented as 
means ± SEM; * p<0.05 vs. control; †  p<0.05 vs. previous time point. 
 
4.11.5 Total volume of endocrine non-B-cells  
 
At 10 days of age, the total volume of endocrine non-B-cells of islets (V(Non-B-cells,Islet)) 
was similar in transgenic and age-matched control mice. 30-day-old male transgenic 
mice already exhibited a significantly higher V(Non-B-cells,Islet), mainly due to a signifi-
cantly higher total volume of A-cells, as compared to male control mice. At 90 days of 
age, V(Non-B-cells,Islet) was significantly higher in male and female transgenic mice vs. 
control mice (Fig. 4.23 A/B). This increase of V(Non-B-cells,Islet) was due to a significantly 
higher total volume of A-cells (male transgenic vs. male control: 0.25 ± 0.07 mm3 vs. 
0.10 ± 0.03 mm3; female transgenic vs. female control: 0.39 ± 0.01 mm3 vs. 0.13 ± 
0.01 mm3) and D-cells (male transgenic vs. male control: 0.09 ± 0.02 mm3 vs. 0.04 ± 
0.01 mm3 and female transgenic vs. female control: 0.16 ± 0.4 mm3 vs. 0.04 ± 0.01 
mm3). In addition, a significantly higher total volume of PP-cells was found in female 
transgenic mice as compared to female controls (0.08 ± 0.04 mm3 vs. 0.04 ± 0.01 
mm3). The V(Non-B-cells,Islet) was similar when comparing 10- and 30-day-old animals. At 
90 days of age, the V(Non-B-cells,Islet) was significantly increased in all animals, apart 
from female controls, as compared to the previous time point (Fig. 4.23 A/B).  
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Figure 4.23 Total volume of endocrine non-B-cells (V(Non-B-cells,Islet)) of GIPRdn trans-
genic and control mice; (A) male, (B) female animals. At 30 days of age, V(Non-B-cells,Islet) is 
significantly higher in transgenic (tg) males vs. male controls (co). The V(Non-B-cells,Islet) is significantly 
higher in both male and female transgenic animals at 90 days of age vs. age- and sex-matched control 
mice. The V(Non-B-cells,Islet) increases markedly in transgenic mice between 30 and 90 days of age. Data 
are presented as means ± SEM; * p<0.05 vs. control; †  p<0.05 vs. previous time point. 
 
4.11.6 Volume density of endocrine non-B-cells in islets 
 
At all time points examined, the volume density of endocrine non-B-cells in islets 
(Vv(Non-B-cells/Islet)) was significantly elevated in transgenic mice, as compared to age- 
and sex-matched littermate controls (Fig. 4.24 A/B). This elevation was by virtue of a 
higher A- and D-cell volume fraction in islets at 10, 30 and 90 days of age. The vol-
ume density of PP-cells was significantly increased in 10- and 90-day-old male and in 
90-day-old female transgenic mice, respectively (Table 4.12). The Vv(Non-B-cells/Islet) 
remained stable between 10 and 30 days of age in all animals, only in female trans-
genic mice, there was a significant increase of Vv(Non-B-cells/Islet). There was an age-
related significant increase of Vv(Non-B-cells/Islet) from 30 to 90 days of age in GIPRdn 
transgenic mice (Fig. 4.24 A/B). This increase was due to an elevated volume frac-
tion of the three major non-B-cells (A-, D- and PP-cells; Table 4.12 A-C).  
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Figure 4.24 Volume density of endocrine non-B-cells in the islets (Vv(Non-B-cells/Islet)) of 
GIPRdn transgenic and control mice; (A) male, (B) female animals. At all time points in-
vestigated Vv(Non-B-cells/Islet) is significantly higher in transgenic (tg) male and female animals as com-
pared to age- and sex-matched littermate controls (co). The Vv(Non-B-cells/Islet) increases significantly be-
tween 30 and 90 days of age in transgenic mice. Data are presented as means ± SEM; * p<0.05 vs. 
control; †  p<0.05 vs. previous time point. 
 
(A) Volume density of A-cells in the islets 
 
 
  Vv(A-cells/Islet)   
Group (n)  10 30 90 
Co male (4)  0.08* ± 0.02 0.05* ± 0.01 0.05* ± 0.01 
Tg male (4)  0.19* ± 0.03 0.30* ± 0.05 0.36* ± 0.03 
Co female (4)  0.11* ± 0.02 0.10* ± 0.01 0.07* ± 0.01 
Tg female (4)  0.18* ± 0.01 0.23* ± 0.05 0.45* ± 0.04 
 
(B) Volume density of D-cells in the islets 
 
 
 
  Vv(D-cells/Islet)   
Group (n)  10 30 90 
Co male (4)  0.03* ± 0.02 0.02* ± 0.01 0.02* ± 0.01 
Tg male (4)  0.12* ± 0.02 0.10* ± 0.04 0.14* ± 0.01 
Co female (4)  0.05* ± 0.01 0.04* ± 0.01 0.02* ± 0.01 
Tg female (4)  0.07* ± 0.01 0.14* ± 0.02 0.19* ± 0.02 
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(C) Volume density of PP-cells in the islets 
 
 
 
  Vv(PP-cells/Islet)   
Group (n)  10 30 90 
Co male (4)  0.02* ± 0.01 0.02 ± 0.01 0.03* ± 0.01 
Tg male (4)  0.14* ± 0.03 0.06 ± 0.04 0.08* ± 0.01 
Co female (4)  0.04* ± 0.01 0.02 ± 0.02 0.02* ± 0.01 
Tg female (4)  0.06* ± 0.01 0.05 ± 0.01 0.10* ± 0.02 
 
Table 4.12 (A-C) Volume densities of A-cells (A), D-cells (B), and PP-cells (C) in the 
islets (Vv(X-cell, Islet)) of GIPRdn transgenic and control mice. The Vv(A-cell, Islet) and Vv(D-cell, Islet) 
is significantly higher in transgenic (tg) male and female animals as compared to age- and sex-
matched controls (co). Data are presented as means ± SEM; * p<0.05 vs. control. 
 
4.11.7 Total volume of isolated B-cells 
 
The total volume of isolated B-cells (single interstitial insulin positive cells and small 
interstitial B-cell clusters, indicating neogenesis of islets) was significantly lower in 
transgenic mice vs. control mice, irrespective of the age investigated. The total vol-
ume of isolated B-cells remained stable in transgenic animals until 90 days of age 
(Fig. 4.25 A/B).  
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Figure 4.25 Total volume of isolated B-cells in pancreata of GIPRdn transgenic and 
control mice; (A) male, (B) female animals. In transgenic (tg) male and female animals, the 
total volume of isolated B-cells is significantly reduced at all time points examined as compared to 
age- and sex-matched littermate controls (co). Data are presented as means ± SEM; * p<0.05 vs. 
control; †  p<0.05 vs. previous time point. 
4.11.8 Volume density of isolated B-cells in the pancreas 
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The volume density of isolated B-cells in the pancreas was significantly lower in 
transgenic vs. control mice at all time points investigated. There was an over 80% 
reduction in the volume density of isolated B-cells in all animals at 30 days of age as 
compared to the preceding time point (p<0.05). At 90 days of age, the volume density 
of isolated B-cells was equal in all animals as compared to 30-day-old animals 
(Fig. 4.26 A/B). 
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Figure 4.26 Volume density of isolated B-cells in pancreata of GIPRdn transgenic and 
control mice; (A) male, (B) female animals. In transgenic (tg) male and female animals, the 
volume density of isolated B-cells is significantly reduced at all time points examined as compared to 
age- and sex-matched littermate controls (co). In all animals, the volume density of isolated B-cells is 
more than 80% lower at 30 days as compared to the previous time point. Data are presented as 
means ± SEM; * p<0.05 vs. control; †  p<0.05 vs. previous time point. 
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4.12 Urine protein analysis 
 
Urine creatinine concentration of all transgenic animals was significantly lower than of 
age- and sex-matched controls (Fig. 4.27). 
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Figure 4.27 Urine creatinine concentration. Transgenic (tg) male (m) and female (f) animals 
exhibit significantly lower urine creatinine concentrations than non-transgenic controls (co). Data are 
presented as means ± SEM; (n), number of animals investigated. * p<0.05 vs. control. 
 
As evidenced by SDS-PAGE, four out of six 56-day-old transgenic males showed a 
band of approximately 66 kDa, which meets the size of albumin. At 84 days of age, 
all transgenic males and one transgenic female displayed albuminuria. At 110 days of 
age, another female transgenic animal was albuminuric; all female transgenic mice 
showed urine albumin excretion at 240 days of age (Fig. 4.28 A/B). Therefore, all 
GIPRdn transgenic animals exhibited selective glomerular proteinuria by the end of 
the survey. Excretion of proteins larger than 37 kDa was not detectable in urine sam-
ples of controls. Transgenic animals did not exhibit unselective glomerular or tubular 
proteinuria at any age sampled. Albuminuria was confirmed in animals at 240 days of 
age, using Western blot analysis (Fig. 4.29 A/B).  
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 (A) SDS-PAGE gel 1  (B) SDS-PAGE gel 2 
   
Alb co  co   co   co  co  M  tg   tg    tg  Alb  tg   tg   tg   M   co  co   tg   tg   tg 
           
                  
Figure 4.28 (A/B) SDS-PAGE of urine samples of GIPRdn transgenic (tg) and control 
(co) mice at eight months of age. Alb: Mouse albumin standard, M: Precision Protein Standard 
(BIORAD, Germany), molecular weight from top to bottom: 150, 100, 75, 50, 37 kDa. 
 
 (A) Western blot gel 2    (B) SDS-PAGE gel 2 
      
 Alb  tg   tg   tg   M   co  co   tg   tg   tg Alb  tg   tg   tg   M   co  co   tg   tg   tg 
      
                      
 
Figure 4.29 Western blot (A) and corresponding SDS-PAGE (B) of urine samples of 
GIPRdn transgenic (tg) and control (co) mice at eight months of age. Alb: Mouse albumin 
standard, M: Precision Protein Standard (BIORAD, Germany), molecular weight from top to bottom: 
150, 100, 75, 50, 37 kDa. 
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4.13 Macroscopical, histological and immunohistochemical findings of the kidneys 
 
a) Animals receiving standard rodent chow 
 
Animals studied were 4- and 8-month-old transgenic and control mice fed standard 
rodent chow. All transgenic animals exhibited severe renal and glomerular hypertro-
phy (Fig 4.30 A-C). Glomerular lesions were diffuse segmental to panglomerular, in-
cluding mesangial expansion, hyalinosis and sclerosis, as well as adhesions between 
the glomerular tuft and the capsule of Bowman, distension of glomerular capillaries 
and sometimes cystic appearance of the capsule of Bowman with collapsed capillary 
tuft (Fig 4.30 E, G-I). Tubulo-interstitial lesions found were tubular atrophy, interstitial 
fibrosis and proteinuria (Fig 4.30 H/I). Immunohistochemistry for the extracellular ma-
trix proteins collagen type IV (J/K), laminin (L/M) and fibronectin (N/O) revealed a 
marked deposition of all three extracellular matrix proteins in the glomeruli of trans-
genic animals as compared to controls. Tubular glycogen storage was demonstrated 
in a transgenic animal aged eight months (Fig 4.30 P/Q). In the control animal, no 
Armanni Ebstein lesions were observed. The renal pelvis, ureters and the bladder 
were largely distended in all transgenic animals fed Diet 1.  
   
 
(A) Macroscopic appearance of the right kidney, male control (left), transgenic (right), 
 8 months  
A 
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(B) Overview of the renal cortex, co, (C) Overview of the renal cortex, tg, male,  
 male, 4 months H&E (6.3 x 25)  4 months H&E (6.3 x 25) 
     
(D) Glomerulus, co, male, 4 months,  (E) Glomerulus, tg, male, 4 months, 
  PAS (12.5 x 40)  PAS (12.5 x 40) 
     
(F) Glomerulus, co, male, 4 months, (G) Glomerulus, tg, male, 4 months,  
  PASM-PAS (12.5 x 40)  PASM-PAS (12.5 x 40) 
B C 
D E 
F G 
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(H) Overview of the renal cortex, tg, (I) Glomerulus and tubules, tg, male,   
male, 4 months, PASM-PAS 4 months, PASM-PAS (6.3 x 40) 
 (6.3 x 10) 
     
(J) Glomerulus, co, female, 8 months, (K) Glomerulus, tg, female, 8 months,  
  IHC collagen type IV (10 x 40)  IHC collagen type IV (10 x 40) 
     
(L) Glomerulus, co, female, 8 months, (M) Glomerulus, tg, female, 8 months,  
  IHC laminin (10 x 40)  IHC laminin (10 x 40) 
H I 
L M
J K 
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(N) Glomerulus, co, female, 8 months, (O) Glomerulus, tg, female, 8 months,  
  IHC fibronectin (10 x 40)  IHC fibronectin (10 x 40) 
     
(P) Overview of the renal cortex and  (Q) Glycogen storage in tubular epithe- 
 medulla, tg, male, 8 months,  lial cells, tg, male, 8 months, Best’s  
 Best’s carmine (6.3 x 25)    carmine (12.5 x 40) 
 
Figures 4.30 (A-Q) Macroscopical and histological appearance of the kidneys of ani-
mals fed Diet 1. (A) Kidney male control (left) and a GIPRdn transgenic male (right), age: eight 
months. Note the renal hypertrophy of the transgenic animal. (B) H&E stained section of the renal 
cortex of a male control mouse, four months and (C) a male transgenic mouse, four months; note the 
increased size of glomerular profiles in the transgenic animal as compared to the control. (D) PAS 
stained glomerular profile of a male control mouse and (E) a male transgenic mouse at four months of 
age. The transgenic animal shows mesangial expansion, hyalinosis and widespread adhesion be-
tween the glomerular tuft and the capsule of Bowman. (F) Silver stained glomerular profile of a 4-
month-old control male and (G) an age-matched transgenic animal. Note the glomerular obsolescence 
due to mesangial expansion, hyalinosis, collapse of capillaries and the circumferential adhesion be-
tween the glomerular tuft and the capsule of Bowman. Further, splitting of the basal membrane of 
Bowman’s capsule can be seen, as well as protein casts in the tubular lumen. (H,I) Overviews of the 
renal cortex of a 4-month old transgenic male; note the glomerulosclerosis, tubular atrophy, protein 
casts in tubules, interstitial fibrosis and inflammatory cell infiltration. (J-O) Immunohistochemical 
glomerular staining for type IV collagen (J,K), laminin (L,M) and fibronectin (N,O) in transgenic mice 
and controls, indirect immunoperoxidase method. (J) collagen type IV detection in the glomerular pro-
N O 
P Q 
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file of a control mouse; (K) glomerular obsolescence due to mesangial expansion with increased 
deposition of collagen type IV, transgenic animal. (L) Control mouse: staining of a glomerular profile 
for laminin;  (M) glomerulus of a transgenic animal, the expanded glomerular matrix stains positive for 
laminin. (N) Staining for fibronectin, glomerulus of a control mouse; (O) glomerular obsolescence with 
abnormal accumulation of fibronectin. (P,Q) Glycogen storage in tubular epithelial cells of a 8-month-
old transgenic male (Best’s carmine).  
 
b) Animals receiving the carbohydrate-restricted diet 
 
Transgenic animals permanently fed the carbohydrate-restricted diet were studied at 
the age of 10 and 14 months. In both age groups, transgenic mice did not exhibit 
marked hyperglycemia, polydipsia, polyuria, or proteinuria. The renal and glomerular 
changes found in this group were not comparable to those observed in the group fed 
standard rodent chow. Renal and glomerular hypertrophy was not as pronounced or 
could not be observed, glomerular changes were rarely observed, only in a focal pat-
tern, including mild mesangial expansion, segmental hyalinosis and sclerosis, and 
sometimes tubular atrophy (Fig. 4.30 R-U).  
 
     
(R) Overview of the renal cortex, co,  (S) Overview of the renal cortex, tg,  
 female, 14 months, PASM-PAS   female, 14 months PASM-PAS  
 (6.3 x 25)   (6.3 x 25) 
S R 
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(T) Glomerulus, tg, female, 14 months, (U) Glomerulus, tg, male, 14 months,  
 PASM-PAS (12.5 x 40)  PASM-PAS (12.5 x 40) 
 
Figures 4.30 (R-U) Macroscopical and histological appearance of the kidneys of ani-
mals fed Diet 2. (R) Overview of the renal cortex, 14-month-old control female and (S) age-
matched female transgenic mouse. Glomerular hypertrophy can be observed in the kidney section of 
the transgenic mouse; (T) Glomerular profile, 14-month-old transgenic female and (U) age-matched 
transgenic male. The glomerular profile of the female mouse is inconspicuous; the glomerular profile of 
the male transgenic animal shows mesangial expansion with an increased amount of silver staining 
matrix. 
 
4.14 Quantitative-stereological findings of the kidneys 
 
4.14.1 Kidney volume 
 
In the 4-month age group, five male GIPRdn transgenic and four male littermate con-
trol mice were studied. The kidney volume was increased by 46% in transgenic vs. 
control mice (979.4 ± 100.4 vs. 670.2 ± 79.7 mm3, p<0.05). The kidney weight to 
body weight ratio (relative kidney weight) was increased by 126% (p<0.05) in trans-
genic vs. control males (Table 4.13). 
 
 Body weight Kidney weight Relative kidney weight 
Group (n) (g) (mg) (%) 
    
Co male (4)      44.2 ± 4.8 703.8 ± 83.7 1.6 ±  0.1 
 
Tg male (5)        
 
28.7* ± 0.7 
 
1028.4* ± 105.4 
 
3.6* ± 0.4 
 
   
 
T U 
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Table 4.13 Body and kidney weight (four months). Transgenic (tg) males show a signifi-
cantly lower body weight and a significantly higher absolute and relative kidney weight as compared to 
control (co) males. Data are means ± SEM; * p<0.05 vs. control. 
At the age of eight months, four GIPRdn transgenic and four control males, as well as 
three GIPRdn transgenic and three control females were examined. In transgenic 
males, the kidney volume was increased by 47% (1078.8 ± 124.4 vs. 733.1 ± 43.5 
mm3, p<0.05) and by 92% (963.5 ± 11.3 vs. 500.6 ± 15.3 mm3, p<0.05) in females, 
respectively. Male controls showed a significantly higher kidney volume than female 
control mice. The body weight of male control mice was significantly higher than that 
of male transgenic and female mice (Table 4.14). The kidney weight-to-body weight 
ratio was increased by 137% in male and by 105% in female transgenic mice as 
compared to age- and sex-matched controls (Table 4.14). 
 
 Body weight Kidney weight Relative kidney weight 
Group (n) (g) (mg) (%) 
    
Co male (4)       43.7 ± 0.7 770   ± 46 1.8 ± 0.8 
Tg male (4)        27.5* ± 2.2 1133* ± 130 4.2* ± 0.5 
Co female (3)    30.4 ± 0.9 526   ± 16 1.7 ± 0.1 
Tg female (3)     28.5 ± 0.5 1012* ± 120 3.6* ± 0.1 
 
   
 
Table 4.14 Body and kidney weight (eight months). Transgenic (tg) males show a signifi-
cantly decreased body weight as compared to control (co) males. All transgenic animals studied show 
a significantly higher absolute and relative kidney weight than sex-matched controls. Data are means 
± SEM; (n), number of animals investigated. * p<0.05 vs. control. 
 
4.14.2 Mean glomerular volume 
 
At four months of age, the mean glomerular volume  (v(Glom), corrected for embedding 
shrinkage) was increased by 122% in male transgenic animals vs. male controls. The 
v(Glom)-to-kidney weight ratio was increased by 51% and the v(Glom)-to-body weight 
ratio was increased by 235% in transgenic animals vs. controls (p<0.05). Data are 
presented in Table 4.15. 
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 v(Glom)
 v(Glom) / 
Kidney weight 
v(Glom) / 
Body weight 
Group (n) (103µm3) (103µm3/mg) (103µm3/g) 
    
Co male (4)      312.8 ± 35.5 0.5 ± 0.1 7.2 ± 0.8 
Tg male (5)        694.3* ± 79.2 0.7* ± 0.1 24.1* ± 2.4 
 
   
 
Table 4.15 Morphometric results (four months). The absolute and relative mean glomerular 
volume (v(Glom)) is significantly increased in transgenic (tg) mice as compared to controls (co). Data are 
means ± SEM; (n), number of animals investigated. * p<0.05 vs. control.  
 
In 8-month-old transgenic males, the v(Glom) was increased by 71% in male and by 
80% in female transgenic mice as compared to age- and sex-matched controls. 
The v(Glom)-to-kidney weight ratio did not differ between sex-matched control and 
transgenic mice. Comparing control mice, females had a 41% higher v(Glom)-to-kidney 
weight ratio. The v(Glom)-to-body weight ratio was 180% increased in male transgenic 
mice and 91% increased in female transgenic mice vs. sex-matched controls 
(p<0.05). Data are presented in Table 4.16. 
 
 v(Glom) v(Glom) / 
Kidney weight 
v(Glom) / 
Body weight 
Group (n) (103µm3) (103µm3/mg) (103µm3/g) 
    
Co male (4)       347.5 ± 23.7 0.5 ± 0.1 8.0 ± 0.6 
Tg male (4)        594.7* ± 38.7 0.6 ± 0.1 22.4* ± 3.3 
Co female (3)    341.2 ± 26.4 0.7 ± 0.1 11.3 ± 1.2 
Tg female (3)     614.6* ± 74.0 0.6 ± 0.1 21.5* ± 2.4 
 
 
   
 
Table 4.16 Morphometric results (eight months). The mean glomerular volume (v(Glom)) and 
the v(Glom)-to-body weight ratio is significantly increased in transgenic (tg) mice as compared to controls 
(co). Data are means ± SEM; (n), number of animals investigated. * p<0.05 vs. control.  
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4.15 Twelve-month survival  
 
a) Animals receiving standard rodent chow 
 
All transgenic male animals (n=9) died/had to be killed until the end of survey. All 
male animals died from diabetes mellitus, aged 49, 78, 104, 150, 223, 267 and 278 
days. One animal was killed at the age of 234 days due to severely disturbed general 
condition; gross morphology and histology revealed large abscesses in both kidneys. 
Since the bladder appeared normal a hematogenous pathway was considered as 
pathogenic mechanism, the etiology was considered a bacterial infection. Finally one 
animal was euthanized due to a retro-orbital abscess (age 342 days). 16/20 female 
transgenic animals died from diabetes mellitus or had to be euthanized because of 
severely disturbed general condition, resulting from the metabolic state at the age of 
108, 108, 135, 147, 148, 171, 201, 204, 214, 226, 228, 241, 279, 284, 301, and 321 
days. Therefore, all transgenic animals fed Diet 1 died as a result from the metabolic 
state and all male transgenic animals had died before the age of 12 months (Fig. 
4.31 A/B).  
1/18 male and 2/7 female control animals had died or had to be euthanized. The 
male control animal exhibited an untreatable dermatitis and one female animal was 
killed because of a malignant tumor (lymphoma). The other female control mouse 
had died at 270 days of age; neither gross morphology nor histology revealed the 
cause of death. Taken together, both male and female transgenic animals show a 
significantly reduced life span as compared to sex-matched controls fed standard 
rodent chow (Table 4.17). 
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Figure 4.31 Twelve-month survival; (A) male animals, (B) female animals. All male 
transgenic (tg) animals and 80% of the female transgenic animals died within the period investigated. 
Data are percentage of living animals out of all animals investigated per group; (n), number of animals 
examined; co, control. 
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b) Animals receiving the carbohydrate restricted diet  
 
In the group Diet 2, none of the control males or females had died until the age of 
twelve months. Four of seven male GIPRdn transgenic animals had died within that 
period. An 80-day-old animal had died of diabetes mellitus as evidenced by signs of 
dehydration and of cardiovascular failure (hyperemia of the liver and kidneys, as well 
as hyperemia, edema and emphysema of the lungs). At the age of 241 days, one 
GIPRdn transgenic male had to be killed because of a retro-orbital abscess. Another 
had to be euthanized because of severe, untreatable diabetes-associated opstipa-
tion, aged 363 days (Fig. 4.32). One of the GIPRdn transgenic males had to be killed 
because of a malignant tumor (lymphoma) at the age of 284 days. Until the age of 
twelve months, 3/12 female transgenic animals from the group Diet 2 had died, two of 
which died from severe opstipation (aged 114 and 293 days) and one had to be killed 
due to a retro-orbital abscess at the age of 280 days (Fig. 4.33 A/B). Taken together, 
both male and female transgenic animals lived significantly shorter than sex-matched 
controls (Table 4.17). 
 
 
(A) Corpse of GIPRdn transgenic male with open abdominal cavity 
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(B) Intestine of the same animal as shown in (A) 
 
(C) Large bowel (opened) from the same animal as shown in (A) 
 
Fig 4.32 (A-C) Pathological findings in a GIPRdn transgenic male that had died from 
opstipatio coli. A: View of the opened abdominal cavity. Note the marked distension of the caecum. 
B: Intestine (closed). The caecum and colon are largely distended. The stomach is nearly empty. C: 
Intestine after removal of the content. The caecum content (not shown) was fluid and the caecum wall 
appears very thin (left). Note the solid piece of faeces on the top right of the colon, which was thought 
to be the cause of opstipation. 
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Figure 4.33 Twelve-month survival rate; (A) male animals, (B) female animals. 57% of 
the male transgenic (tg) animals and 25% of the female transgenic animals died within the period in-
vestigated. However, only 29% of the male and 13% of the female transgenic animals died from diabe-
tes mellitus. All control (co) animals survived the twelve-month period. Data are percentage of living 
animals out of all animals investigated per group. 
 
c) Comparison of both diet groups 
 
Comparing both diet groups, transgenic animals fed the carbohydrate-restricted diet 
lived significantly longer than those receiving standard rodent chow. The diet had no 
effect on the 12-month life expectancy of control animals (Table 4.17). 
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 12 month Life expectancy 
Group (n,n) Diet 1 Diet 2 
   
Co male (18,11) 359.7* ± 17.3 365.0† * ± 22.1 
Tg male (9,7) 191.7* ± 24.4 267.0*†  ± 25.9 
Co female (7,13) 346.1* ± 27.7 365.0*†  ± 20.3 
Tg female (20,12) 238.8* ± 16.4 289.5*†  ± 18.9 
   
 
Table 4.17 12-month life expectancy of animals, comparison of both diet groups. 
Transgenic (tg) animals lived significantly shorter than sex- and diet-matched controls (co). Transgenic 
animals fed Diet 2 lived significantly longer than transgenic animals fed Diet 1. (SEM), standard error 
of least squares means; (n,n), number of animals fed Diet 1/ number of animals fed Diet 2; * p<0.05 
transgenic vs. control; †  p<0.05 Diet 1 transgenic vs. Diet 2 transgenic. 
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Transgenic mice expressing a mutated GIPR under the control of the rat pro-insulin 
gene promoter were found to develop severe diabetes mellitus (HerbachHWDO 2001; 
Volz-Peters HW DO 2000). The present study was performed in order to characterize 
clinical and pathological alterations in this new animal model of diabetes in detail.
Based on the results obtained in the present study the onset of diabetes mellitus in 
GIPRdn transgenic mice was further defined. In all transgenic animals observed, urine 
glucose excretion was found to occur between 14 and 21 days of age. The develop-
ment of a diabetic phenotype in suckling GIPRdn transgenic mice could be due to the 
beginning intake of rodent chow, leading to an increasing importance of the enteroin-
sular- and especially the GIP-/GIPR-axis in glucose homeostasis. This is supported 
by the findings in 10-day-old transgenic mice, which did not yet show an altered 
blood glucose level, despite lower serum insulin concentrations. From 21 days of age 
onwards, blood glucose levels obviously exceeded the renal threshold. At 30 days of 
age, significantly elevated serum glucose levels in transgenic animals paralleled uri-
nary glucose excretion. 
  
The diabetic phenotype was further defined by measurement of blood and serum 
glucose levels, as well as serum insulin values. By the age of 30 days, blood glucose 
values were largely elevated while insulin levels of transgenic mice were significantly 
lower in comparison to control mice, demonstrating an absolute insulin deficiency. 
Both, the high glucose and low insulin levels result from the expression of the domi-
nant negative GIP receptor. However, it is not yet defined whether a defect in GIP 
receptor signaling is responsible for the phenotype of GIPRdn transgenic mice. The 
alterations in glucose homeostasis in GIPRdn transgenic mice are much more dra-
matic than those observed in both GIPR-/- and GLP-1R-/- mice (MiyawakiHWDO 1999; 
ScrocchiHWDO 1996). Pederson HWDO (1998) could show that the GIP component of 
the enteroinsular axis, at the level of GIP secretion and action, is upregulated in GLP-
1R-/- mice. These findings provide evidence for plasticity in the enteroinsular axis, 
suggesting that in the mouse, the lack of GLP-1 action is in part compensated by 
upregulation of the GIP-insulin axis. A similar adaptive mechanism could contribute to 
the modest changes in GIPR-/- mice (BaggioHWDO 2000; LewisHWDO 2000). A func-
tional endogenous receptor is present in GIPRdn transgenic mice and therefore, the 
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various possible adaptive or compensatory mechanisms might not be triggered. A 
functional defect in signal transduction of the GIPRdn was proven LQYLWUR, where the 
GIPRdn was found to bind the ligand GIP with normal affinity but to fail to induce sig-
nal transduction (Volz 1997). It was not yet possible to evaluate a disturbance in sig-
nal transduction resulting from the expression of the GIPRdn LQYLYR. Since the isola-
tion of intact islets from GIPRdn transgenic animals was found to be impossible so far, 
signal transduction studies could not be performed. It is possible that signal transduc-
tion pathways are disturbed in general, leading to a failure to increase intracellular 
cAMP levels. That would lead to the loss of both the GIP and GLP-1 mediated insulin 
secretion and in part explain the unresponsiveness of the B-cells following oral glu-
cose administration observed in GIPRdn transgenic animals. A different line of GIPRdn 
transgenic animals exhibiting only mild disturbance in glucose homeostasis (Line 
GIPRdn-C) has been studied concerning the specificity of the phenotype to transgene 
expression. Administration of 10 g GIP before oral glucose challenge did not lower 
the glucose curve of transgenic animals as compared to control animals and to 
transgenic animals not receiving the peptide prior to glucose challenge. GLP-1 (10 
g) and administration of 100 g GIP though had the same effect on lowering the 
glucose curve in transgenic and control mice. Therefore, signaling of the GLP-1 re-
ceptor was proven to be unchanged in GIPRdn-C transgenic mice and a competitive 
mechanism between the mutated and the endogenous GIP receptor was confirmed 
by excess administration of the ligand (Göke B., Berghöfer P., personal communica-
tion). The SCGTT performed in this study could show that GLP-1 but not GIP is ca-
pable to reduce the AUC glucose as compared to SCGTT without the peptide. Since 
neither glucose alone nor the peptides GIP and GLP-1 augmented the serum insulin 
levels of transgenic mice during SCGTT, the glucose lowering actions of GLP-1 might 
be due to extrapancreatic actions of GLP-1, such as the increase of liver-glycogen 
synthesis. However, due to the severe changes of the endocrine pancreas (as further 
discussed below) in these mice a physiologic glucose-induced insulin secretion can-
not be expected. The malformation of the endocrine pancreas might be the leading 
cause of the unresponsiveness of the islets following oral glucose challenge, rather 
than the competitive inhibition of GIP receptor signaling (in transgenic mice of the 
Line GIPRdn-C, islet-cell composition and distribution seemed to be unchanged, B. 
Göke, personal communication). 
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GIPRdn transgenic mice show all signs of early onset diabetes. Fasting and post-
prandial blood or serum glucose levels and glucose tolerance after oral administra-
tion of glucose are severely altered. Abnormally high glucose values are associated 
with largely reduced fasting insulin levels as well as reduced insulin secretion after 
oral glucose challenge and nutrient ingestion. The reduction of caloric intake has 
been shown to improve the diabetic state. Transgenic animals transiently fed a car-
bohydrate-restricted diet showed lower fasted blood glucose levels than animals fed 
standard rodent chow. The modulation of blood and serum glucose values using a 
carbohydrate-restricted diet is therefore considered an important tool for studying the 
correlation between glucose values and secondary organ lesions. Further, it might be 
possible to gain insight into the pathogenesis of diabetes mellitus in these rather 
mildly diabetic animals and to perform signal transduction studies. 
 
The relative physiological roles of GIP and GLP-1 have been studied intensively. The 
results remain controversial; some investigators found GIP and GLP-1 to be equally 
potent in their capacity to stimulate insulin release (SuzukiHWDO 1990), whereas oth-
ers have suggested GLP-1 to possess greater insulinotropic effects (Siegel HW DO 
1992; WangHWDO 1995). There is evidence that the importance of GLP-1 has been 
overestimated (Deacon HW DO 1995; Gremlich HW DO 1995; Wheeler HWDO 1995) and 
the participation of GLP-1 in the incretin effect (in non-diabetic subjects) has even 
been questioned (Nauck 1999). Data obtained from studying the human enteroinsu-
lar axis suggested GIP to be the more potent incretin hormone (NauckHWDO 1993 a). 
An investigation by Lewis HW DO (2000) using purified GIP receptor antibody in rats, 
clearly revealed the importance of GIP as an incretin hormone in the postabsorptive 
state. Inhibition of GIP-induced insulin release, using the receptor antagonist GIP(7-
30)amide reduced circulating insulin concentrations by 72%, when GIP(7-30)amide 
was administered to rats (TsengHWDO 1996 b). The N-terminally modified GIP ana-
logue (Tyr1-glucitol GIP), which displays profound resistance to degradation in obese 
mouse plasma, was found to increase both antihyperglycemic and insulin-releasing 
actions of the peptide in an animal model of type 2 diabetes (O’Harte HW DO 2000). 
This finding is in contrast to recent studies, which could only show an improvement of 
glycemic control by exogenous administration of GLP-1 but not by GIP (CreutzfeldtHW
DO 1996; ElahiHWDO 1994; NauckHWDO 1993 a). 
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It is well known that the incretin effect is diminished in diabetic patients and rodent 
models of diabetes (ElahiHWDO 1994; NauckHWDO 1986 a; SuzukiHWDO 1990). The 
mechanism of impaired insulin secretion was thought to be associated with a ho-
mologous desensitization of the GIP receptor. In the present study, a severe diabetic 
phenotype was observed in GIPRdn transgenic mice, suggesting that a disturbed 
GIP/GIPR axis is involved in the pathogenesis of diabetes. The findings of disturbed 
fasting glucose and insulin levels were somewhat unexpected, considering GIP as 
incretin hormone, acting predominantly in the postabsorptive state. Neither studies in 
GIPR knockout mice nor studies using GIPR antibodies in healthy rats revealed a 
role of GIP in glucose regulation and B-cell function in the fasting state (BaggioHWDO 
2000). The disturbed fasting glucose and insulin levels could be the reflection of the 
loss of a still undefined non-incretin mediated action of GIP or could result from mal-
formation of the endocrine pancreas (as discussed below). As mentioned above, in-
sulin secretion might be disturbed due to a more complex alteration in signal trans-
duction pathways. 
 
Glycated hemoglobin (HbA1c) was determined in order to underline the long duration 
of the disturbance in glucose homeostasis. Transgenic animals fed Diet 1 and 2 both 
showed significantly elevated HbA1c levels, with values obtained from transgenic 
animals fed the carbohydrate-restricted diet being significantly lower than those ob-
tained from transgenic animals permanently fed standard rodent chow. The latter re-
sult is in coincidence with significantly lower blood glucose levels of transgenic ani-
mals fed the carbohydrate-restricted diet. The findings in transgenic animals and the 
fact that HbA1c levels among control mice of the different diet groups, which exhibited 
similar blood glucose levels, did not differ irrespective of the type of rodent chow, led 
to the conclusion that HbA1c levels do reflect the metabolic control in mice. HbA1c 
levels in control mice are lower than those obtained from non-diabetic humans. This 
could be due to a lower life span of murine erythrocytes. The half-life of glycated he-
moglobin A1c is suggested to be 35 days when a human erythrocyte life span is as-
sumed to be 120 days. Since the murine erythrocyte life span was shown to be 40 
days, mouse HbA1c levels may only reflect the average past plasma glucose levels 
for 2 weeks (DanHWDO 1997).  
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The diabetic state in GIPRdn transgenic mice is associated with severe hyperphagia, 
polydipsia and polyuria, irrespective of the carbohydrate intake. These are well 
known findings, associated with diabetes mellitus (Böhles & Herwig 1999). All ani-
mals fed the carbohydrate-restricted diet showed a significantly higher food intake 
than animals fed standard rodent chow. This finding can be explained by the low ca-
loric content of the carbohydrate-restricted diet. The water intake of control animals 
was significantly higher when fed Diet 2, which is probably due to the high fiber con-
tent of the carbohydrate-restricted diet. Transgenic animals fed the standard diet 
showed a significantly higher water intake than animals fed the carbohydrate-
restricted diet. The explanation of this difference between both diet groups is the sig-
nificantly higher blood glucose level, or less precise, the bad metabolic control in 
animals of the group Diet 1, leading to a higher urine glucose excretion, which in turn 
results in greater renal loss of water. Due to the high amounts of urine excreted, ani-
mals fed standard rodent chow had to be kept on several layers of tissue or even on 
metal grids while food and water intake was measured. When the diet was changed, 
blood glucose values were similar in transgenic animals of both diet groups and wa-
ter intake in turn equalized. As well as that, the 24-hour urine volume was near iden-
tical, underlining the explanation above. 
 
With respect to the alterations of serum parameters, GIPRdn transgenic mice exhib-
ited further signs of a diabetic metabolic state. The acute and chronic insulin defi-
ciency has different effects on various organs and metabolic pathways. In adipose 
tissue, the glucose uptake is reduced; lipogenesis is low and lipolysis increased. Glu-
cose uptake in muscles, too, is insulin dependent and therefore reduced in insulin-
deficient diabetes. Further, the amino acid uptake and protein synthesis is disturbed 
and proteolysis increased. Despite increased supply of free fatty acids, the insulin 
deficiency results in a catabolism of muscular tissue. The effect of the diabetic me-
tabolism on the liver is an increased glycogenolysis and gluconeogenesis as well as 
elevated triglyceride synthesis. An increase in hepatic proteolysis results in an in-
crease of urea synthesis (Hepp & Häring 1999; JankaHWDO 1999). 
Serum urea and creatinine were both significantly elevated in GIPRdn mice. This az-
otemia was not associated with clinical signs of renal failure and is therefore thought 
to be due to severe diabetes-associated polyuria, resulting in sodium-chloride loss 
and exsiccosis, leading to the so-called hyponatremic syndrome/chloropenic az-
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otemia (Hepp & Häring 1999). Another reason for the occurrence of azotemia in 
GIPRdn transgenic mice could be decreased glomerular filtration due to advanced 
kidney changes and therefore compensated retention of urinary excreted substances 
or a catabolic metabolic state.  
The reduced values for total protein and albumin result from protein catabolism 
and/or renal loss of proteins (Hepp & Häring 1999).  
Recently, a significant correlation between serum triglyceride levels, but not between 
cholesterol levels and severe cardiovascular complications was found (Janka HW DO 
1999). A significant increase in serum triglyceride levels was observed in GIPRdn 
transgenic mice and thought to result from insulin deficiency and increased hepatic 
triglyceride synthesis (Rett & Häring 1999). 
 
Male GIPRdn transgenic mice show delayed body weight gain, and the 12-hour fast-
ing body weight is significantly lower, as compared to non-transgenic males. The 
body weight of transgenic individuals is equal to that of control animals before the 
onset of diabetes, which was found to occur between two and three weeks of age. 
The reduced body weight of diabetic GIPRdn transgenic animals was mainly due to 
the reduction of the weight of skin, carcass and abdominal fatty tissue. The severe 
reduction of abdominal fat weight is thought to result from absolute insulin deficiency 
and disturbed lipogenesis (Hepp & Häring 1999).  
Taking into account that only the absolute heart weight was decreased, this reduction 
might be the reflection of the weight loss seen in GIPRdn transgenic mice, resulting in 
protein catabolism.  
The increase in weight of gastric and intestinal content is attributable to diabetes-
associated hyperphagia; the same is probably true for the increase of intestine 
weight. In experimental diabetes of rats, hyperplasia of crypt and villous epithelial 
cells of the small intestine was found, which was thought to be a consequence of hy-
perphagia or/and the action of various growth stimulators, e.g. TGFα, EGF, ornithine 
decarboxylase and polyamines (ZoubiHWDO 1995). 
Hepatomegaly is a well-known finding in both type 1 and 2 diabetic humans (Chatila 
& West 1996; Marangiello & Giorgetti 1996) and animal models of diabetes (Herrman
HW DO 1999), although the mechanisms involved are still unknown. Recent findings 
indicate that hepatomegaly could be due to early hyperplasia and later decreased 
apoptosis of hepatocytes in streptozotocin diabetic rats (Herrman HW DO 1999). 
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Herrman HWDO. (1999) suggest glucose stimulated protein kinase C (PKC) and mito-
gen-activated protein (MAP) kinase activation as a possible explanation for the ob-
served high proliferation rate. The most common hepatic lesion in diabetics is in-
creased glycogen deposition in both cytoplasm and nucleus of the hepatocytes. 
Steatosis is seen 10 times more often in obese type 2 than in type 1 diabetics. In type 
1 diabetics, poor glycemic control and inadequate insulin levels are thought to induce 
triglyceride accumulation in the liver (Falchuk & Conlin 1993). There is no macro-
scopical or histological evidence for hepatic steatosis in GIPRdn transgenic mice. 
Glycogen storage has been looked at qualitatively in alcohol fixed liver tissue, stained 
with Best’s carmine. The amount of glycogen seemed to be equal in transgenic and 
control mice.  
 
In summary, these clinical results demonstrate that the expression of a dominant 
negative GIP receptor under the control of the rat insulin gene promoter is associated 
with severe diabetes mellitus in transgenic mice. Despite the role of GIP as incretin 
hormone acting predominantly in the postabsorptive state, even fasted glucose and 
insulin levels are altered in GIPRdn transgenic mice. In addition, several secondary 
features of the diabetic state, e.g. hyperphagia, polydipsia, polyuria and delayed 
body weight gain were shown to be overt in this novel animal model of diabetes. 
Therefore, GIPRdn transgenic mice are a valuable model for answering further ques-
tions concerning incretin regulated glucose homeostasis and B-cell function.  
 
The pancreas weight was not altered and both gross morphology and histologic ap-
pearance of the exocrine pancreas were inconspicuous in GIPRdn transgenic mice. 
The endocrine pancreas though, showed striking light microscopic changes: in H&E-
stained sections, both number and size of islet profiles appeared to be reduced in 
GIPRdn transgenic mice as compared to controls. Immunohistochemistry revealed a 
disturbed islet composition accompanied by a changed distribution of the endocrine 
cells in islets. Comparable alterations have been observed in GLP-1R knockout mice 
where the absence of GLP-1R signaling led to a shift of A-cells to the center of the 
islets. The total volume of A-cells though was only slightly increased (n.s.) and the 
total B-cell volume was unchanged as compared to wildtype mice (LingHWDO 2001). 
 132 
The morphological changes of the endocrine pancreas in GIPRdn transgenic mice 
were evaluated quantitatively using unbiased model-independent stereological meth-
ods (GundersenHWDO 1988; Gundersen & Jensen 1987; WankeHWDO 1994). 
The expression of a dominant negative GIP receptor was found to be associated with 
a severe reduction of the total volumes of islets, B-cells and isolated B-cells in 
GIPRdn transgenic animals as compared to control mice, irrespective of the age at 
sampling.  
The total islet volume and total B-cell volume did not change between 10 and 30 
days of age in control mice. These findings are in agreement with the postnatal re-
modeling of rodent pancreas described in the literature; until weaning, the B-cell 
mass remains stable due to a wave of apoptosis of B-cells, which occurs during the 
second week of life, in parallel to a high cell replication rate (ScagliaHWDO 1997). This 
remodeling phase is thought to prepare the endocrine pancreas to the changing func-
tional demands (Trudeau HW DO 2000). Both the total islet and total B-cell volume 
nearly doubled in control mice between 30 and 90 days of age, which is known to be 
due to increased islet neogenesis and B-cell replication at a low rate of apoptosis 
(ScagliaHWDO 1997; TrudeauHWDO 2000). In transgenic mice, the total islet volume 
was also increased at 90 vs. 30 days of age, whereas the total B-cell volume re-
mained unchanged. The islet cell population has therefore been distorted towards 
non-B-cells. A similar tendency has been observed in PDX-1+/- mice, where the 
knockout of one allele of the PDX-1 gene was thought to skew the islet cell lineage 
towards developing into non-B-cells (DuttaHWDO 1998). It has not yet been evaluated 
whether disturbed GIPR-signaling affects the expression of transcription factors, such 
as PDX-1. However, the findings of severely reduced total islet and total B-cell vol-
ume and the reduction in islet neogenesis, the latter being evidenced by the dramati-
cally lower total volume of isolated B-cells in GIPRdn transgenic mice, imply an es-
sential effect of GIPR-signaling on B-cell growth and differentiation LQYLYR.  
GLP-1 is known to exert its effects on the insulin gene through upregulation of PDX-1 
expression and binding of PDX-1 to the insulin gene promoter (Wang HW DO 1999). 
Furthermore, in a partial pancreatectomy rat model of diabetes, GLP-1 analogues 
stimulated regeneration of the endocrine pancreas by both neogenesis and prolifera-
tion of B-cells (XuHWDO 1999). Stoffers HWDO (2000) found the administration of GLP-
1 to diabetic mice to stimulate PDX-1 expression and to enhance B-cell neogenesis 
and islet size.  
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Studies in beta (INS-1)-cells revealed GIP as a mitogenic factor for B-cells via plei-
otropic signaling pathways (TrümperHWDO 2001 b). As evidenced by BrdU (5-bromo-
deoxyuridine) incorporation, the proliferation of beta (INS-1)-cells was stimulated 
dose-dependently by glucose, and GIP addition further instigated the INS-1 cell pro-
liferation at glucose concentrations between 2.5 and 15 mM. The GIP-induced rise in 
proliferation was found to be dose dependent at 15 mM glucose. The PKA/CREB 
signaling module activation was measured and GIP was found to instigate a dose-
dependent increase in CREB phosphorylation. Further, MAPK pathway signaling 
module activation and PI3K/PKB stimulation was determined in beta (INS-1)-cells 
following GIP administration. The findings in GIPRdn transgenic mice provide evi-
dence for the role of GIP in islet and B-cell development LQYLYR. The alterations of the 
endocrine pancreas in GIPRdn transgenic mice were already observed before onset 
of diabetes and therefore could not be secondary to the diabetic state. The results 
obtained in the present study rather suggest GIP to stimulate islet neogenesis involv-
ing an intact GIP receptor mediated signal cascade. However, it is also possible that 
a general loss of function of signal transduction pathways is attributable to the 
changes of the endocrine compartment of the pancreas observed in GIPRdn trans-
genic mice. The further deterioration of the islet and B-cell volume between 30 and 
90 days of age could contribute in part to chronic hyperglycemia (JonasHWDO 1999). 
The severely reduced total B-cell volume and the disturbed distribution of endocrine 
cells in the islets, as well as the increased A-cell volume provide further explanation 
for the severely altered glucose homeostasis in GIPRdn transgenic mice (PipeleersHW
DO 1982).  
 
Since GIPRdn transgenic animals exhibit such a severe diabetic phenotype it was 
interesting to know whether transgenic mice develop secondary kidney lesions. Re-
nal hypertrophy is a characteristic change in early stages of human diabetes 
(Schwieger & Fine 1990) and various rodent models of diabetes (Velasquez HW DO 
1990). Both male and female GIPRdn transgenic animals show an at least 75% in-
crease in kidney weight; these pathological findings were in coincidence with severe 
polyuria, reflecting renal hyperfunction. Renal damage was identified clinically and 
histologically. Clinically, all transgenic animals examined developed albuminuria until 
the age of 8 months, indicating overt diabetic kidney disease (Parving HW DO 1996). 
The urinary loss of albumin was in concurrence with significantly lower serum albu-
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min levels in transgenic animals, however, it is not clear whether the reduced serum 
albumin levels result from urinary loss of albumin or the catabolic state due to severe 
weight loss. Another clinically relevant parameter concerning kidney damage is az-
otemia. Both urea and creatinine levels were increased in transgenic animals, how-
ever, no signs of renal failure, such as anemia, oliguria, gastric ulcers, were observed 
in 4- or 8-month-old animals and therefore dehydration might account for the ob-
served azotemia (Hepp & Häring 1999). Histological examination of the kidneys 
showed the development of glomerulosclerosis, including mesangial expansion with 
hyalinosis, increased deposition of the extracellular matrix proteins collagen type IV, 
laminin and fibronectin, collapse of glomerular capillaries and adhesions between the 
glomerular tuft and the capsule of Bowman. Further capillary distension and some-
times cystic appearance of Bowman‘s capsule was observed. Tubulo-interstitial le-
sions included tubular atrophy, tubular glycogen storage and PAS positive, eosino-
philic hyalin casts in the tubular lumen indicating proteinuria. Interstitial inflammatory 
cell infiltration and mild to severe interstitial fibrosis could be seen in transgenic mice. 
The findings appear more marked than in other rodent models of diabetic kidney dis-
ease (Janssen HW DO 1999; Steffes & Mauer 1984), however, the lesions typically 
been found in the human diabetic kidney, such as the so-called nodular glomerulo-
sclerosis and arteriolar hyalin changes (Heptinstall 1991; Olsen 1969) were not ob-
served in the age groups studied. Further examinations on older animals are cur-
rently being performed in order to study advanced kidney lesions. Quantitative-
stereological data from the current investigation show a large increase in glomerular 
size, which is in coincidence with the clinically observed renal hyperfunction. Prelimi-
nary data from animals studied receiving a carbohydrate-restricted diet provide good 
evidence for the correlation between kidney damage and glucose control. In contrast 
to preexisting rodent models of diabetic kidney disease, the renal changes in GIPRdn 
transgenic animals have many features in common with the changes in human dia-
betic kidney disease. Large animals models of diabetic nephropathy do show kidney 
damage closely related to the changes observed in humans but as discussed earlier, 
large animals are more difficult to handle, lesions take a long time to develop and are 
more expensive to obtain and maintain (Steffes & Mauer 1984). This novel animal 
model of diabetes mellitus characterized in the present study is considered a valu-
able model for studying the pathomechanisms of diabetes-associated kidney 
changes.  
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The twelve-month life expectancy demonstrated that all GIPRdn transgenic animals, 
receiving standard rodent chow died until the age of twelve months. One of the main 
causes of death was cardiovascular failure. Interestingly cases of opstipation were 
observed, which can be found frequently in human patients with diabetes mellitus 
(Vogt HW DO 1999). Another frequent disease of GIPRdn transgenic animals was the 
development of retroorbital abscesses, which are thought to result from diabetes-
associated increased susceptibility to infections (Haupt 1999). Whereas about 80% of 
all transgenic animals in this diet group died from diabetes mellitus, less than half of 
the animals on the carbohydrate-restricted diet died from disturbance in the metabolic 
state. Preliminary data on diabetes development in mice receiving the diet, which is 
low in carbohydrate content, showed that all animals exhibited lower fasting blood 
glucose and insulin levels. Some animals even lost the diabetic phenotype despite 
changing the diet from carbohydrate restricted to standard rodent chow. Taken to-
gether, these results indicate that metabolic control can increase life expectancy in 
GIPRdn transgenic mice. However, if diabetes-associated organ changes are to be 
examined, feeding a carbohydrate-restricted diet is not advisable, since kidney le-
sions observed in 14-month-old transgenic mice, fed this diet from weaning were only 
mild.  
 
In summary, the clinical and pathological findings show that GIPRdn transgenic mice 
are valuable for further studies concerning the role of the enteroinsular axis in the 
pathogenesis of diabetes mellitus. The quantitative-stereological findings of the en-
docrine pancreas imply the importance of the GIP/GIP receptor axis in pancreas de-
velopment. Further, the present study provides evidence that GIPRdn transgenic mice 
are a promising model for studying diabetes-associated organ lesions.  
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The mechanisms of disturbance in pancreas development should be studied in detail, 
including quantitative evaluation of mitotic and apoptotic indices and the expression 
of several B-cell specific transcription factors involved in the development of the en-
docrine pancreas on protein and RNA level.  
Prenatal and early postnatal examinations, regarding pancreas development would 
be helpful for getting insight into the mechanisms involved in disturbed pancreas de-
velopment in GIPRdn transgenic mice. ,QYLWUR studies, using cells stably transfected 
with the mutated GIP receptor would answer questions about the changes in signal 
transduction and factors altered, acting downstream of the ligand-receptor level.  
 
The changes involved in the increase of liver and intestine weight should be looked 
at, since those changes are frequently observed in human diabetes. Many diabetic 
animals from the life expectancy experiment observed in the present study had died 
from opstipation and therefore, clinical observations would include the motility and 
absorption capacity of the small intestine of GIPRdn transgenic animals. Measure-
ment of intestine length and morphometric evaluations of different compartments of 
the intestine should additionally be carried out.  
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Gastrointestinal hormones like glucose-dependent insulinotropic polypeptide have 
recently been shown to be involved in the pathogenesis of diabetes mellitus in hu-
mans and animals models of diabetes mellitus. The aim of this study was to charac-
terize a novel transgenic mouse model expressing a dominant negative glucose-
dependent insulinotropic polypeptide receptor (GIPRdn) under the control of the rat 
insulin gene promoter and their non-transgenic counterparts. Detailed analysis of 
clinical parameters was performed, including urine glucose, blood or serum glucose 
and serum insulin values. In addition, oral and subcutaneous glucose tolerance tests 
were performed, and HbA1c levels and various serum parameters were determined. 
The detection of the daily food and water intake and the daily urine volume was per-
formed in two age groups. Further, body and organ weights were determined. Quali-
tative and quantitative morphological changes of the pancreas and the kidneys were 
investigated in several age groups. Some of the parameters were studied in different 
diet groups, one of them received standard rodent chow, and the other received a 
carbohydrate-restricted diet until four months of age. All transgenic mice studied ex-
hibited severe glucosuria from 21 days of age onwards. From 30 days of age on-
wards, GIPRdn transgenic males and females showed severe hyperglycemia and hy-
poinsulinemia (p<0.05). In male transgenic animals, the fasted body weight was 
found to be lower than in age-matched male control mice. The daily food and water 
intake and the 24-hour urine volume were significantly higher in all transgenic ani-
mals investigated. Histological and immunohistochemical survey of the pancreas re-
vealed a striking change of the islet cell composition and distribution. Further, quanti-
tative-stereological analysis of the pancreas revealed a significant reduction of the 
total volumes of pancreatic islets, B-cells in the islets and isolated B-cells in the exo-
crine pancreas indicating neogenesis of islets. Kidney changes included renal and 
glomerular hypertrophy, glomerulosclerosis and tubulo-interstitial changes. In conclu-
sion, transgenic mice expressing a dominant negative GIP receptor under the control 
of the rat insulin gene promoter develop a severe diabetic phenotype and striking 
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histological changes of the endocrine pancreas. Further, advanced diabetes-
associated organ lesions, particularly of the kidney were observed and therefore, 
GIPRdn transgenic mice are considered a valuable model for studying long-term 
complications of diabetes mellitus. 
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In den letzten Jahren wurde beim Studium der Pathogenese des Diabetes mellitus 
die Aufmerksamkeit zunehmend auf die Beteiligung gastrointestinaler Hormone wie 
zum Beispiel glucose-dependent insulinotropic polypeptide gerichtet. Ziel dieser Stu-
die war es, bei einem neuartigen transgenen Tiermodell, klinische und pathomorpho-
logische Veränderungen eingehend zu charakterisieren. Bei den untersuchten Tieren 
handelte es sich um transgene Mäuse, die einen dominant negativen glucose-
dependent insulinotropic polypeptide Rezeptor (GIPRdn) unter der Kontrolle des Rat-
teninsulingenpromotors exprimieren und um nicht-transgene Geschwistertiere. Es 
erfolgte eine detaillierte Untersuchung Diabetes-relevanter klinischer Parameter, un-
ter der Berücksichtigung von Harnglukoseausscheidung, Blut- bzw. Serumglukose- 
und Seruminsulinwerten. Zusätzlich wurden orale und subkutane Glukosetoleranz-
tests durchgeführt und HbA1c -Werte sowie verschiedene Serumparameter bestimmt. 
Die tägliche Futter- und Wasseraufnahme und das tägliche Harnvolumen wurden bei 
zwei Altersgruppen gemessen. Körper- und Organgewichte wurden ebenfalls erfasst. 
Die Erfassung morphologischer und histopathologischer Veränderungen des Pank-
reas und der Nieren erfolgte sowohl qualitativ als auch quantitativ-stereologisch an 
mehreren Altersgruppen. Einige der untersuchten Parameter wurden an Tieren, die 
mit Haltungsfutter gefüttert wurden und an Vergleichstieren erhoben, die bis zum Al-
ter von 4 Monaten mit einer kohlenhydratarmen Diät ernährt wurden. Alle untersuch-
ten transgenen Tiere zeigten ab einem Alter von 21 Tagen eine schwere Glukosurie. 
Im Alter von 30 Tagen zeigten GIPRdn transgene männliche und weibliche Mäuse 
eine hochgradige Hyperglykämie und eine hochgradige Hypoinsulinämie. Bei männ-
lich-transgenen Tieren war das Köpergewicht im Vergleich zu gleichgeschlechtlichen 
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Kontrolltieren reduziert (p<0.05). Die tägliche Futter- und Wasseraufnahme und das 
tägliche Harnvolumen war bei allen untersuchten transgenen Tieren signifikant höher 
als bei Kontrolltieren. Histologische und immunhistochemische Untersuchungen am 
Pankreas zeigten schwere Veränderungen der Zusammensetzung und Verteilung 
der Inselzellen auf. Diese qualitativen Befunde konnten durch quantitativ-
stereologische Untersuchungen eingehend charakterisiert werden. Das Gesamtvo-
lumen der Pankreasinseln und der B-Zellen in den Inseln war bei GIPRdn transgenen 
Mäusen signifikant niedriger als bei Kontrolltieren. Gleiches gilt für das Gesamtvolu-
men isolierter B-Zellen im exokrinen Pankreas, die als Indikator für Inselneogenese 
angesehen werden. Die festgestellten Nierenveränderungen umfassen renale und 
glomeruläre Hypertrophie, Glomerulosklerose und tubulointerstitielle Veränderungen. 
Die quantitativ-stereologische Auswertung konnte die subjektiven Befunde bestäti-
gen, sowohl das Nierenvolumen als auch das mittlere Glomerulumvolumen waren bei 
transgenen Mäusen signifikant erhöht. Aus den erhobenen Befunden ergibt sich die 
Schlussfolgerung, dass transgene Mäuse, die einen dominant-negativen GIP Rezep-
tor unter der Kontrolle des Ratteninsulingenpromoters exprimieren eine hochgradigen 
diabetischen Phänotyp und prägnante histologische Veränderungen am endokrinen 
Pankreas entwickeln. Weiterhin konnten Diabetes-assoziierte Alterationen diverser 
Organe, insbesondere der Niere festgestellt werden, woraufhin GIPRdn transgene 
Mäuse als ein wertvolles Tiermodell für die Untersuchung diabetischer Spätkomplika-
tionen angesehen werden.  
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9.1 Silver stain for SDS-PAGE gels 
 
1. Fixation solution      60 minutes 
 99.6% Ethanol     500 ml 
 Glacial acetic acid (Applichem, Germany) 120 ml 
 37% Formaldehyde (Applichem, Germany) 0.5 ml 
 Ad 1000 ml distilled water 
2. Washing in 50% ethanol    3 times 20 min 
3. Pre-treatment      1 minute 
 Sodium thiosulphate (Applichem, Germany) 0.05 g 
 in 50 ml distilled water 
4. Washing in distilled water    3 times 20 seconds 
5. Impregnation      20 minutes 
 Silver nitrate (Applichem, Germany)  0.05 g 
 37% Formaldehyde     35 µl 
 ad 50ml distilled water 
6. Washing in distilled water    2 times 20 seconds 
7. Develop       until bands become visible 
 Sodium carbonate (Merck, Germany)  3 g 
Sodium thiosulphate    0.2 mg 
37% Formaldehyde     50 µl 
ad 100 ml distilled water 
8. Wash in distilled water     20 seconds 
9. Stop solution 
 0.1 M EDTA (Sigma, Germany)      
  
9.2 Drying of SDS-PAGE gels 

The DryEase™ Mini-Gel Drying System, Novex, Germany was used for drying poly-
acrylamid gels. 
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DryEase Mini-Gel Dryer Frame 
DryEase Mini-Gel Drying Base 
DryEase Mini Cellophane 
Gel-Dry Drying Solution 
 
0HWKRG
Stained gels are washed in distilled water 3 times for 2 minutes 
Equilibration of gels in Gel-dry Solution for 15-20 minutes (rotary shaker) 
Cutting of rough edges with a razor blade 
Pre-wet 2 pieces of cellophane in Gel-Drying Solution for 15-20 seconds 
DryEase gel drying frame, placed on the gel dryer base is covered with one cello-
phane piece 
Gel is being placed in the center of the cellophane sheet; no air should be trapped 
between gel and cellophane 
Cover gel with second layer of cellophane; no air should be trapped; wrinkles are re-
moved with a gloved hand 
Remaining frame is aligned so that its corner pins fit into the holes on the bottom 
frame. Plastic clamps are pushed onto the four edges of the frame 
The assembly is to stand upright on a benchtop; drafts should be avoided. 
Drying of gels for 12-36 hours 
The gel/cellophane sandwich is removed and excess cellophane is trimmed off. 
Dried gels are pressed between pages of a book for approximately 2 days 
 
9.3 Staining procedures for plastic embedded sections 

9.3.1 H&E 
 
1. Mayer‘s hemalaun (Applichem, Germany)  30 minutes 
2. Rinse in tap water     10 minutes 
3. 1% HCl-Alcohol      1 second 
4. Rinse in tap water     10 minutes 
6. Dry 
7. Eosine Y (Merck, Germany)    5 minutes 
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8. Distilled water      3 times 3 seconds 
9. Dry 
10. Mount with glass cover slips using Histofluid® (Superior, Germany) 
 
9.3.2 Periodic acid-Schiff stain (PAS) 
 
1. 1% periodic acid (Applichem, Germany)  15 minutes 
2. Distilled water      3 times 3 seconds 
3. Schiff‘s reagent (Merck, Germany)   30-60 minutes 
4. Rinse in tap water     30 minutes 
Dry 
Mayer‘s hemalaun (Applichem, Germany)  35 minutes 
Rinse in tap water      10 minutes 
1% HCl alcohol      1 second 
Rinse in tap water      10 minutes 
Dry 
Mount under glass cover slips using Histofluid® (Superior, Germany) 
 
9.3.3 Periodic acid silver methenamine PAS stain (Gomori 1946), modified 
 
1.  1% periodic acid (Applichem, Germany)  15 minutes 
2.  Distilled water     3 times 3 seconds 
Dry 
Silver-methenamine solution containing:  
 3% Methenamine solution    50 ml 
5% Silver nitrate (Applichem, Germany)  2.5 ml 
2% Sodium tetraborate decahydrate (Borax) 6 ml 
Distilled water     45 ml 
Pre-heat to 60° in a water bath    5 minutes 
Staining (shake in a closed water bath at 60°C) 15-50 minutes, staining  
intensity has to be controlled  
repeatedly  
Distilled water      3 times 3 seconds 
1.5% Sodium thiosulphate solution    2 minutes 
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Rinse in tap water      5 minutes 
Dry 
Schiff‘s reagent (Merck, Germany)   60 minutes 
Rinse in tap water      30 minutes 
Dry 
Mayer‘s hemalaun (Applichem, Germany)  25 minutes 
Rinse in tap water      10 minutes 
1% HCl alcohol      1 second 
Rinse in tap water      10 minutes 
Dry 
Mount under glass cover slips using Histofluid® (Superior, Germany) 
     
9.4 Staining procedures for paraffin embedded sections 
 
9.4.1 H&E 
 
1. Xylene       10 minutes 
2. Descending series of alcohols     
3. Mayer’s hemalaun solution    5 minutes 
4. Rinse in tap water     5 minutes 
5. 0.5% HCl-alcohol     until slides have cleared 
6. Rinse in tap water     5 minutes 
7. Eosine       dip 2-7 times 
8. Rinse in distilled water 
9. Ascending series of alcohols 
10. Carbolxylene 
11. Xylene 
Mount under glass cover slips using Histofluid (Superior, Germany) 
 
9.4.2 PAS 
 
1. Xylene       10 minutes 
2. Descending series of alcohols     
3. 1% periodic acid (Applichem, Germany)  10 minutes 
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4. Rinse in tap water     10 minutes 
5. Rinse in distilled water 
6. Schiff‘s reagent (Merck, Germany)   30 minutes 
7. Rinse in tap water     5 minutes 
8. Mayer‘s hemalaun (Applichem, Germany)  2 minutes 
9. Rinse in tap water     5 minutes 
10. 1% HCl alcohol       
11. Rinse in tap water     5 minutes 
12. Ascending series of alcohols 
13. Xylene 
Mount under glass cover slips using Histofluid  
 
9.4.3 Gomori’s silver stain (modified) 
 
1. Xylene       10 minutes 
2. Descending series of alcohols  
3. Potassium permanganate 0.5% (Merck, Germany) 1-2 minutes 
4. Rinse in tap water     5 minutes 
5. Potassium disulphite 2% (Merck, Germany)  1 minute 
6. Rinse in tap water     5 minutes 
7. Ammonium iron (III) sulphate 2% 
(Merck, Germany)     1 minute 
8. Rinse in tap water     5 minutes 
9. Distilled water      2 minutes 
10. Distilled water      2 minutes 
11. Silver nitrate in ammonia (see below)  1 minute 
12. Formaldehyde 4%     5 minutes 
13. Rinse in tap water     5 minutes 
14. Gold chloride 0.1% (Applichem, Germany)  30 seconds 
Rinse in distilled water    
Potassium disulphite 2% (Merck, Germany)  1 minute 
Rinse in tap water      5 minutes 
Sodium thiosulphate 1% (Merck, Germany)  1 minute 
Rinse in tap water 
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Ascending series of alcohols 
Xylene 
Mount under glass cover slips using Histofluid   
 
Silver nitrate in ammonia: 
Silver nitrate (Applichem, Germany) 10%  25 ml 
Potassium hydroxide (Merck, Germany) 10%  5 ml 
Ammonia solution 25% (Applichem, Germany)  approximately 4 ml, add slowly  
until brown precipitate dissolves 
Silver nitrate (Applichem, Germany) 10%  approximately 1 ml, until  
solution turns brownish 
Distilled water      30 ml 
Use within 2 days, store at 4°C in a dark bottle 
 
9.4.4 Best’s Carmine 
 
Cut sections for glycogen determination have to be transferred into 85% Ethanol for 
mounting on glass slides. 
 
a) Impregnation of sections: 
 1. Xylene      10 minutes 
 2. Ethanol 100%  
 3. Ether-Ethanol (50:50)    1-2 minutes 
 4. Collodion solution 1%    2-3 minutes 
 5. Ethanol 80%     2 minutes 
b) Staining procedure 
 1. Mayer’s hemalaun (Applichem, Germany) 10 minutes 
 2. Rinse in tap water     10-15 minutes 
 3. Carmine solution (see below)   10-30 minutes 
 4. Differentiate (see below)   1 minute 
 5. Differentiate (see below)   1 minute 
 6. Ethanol 80%      
 7. Ether-Ethanol (50:50)    3-5 minutes 
 8. Ethanol 99.6%      
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 9. Xylene 
 10. Mount under glass cover slips using Histofluid 
 
Carmine stock solution: 
Carmine (Merck, Germany)    2g 
Potassium carbonate (Applichem, Germany)  1g 
Potassium chloride (Merck, Germany)   5g 
Distilled water      60 ml 
Boil for 2-3 minutes 
Ammonia solution (Applichem, Germany)  20 ml 
Store at 4°C in a dark bottle, use within 2 months 
 
Carmine solution, ready to use: 
Stock solution      20 ml 
Ammonia solution (Applichem, Germany)  30 ml 
Methanol (Applichem, Germany)    30 ml 
 
Differentiation solution: 
Methanol (Applichem, Germany)    40 ml 
Ethanol 99.6%      80 ml 
Distilled water      100 ml 
 
9.5 Fat Red stain 
 
1. Transfer cut sections into distilled water 
2. Ethanol 50%      0.5 minutes 
3. Fat red solution (see below)    5 minutes 
4. Ethanol 50%      2 seconds 
5. Rinse in distilled water  
6. Mayer’s hemalaun (Applichem, Germany)  2 seconds 
7. Rinse in distilled water 
8. Rinse in tap water 
9. Mount on glass slides 
10. Dry 
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11. Mount under glass cover slips using Kaiser’s glycerol gelatin (Merck, Germany) 
 
Fat red solution: 
Ethanol 96%       140 ml 
Distilled water      52 ml 
Boil shortly 
Fat red 7B (Serva, Germany)    0.5g  
Boil shortly and stir for 30 minutes 
Filtrate before using 
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